sv4za
As filed with the Securities and Exchange Commission on
October 14, 2011
Registration No. 333-176640
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Amendment No. 1
to
Form S-4
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933
MERGE HEALTHCARE
INCORPORATED
(Exact name of registrant as
specified in its charter)
SEE TABLE OF ADDITIONAL REGISTRANTS
|
|
|
|
|
Delaware
(State or other jurisdiction
of
incorporation or organization)
|
|
7373
(Primary Standard
Industrial
Classification Code Number)
|
|
39-1600938
(I.R.S. Employer
Identification No.)
|
200 East Randolph Street, 24th Floor
Chicago, Illinois 60601-6436
(312) 565-6868
(Address, including zip code,
and telephone number, including area code, of Registrants
principal executive offices)
Jeffery A. Surges
Chief Executive Officer
Merge Healthcare Incorporated
200 East Randolph Street, 24th
Floor
Chicago, Illinois
60601-6436
(312) 565-6868
(Name, address, including zip
code, and telephone number, including area code, of agent for
service)
Copy to:
Ann Mayberry-French
Vice President, General Counsel and Secretary
Merge Healthcare Incorporated
900 Walnut Ridge Drive
Hartland, Wisconsin 53029
(262)
367-0700
Approximate date of commencement of proposed sale to the
public: As soon as practicable after this registration
statement becomes effective.
If the securities being registered on this form are being
offered in connection with the formation of a holding company
and there is compliance with General Instruction G, check
the following
box. o
If this form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act,
check the following box and list the Securities Act registration
statement number of the earlier effective registration statement
for the same
offering. o
If this form is a post-effective amendment filed pursuant to
Rule 462(d) under the Securities Act, check the following
box and list the Securities Act registration statement number of
the earlier effective registration statement for the same
offering. o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in
Rule 12b-2
of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large Accelerated
filer o
|
|
Accelerated
filer þ
|
|
Non-accelerated
filer o
|
|
Smaller reporting company o
|
|
|
(Do not check if a small reporting
company)
|
If applicable, place an X in the box to designate the
appropriate rule provision relied upon in conducting this
transaction:
Exchange Act Rule 13e-4(i) (Cross-Border Issues Tender
Offer) o
Exchange Act Rule 14d-1(d) (Cross-Border Third
Party Tender
Offer) o
The Registrants hereby amend this Registration Statement on
such date or dates as may be necessary to delay its effective
date until the Registrants shall file a further amendment which
specifically states that this Registration Statement shall
thereafter become effective in accordance with Section 8(a)
of the Securities Act of 1933 or until this Registration
Statement shall become effective on such date as the Securities
and Exchange Commission, acting pursuant to said
Section 8(a), may determine.
TABLE OF
ADDITIONAL REGISTRANTS
The following subsidiaries of Merge Healthcare Incorporated are
Registrant Guarantors:
|
|
|
|
|
|
|
|
|
|
|
|
|
State or Other
|
|
|
|
|
|
|
Jurisdiction of
|
|
Primary Standard
|
|
I.R.S. Employer
|
Exact Name of Registrant Guarantor as
|
|
Incorporation or
|
|
Industrial
|
|
Identification
|
Specified in its Charter
|
|
Organization
|
|
Classification Number
|
|
Number
|
|
Abraxas Medical Solutions, Inc.
|
|
Delaware
|
|
|
3841
|
|
|
|
26-1525385
|
|
AMICAS, Inc. (now Merge Healthcare Solutions Inc.)
|
|
Delaware
|
|
|
7372
|
|
|
|
59-2248411
|
|
Confirma Europe LLC
|
|
Washington
|
|
|
7373
|
|
|
|
N/A
|
|
Merge Asset Management Corp.
|
|
Delaware
|
|
|
7373
|
|
|
|
N/A
|
|
Merge eClinical Inc.
|
|
Delaware
|
|
|
7373
|
|
|
|
20-0308891
|
|
Ophthalmic Imaging Systems
|
|
California
|
|
|
3841
|
|
|
|
94-3035367
|
|
Requisite Software Inc.
|
|
Delaware
|
|
|
7373
|
|
|
|
27-1023435
|
|
Stryker Imaging Corporation
|
|
Delaware
|
|
|
7373
|
|
|
|
65-1017159
|
|
The address, including zip code, and telephone number,
including area code, of the principal executive office of each
Registrant Guarantor listed above are the same as those of Merge
Healthcare Incorporated.
The
information in this prospectus is not complete and may be
changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission
relating to these securities is effective. This prospectus is
not an offer to sell these securities and it is not soliciting
an offer to buy these securities in any jurisdiction where the
offer or sale is not permitted.
|
SUBJECT TO COMPLETION DATED
OCTOBER 14, 2011.
PRELIMINARY PROSPECTUS
Merge Healthcare
Incorporated
Offer to Exchange
$52,000,000 principal amount of its 11.75% Senior Secured
Notes due 2015,
which have been registered under the Securities Act of 1933, for
any and all of
its outstanding 11.75% Senior Secured Notes due 2015
We are offering to exchange all of our outstanding
11.75% Senior Secured Notes due 2015 that we issued on June
20, 2011, which we refer to as the old notes, for new
11.75% Senior Secured Notes due 2015, in an exchange
transaction that is being registered hereby. The terms of the
exchange notes are identical to the terms of the old notes
except that the transaction in which you may elect to receive
the exchange notes has been registered under the Securities Act
of 1933, as amended, or the Securities Act, and, therefore, the
exchange notes are freely transferable.
The old notes constitute a further issuance of the $200,000,000
aggregate principal amount of 11.75% Senior Secured Notes due
2015 that we issued on April 28, 2010 (the April 2010
notes) and form a single series of debt securities with
the April 2010 notes. Unless the context requires otherwise, we
refer to the old notes, the exchange notes and the April 2010
notes together as the notes or Notes.
The old notes have identical terms to the April 2010 notes (as
modified by the consent solicitation described herein), other
than the issue date and offering price and, following the
completion of this exchange offer, the exchange notes will be
fungible with the April 2010 notes. The aggregate principal
amount of notes is $252,000,000. Accordingly, the $52,000,000
aggregate principal amount of exchange notes constitute
approximately one-fifth of the total voting power of the
$252,000,000 of outstanding notes.
We will pay interest on the notes on May 1 and November 1 of
each year, beginning on November 1, 2011. The notes will
mature on May 1, 2015.
At any time on or prior to May 1, 2013, we may redeem any
of the notes at a price equal to 100% of the principal amount
thereof plus an applicable make-whole premium plus
accrued and unpaid interest, if any, to the redemption date, as
described in this prospectus. At any time and from time to time
during the twelve month period commencing May 1, 2013, we
may redeem the notes, in whole or in part, at a redemption price
equal to 105.875% of the principal amount thereof and accrued
and unpaid interest, if any, to the redemption date. At any time
and from time to time after May 1, 2014, we may redeem the
notes, in whole or in part, at a redemption price equal to 100%
of the principal amount thereof and accrued and unpaid interest,
if any, to the redemption date. In addition, prior to
May 1, 2013, we may redeem up to 35% of the notes at a
redemption price equal to 111.75% of the principal amount
thereof plus accrued and unpaid interest, if any, using proceeds
from permitted sales of certain kinds of our capital stock. Upon
the occurrence of a change of control or the sale of
substantially all of our assets, we may be required to
repurchase some or all of the notes.
The obligations under the notes will be fully and
unconditionally guaranteed, jointly and severally, on a senior,
secured basis by all of our current and future domestic
restricted subsidiaries. See Description of the Exchange
Notes. The notes and guarantees will be secured by a
first-priority lien on certain collateral which comprises
substantially all of our and the guarantors tangible and
intangible assets, subject to certain exceptions.
The principal features of the exchange offer are as follows:
|
|
|
|
|
The exchange offer expires at 5:00 p.m., Eastern time,
on
2011, unless extended.
|
|
|
|
All old notes that are validly tendered and not validly
withdrawn prior to the expiration of the exchange offer will be
exchanged for exchange notes.
|
|
|
|
You may withdraw tendered old notes at any time prior to the
expiration of the exchange offer.
|
|
|
|
The exchange of old notes for exchange notes pursuant to the
exchange offer should not be a taxable event for United States
federal income tax purposes.
|
|
|
|
We will not receive any proceeds from the exchange offer.
|
|
|
|
We do not intend to apply for listing of the notes on any
securities exchange or for inclusion of the notes in any
automated quotation system.
|
Broker-dealers receiving exchange notes in exchange for old
notes acquired for their own account through market-making or
other trading activities must deliver a prospectus in any resale
of the exchange notes. This prospectus, as it may be amended or
supplemented from time to time, may be used by a broker-dealer
in connection with resales of exchange notes received in
exchange for old notes where the old notes were acquired by the
broker-dealer as a result of market-making or other trading
activities.
See Risk Factors beginning on page 14
to read about important factors you should consider in
connection with the exchange offer.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal
offense.
The date of this prospectus
is ,
2011.
Each broker-dealer that receives exchange notes for its own
account pursuant to the exchange offer must acknowledge that it
will deliver a prospectus in connection with any resale of such
exchange notes. The letter of transmittal accompanying this
prospectus states that, by so acknowledging and by delivering a
prospectus, a broker-dealer will not be deemed to admit that it
is an underwriter within the meaning of the
Securities Act. This prospectus, as it may be amended or
supplemented from time to time, may be used by a broker-dealer
in connection with resales of exchange notes received in
exchange for old notes where the original notes were acquired by
the broker-dealer as a result of market-making or other trading
activities. We have agreed that, starting on the expiration date
of the exchange offer and ending on the close of business
180 days after the expiration date of the exchange offer,
we will make this prospectus available to any broker-dealer for
use in connection with any such resale. See Plan of
Distribution.
This prospectus incorporates important business and financial
information about us that is not included in or delivered with
this document. See Incorporation of Documents by
Reference on page 88 for a listing of documents we
incorporate by reference.
We have not authorized any dealer, salesman or other person
to give any information or to make any representation other than
those contained or incorporated by reference in this prospectus.
You must not rely upon any information or representation not
contained or incorporated by reference in this prospectus as if
we had authorized it. This prospectus does not constitute an
offer to sell or a solicitation of an offer to buy any
securities other than the registered securities to which it
relates, nor does this prospectus constitute an offer to sell or
a solicitation of an offer to buy securities in any jurisdiction
to any person to whom it is unlawful to make such offer or
solicitation in such jurisdiction.
Industry
and Market Data
Market data used throughout this prospectus, including
information relating to our relative position in the commercial
and individual markets in which we operate, is based on the good
faith estimates of management, which estimates are based upon
their review of internal surveys, independent industry
publications and other publicly available information. Although
we believe that these sources are reliable, we do not guarantee
the accuracy or completeness of this information, and we have
not independently verified this information.
Trademarks,
Service Marks and Trade Names
We own or have rights to various trademarks used in our business
including: Frontiers AIMS, eFilm Archive, Merge Mammo, Fusion
PACS, Fusion RIS, Fusion RIS/PACS MX, CADstream, Cedara
WebAccess, Cedara I-Reach, Cedara Open Eyes, Merge-COM, etrials,
CadStream and eFilm Workstation. We do not intend our use or
display of other parties trademarks, trade names or
service marks to imply, and such use or display should not be
construed to imply, a relationship with, or endorsement or
sponsorship of us by, these other parties.
PROSPECTUS
SUMMARY
This summary contains basic information about our company and
the offering and highlights selected information contained
elsewhere or incorporated by reference in this prospectus. This
summary is not complete and does not contain all of the
information that you should consider before deciding whether or
not to complete the exchange offer. For a more complete
understanding of our company and the exchange offer, you should
read this entire prospectus, including Risk Factors,
and the financial information and the related notes thereto
included elsewhere or incorporated by reference in this
prospectus.
In this prospectus, (i) the term Merge means
Merge Healthcare Incorporated and its subsidiaries and
(ii) the terms we, us,
our, and our company refer to Merge,
unless the context suggests otherwise.
Overview
Merge Healthcare Incorporated, along with its subsidiaries and
affiliates (collectively, Merge, we,
us, or our), is an enterprise image
provider dedicated to healthcare information technology
(IT) solutions. We develop software solutions that
automate healthcare data and diagnostic workflow to create a
more comprehensive electronic record of the patient experience.
Our solutions are designed to help solve some of the toughest
challenges in health information exchange today, such as the
incorporation of medical images and diagnostic information into
broader healthcare IT applications, the interoperability of
proprietary software solutions, advanced clinical tools like
computer aided detection (CAD), the profitability of
outpatient imaging practices in the face of declining
reimbursement and the ability to improve the efficiency and cost
effectiveness of our customers businesses.
Merge was founded in 1987 and was reincorporated in Delaware on
December 5, 2008. Our principal executive offices are
located at 200 East Randolph Street, 24th Floor, Chicago,
Illinois,
60601-6436,
and our telephone number there is
(312) 565-6868.
Our website address, which we use to communicate important
business information, can be accessed at: www.merge.com. The
information on our website is not part of this prospectus.
Our products, ranging from standards-based development toolkits
to fully integrated clinical applications, have been used by
healthcare providers worldwide for over 20 years. Our
solutions optimize processes for healthcare organizations
ranging in size from single-doctor practices to health systems,
for the sponsors of clinical trials, for the medical device
industry, for the healthcare commerce system and for consumers
of healthcare. These solutions are licensed by more than 1,500
hospitals; 4,000 clinics and labs, 250 healthcare equipment
manufacturers and 70% of the top pharmaceutical companies. On
April 28, 2010, we acquired AMICAS, Inc. (now Merge
Healthcare Solutions Inc.) and its subsidiaries for total
consideration of approximately $223.9 million.
Merge primarily generates revenue from the sale of perpetual
software licenses (limited by volume), upgrading
and/or
renewing those licenses, hardware, professional services and
maintenance. The first four contract elements comprise the
majority of non-recurring revenue. Our backlog of non-recurring
revenue was approximately $40.1 million as of June 30,
2011. Maintenance, which we renew annually with our customer
base, is the primary component of recurring revenues. Recurring
revenue also includes software licenses sold through contracts
that are annually renewed and recognized ratably over the annual
period and recorded as software revenue, and revenues derived
from SaaS offerings which are recorded as professional services
revenue. During 2010 and the first quarter of 2011, recurring
revenue was approximately 65% of total net
1
sales. During the second quarter of 2011, recurring revenue was
approximately 62.5% of total net sales. The following table
presents our consolidated revenues by category, as a percentage
of total revenues for software and other sales, professional
services and maintenance and electronic data interchange
(EDI):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months
|
|
|
|
|
|
|
|
|
|
|
|
|
Ended
|
|
|
Years Ended December 31,
|
|
|
|
June 30, 2011
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Net sales:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Software and other
|
|
|
31.7
|
%
|
|
|
30.2
|
%
|
|
|
49.4
|
%
|
|
|
48.6
|
%
|
Professional services
|
|
|
18.9
|
%
|
|
|
16.5
|
%
|
|
|
17.7
|
%
|
|
|
15.1
|
%
|
Maintenance and EDI
|
|
|
49.4
|
%
|
|
|
53.3
|
%
|
|
|
32.9
|
%
|
|
|
36.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net sales
|
|
|
100.0
|
%
|
|
|
100.0
|
%
|
|
|
100.0
|
%
|
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Healthcare
IT Industry
We believe there are several factors that are favorable for the
global healthcare IT industry over the next decade. The broad
recognition that healthcare IT is essential to helping control
healthcare costs and improving quality contributed to the
inclusion of healthcare IT incentives in the American Recovery
and Reinvestment Act (ARRA). The ARRA and
accompanying Health Information Technology for Economic and
Clinical Health (HITECH) provisions include more
than $35 billion in incentives, which reward providers who
use certified electronic health records (EHRs) in a
meaningful way. These incentives are contributing to increased
demand for healthcare IT solutions and services in the United
States. We believe long-term revenue growth opportunities
outside the United States remain significant because other
countries are also focused on controlling healthcare spending
while improving the efficiency and quality of care that is
delivered, and many of these countries recognize healthcare IT
as an important piece of the solution to these issues.
We believe that an EHR can only be considered meaningful if
imaging data is included. As providers adopt EHRs, we believe
the need for solutions such as our iConnect platform, which
offers connectivity, access to the image and interoperability
between providers and other healthcare constituents, will be
critical. Imaging continues to be a critical component of
healthcare delivery across the continuum of care. Increasing
physician awareness and utilization of imaging as a standard of
care to aid in patient diagnosis (including its use as a
preventive screening method), as well as an increased
availability of diagnostic imaging equipment in medical centers
and hospitals, has fueled the growth of the diagnostic imaging
industry. In addition, U.S. demographic trends and the
opportunity for greater international adoption of medical
imaging should provide the basis for long-term, sustainable
growth in imaging volumes. Merge is well positioned to benefit
from this expected increase in demand due to our large footprint
in United States hospitals and physician practices and our
proven ability to deliver value to our clients. Based on
information from consulting firm Frost & Sullivan and
our own research, we believe the global market for imaging
software and services, healthcare IT interoperability solutions,
digital pathology and imaging in clinical trials is
$6.5 billion annually.
We believe that we have positioned ourselves to provide value
added solutions and services to our customers amidst potential
changes in industry standards and regulations. We believe the
fundamental value proposition of healthcare IT remains strong
and that the industry will likely benefit as healthcare
providers and governments continue to recognize that these
solutions and services contribute to safer, more efficient
healthcare.
Merge
Growth Strategy
Our strategy is to be a leading provider of integrated, global
healthcare IT solutions and services that improve the exchange
of healthcare information. Our business strategy is anchored by
the breadth and depth of our solutions and services, our proven
ability to deliver value and the success of our customers. We
believe the growth drivers for Merge are the importance of
imaging, the opportunity around meaningful use of EHRs, and the
need for interoperability. Imaging continues to be a critical
component of healthcare delivery across the continuum of care.
We believe it has become abundantly clear that an electronic
medical record can only be considered meaningful if imaging data
is included.
2
A core strength that has led to our strong market position is
our proven ability to innovate, which has driven consistent
expansion of solutions and services and entry into new markets.
We currently own approximately 70 patents issued in various
jurisdictions and continue to expand our IP portfolio. Our
award-winning portfolio of technologies is used across a wide
variety of clinical specialties in addition to being an
increasingly important component of clinical trials. For
example, our iConnect platform offers hospitals, imaging centers
and Health Information Exchanges the ability to create
information exchanges within their environment and with other
entities. As providers adopt electronic health records, we
believe the need for solutions that offer connectivity and
interoperability between providers and other healthcare
constituents will be a new multi-billion dollar opportunity for
which Merge is uniquely positioned to compete.
As part of our strategy, we will look to expand through
strategic acquisitions that will also allow us to further expand
our addressable market and customer base. We believe that our
acquisitions in 2010 and 2009 have allowed, and our recently
completed acquisition of Ophthalmic Imaging Systems
(OIS) will allow, us to expand our product offering
as well as provide greater penetration into existing market
segments. As a result of these acquisitions, we have extended
our addressable market to include other specialties, such as
solutions for the orthopaedics and laboratory markets and have
increased the depth of our solution portfolio for existing
customers and new prospects to include additional automation
capabilities via patient kiosks. Our acquisition of OIS on
August 4, 2011 added opthamalic imaging to our portfolio.
We have an opportunity to grow revenues by expanding our
solution footprint with existing customers, as only a small
percent currently have more than one of our solutions,
representing a significant cross sell opportunity. This is
supported by the fact that no customer accounted for more than
10% of our net sales in three years ended December 31,
2010. With the benefit of a broad customer base and several
product lines undergoing ongoing innovation, we also believe
that we are well-positioned to continue to leverage technologies
into new segments where customers see value. For example, as
providers adopt EHRs and seek to qualify for meaningful use
incentives, our vendor-neutral archiving and web-based image
access products will help providers facilitate meaningful use
and accountable care initiatives.
We believe our strengths position us well to gain market share
in the United States during a period of expected strong demand
driven by the HITECH provisions of ARRA and the nations
focus on improving the efficiency and quality of healthcare. We
also have a strong global brand, as evidenced by our popular
eFilm Workstation that has over 100,000 downloads. Also, Merge
has sold products in more than 50 countries. We believe that we
have a good opportunity to gain market share outside of the
United States.
Our
Product Portfolio
We provide a broad range of products and services to our
customers, including:
|
|
|
|
|
Image Interoperability Platform
|
|
|
|
|
|
iConnect: This interoperability and
connectivity platform offers hospitals, imaging centers,
Integrated Delivery Networks and Health Information Exchanges
the ability to create information exchanges within their
environments and with other entities. This platform provides
access to imaging and diagnostic data across disparate sites,
geographies, specialties and providers. This solution enables
providers to expedite care, reduce duplicate exams, consolidate
infrastructure and limit the expenses associated with moving,
managing and storage of diagnostic content and results.
|
|
|
|
|
|
Clinical and Financial Information Systems
|
|
|
|
|
|
Digital Imaging Solutions: Picture Archiving
and Communication Systems (PACS), specialty
workstations and related applications manage the image workflow
of a medical enterprise. PACS can be used by any medical imaging
provider at a hospital or outpatient imaging site. We offer PACS
solutions for general image review and management, specialty
solutions for cardiology, orthopaedics, mammography and
oncology, and add-on modules like referring physician portals
and critical test results reporting. We also offer the popular
eFilm Workstation for general radiology reading and CADstream
workstation for specialty reading of magnetic resonance imaging
(MRI) breast, liver and prostate studies. With our
recently completed OIS acquisition, we have expanded our product
|
3
|
|
|
|
|
offerings to include ophthalmic imaging systems, integrated
electronic medical records and practice management solutions for
the eye care market.
|
|
|
|
|
|
Clinical information systems: These systems
provide a complete electronic record of a medical procedure
across a variety of specialties including Merge
OrthoEMR for orthopaedics, Merge Anesthesia Information
Management System for surgery, Merge RIS for radiology and OIS
for ophthalmology.
|
|
|
|
Revenue Cycle Management: We offer software
and services for the revenue cycle management of physician
practices. These solutions can be used across a number of
physician specialties, but our solutions are most commonly used
by radiology practices, imaging centers and billing services
|
|
|
|
|
|
Software Development Toolkits, Technologies and
Platforms.
|
|
|
|
|
|
Merge toolkits, technologies and platforms provide software
developers with the necessary resources to assist in the timely
development of new products and enhance existing products. They
can be used by any original equipment manufacturer
(OEM), medical device manufacturer, RIS/PACS vendor
or general healthcare IT vendor. We offer development toolkits
in the basic standards of medical imaging and information
interoperability, as well as advanced toolkits and unfinished
applications for specialized medical image review and
distribution.
|
|
|
|
|
|
Hosted Software Solutions for Clinical Trial Data
Management.
|
|
|
|
|
|
We provide hosted software solutions for the collection,
aggregation, analysis, reporting and overall management of
clinical trials information. These solutions can be sold to
sponsors of clinical trials, including a pharmaceutical company,
a contract research organization (CRO) or an imaging
core lab. Our solutions include electronic data capture
(EDC), interactive voice/web response
(IVR/IWR) and electronic patient reported outcomes
(ePRO) software and devices.
|
Competition
The healthcare IT and imaging markets in which we participate
are highly competitive, rapidly evolving and subject to rapid
technological change. However, we believe that there is no
single company that competes against our entire product
portfolio.
Our principal competitors in the healthcare solutions and
services market include: General Electric Company (Healthcare),
McKesson Corporation, Cerner Corporation, Philips, Carestream,
and Agfa, each of which offers software solutions that compete
with a portion of our product portfolio. Almost all of these
competitors are substantially larger or have more experience and
market share than us in their respective market. We also partner
with certain of these companies to resell our products.
Other competitors focus on only a very specific portion of the
market that we address or against specific products we sell. For
example, there are 30 other companies in the North American PACS
market, according to Frost & Sullivan. These companies
include imaging equipment original equipment manufacturers,
former film companies and healthcare IT companies. Our CAD
product line for breast, liver
and/or
prostate cancer diagnostic support competes with iCAD, InVivo
(Philips), Sentinelle and Hologic. Our eClinical product line is
in a highly competitive market lead by Phase Forward (recently
acquired by Oracle) and Medidata. Our OEM technologies most
often compete with internal development departments. Our OEM
toolkits face a limited number of competitors and we believe
that we are the only vendor to provide a combined Digital
Imaging and Communications in Medicine (DICOM) and
Health Level 7 (HL7) toolkit.
In addition, we expect that major software information systems
companies, large information technology consulting service
providers and system integrators,
start-up
companies, managed care companies and others specializing in the
healthcare industry may offer competitive software solutions or
services. The pace of change in the healthcare IT market is
rapid and there are frequent new software solutions or service
introductions, enhancements and evolving industry standards and
requirements. We believe that the principal competitive factors
in this market include the breadth and quality of solution and
service offerings, the stability
4
of the solution provider, the quality, features and performance
of the products, the ongoing support for the systems and the
potential for enhancements and future compatible software
solutions.
Employees
As of June 30, 2011, we had approximately
800 employees world-wide. Competition for technical
personnel in the industry in which we compete is intense. We
believe that our future success depends in part on our continued
ability to hire, assimilate, and retain qualified personnel.
Software
Development
We commit significant resources to developing new health
information system solutions. As of June 30, 2011,
approximately 200 of our employees were engaged in research and
development activities. Total expenditures for the development
and enhancement of our software solutions were approximately
$20.1 million, $10.7 million and $13.2 million
during 2010, 2009 and 2008, respectively.
Our products, ranging from standards-based development toolkits
to fully integrated clinical applications, have been used by
healthcare providers worldwide for over 20 years. Our
software solutions follow industry standards such as DICOM,
which ensures that images from any DICOM-compliant modality can
be displayed, moved and stored within a standard set of
guidelines; and HL7, which provides standards for the movement
of other health information file formats. In addition, Merge
participates in the Integrating the Healthcare Enterprise
(IHE), an organization dedicated to developing
standard profiles for health information exchange. Our long-time
involvement with the standards committees and continuous
development of products like our DICOM and HL7 toolkits have
enabled Merge to stay closely tied to industry innovation. As
discussed above, continued investment in research and
development remains a core element of our strategy. This will
include ongoing enhancement of our core solutions and
development of new solutions and services.
Sales,
Marketing and Distribution
Sales to large health systems typically take more than nine
months, while the sales cycle is often shorter when selling to
smaller hospitals and imaging centers. In order to ramp up our
sales and market presence, we began aggressively hiring in the
fourth quarter of 2010. As of June 30, 2011, approximately
150 of our employees were engaged in sales and marketing
activities. Our executive sales and marketing management is
located at our Innovation Center in Chicago, Illinois, while our
sales team is deployed across the United States and globally.
We employ quota-based sales teams that specialize in particular
product lines. In addition, we have sales teams dedicated to
establishing and maintaining VAR and distributor relationships
globally. Where feasible, we have concentrated inside and
telesales staff in one location in order to bring economies of
scale in management and process. Our sales teams are
complemented by a staff of lead generation and marketing
employees. These teams have the benefit of online tools and
resources that streamline and track the sales process.
Our marketing efforts are mainly electronic, utilizing our
website and our extensive email database of eStore customers for
our communication campaigns, as well as our website for online
communities and certain social media. Beyond electronic media,
we employ consistent media relations efforts for market
communication. In addition, we participate in the major industry
trade shows for our respective product lines. We also have an
active User Group for our U.S. customers.
Recent
Developments
Acquisition
of Ophthalmic Imaging Systems
On August 4, 2011, we completed our acquisition of
Ophthalmic Imaging Systems (OIS). Under the terms
set forth in the Agreement and Plan of Merger entered into with
OIS on June 5, 2011, each share of OIS common stock was
converted into the right to receive 0.1693 shares of our
common stock. We issued approximately 5,132,000 shares in
connection with the transaction. Based on the per share price of
our
5
common stock as of the close of trading on August 4, 2011, the
aggregate value of our common stock issued as consideration in
the OIS Acquisition was approximately $29,150,000.
Consent
Solicitation and Redemption of Series A Non-Voting
Preferred Stock
On June 7, 2011, we commenced a consent solicitation (the
Solicitation) to holders of the April 2010 notes
pursuant to a consent solicitation statement in order to amend
certain covenants in the indenture governing the April 2010
notes to allow us to redeem and retire our Series A
Non-Voting Preferred Stock and to undertake the offering of the
old notes. On June 14, 2011, the Company received the
requisite consents to approve the proposed amendments to the
indenture in order to facilitate the offering of the old notes.
On June 20, 2011, we issued the old notes and completed the
redemption of our Series A Non-Voting Preferred Stock using
proceeds from the issuance of the old notes.
The
Offering of the Old Notes
On June 20, 2011, we completed an offering of
$52 million in aggregate principal amount of
11.75% Senior Secured Notes due 2015, which was exempt from
registration under the Securities Act.
|
|
|
Old Notes |
|
We sold the old notes to Morgan Stanley & Co. LLC the
initial purchaser on June 20, 2011. The initial purchaser
subsequently resold the old notes to qualified institutional
buyers pursuant to Rule 144A under the Securities Act. |
|
Registration Rights Agreement |
|
In connection with the sale of the old notes, we and the
subsidiary guarantors, which we refer to as the guarantors,
entered into a registration rights agreement with the initial
purchaser. Under the terms of the registration rights agreement,
we and the guarantors agreed to: (1) file a registration
statement for the exchange offer of the new notes with the SEC
not later than 90 days after the date of original issuance
of the old notes, and (2) use commercially reasonable
efforts to have the registration statement declared effective by
the SEC not later than 180 days after the date of original
issuance of the old notes. |
|
|
|
Under specified circumstances, we and the guarantors will, at
our cost, (a) as promptly as practicable (but in no event
more than 60 days after so required or requested in
accordance with the above), file a registration statement (the
shelf registration statement) covering resales of
the notes or the exchange notes, as the case may be,
(b) use our commercially reasonable efforts to cause the
shelf registration statement to be declared effective under the
Securities Act within 120 days after so required or
requested and (c) use our commercially reasonable efforts
to keep the shelf registration statement effective until two
years after its effective date. |
|
|
|
If (a) either the exchange offer registration statement or
the shelf registration statement has not been filed with the SEC
as required |
6
|
|
|
|
|
by the registration rights agreement, (b) either the
exchange offer registration statement or the shelf registration
statement has not been declared effective as required by the
registration rights agreement, or (c) after either the
exchange offer registration statement or the shelf registration
statement has been declared effective, such registration
statement thereafter ceases to be effective or usable (subject
to certain exceptions) in connection with resales of notes or
exchange notes in accordance with and during the periods
specified in the registration rights agreement, (each such event
referred to in clauses (a) through (c), a
registration default), we shall pay liquidated
damages (registration default damages) to the
holders of the old notes and the exchange notes. Registration
default damages shall accrue at a rate of 0.25% per annum for
the first 60 days from and including the date of a
registration default and at a rate of 0.50% thereafter. |
The
Exchange Offer
|
|
|
Exchange Offer |
|
$2,000 principal amount of exchange notes will be issued in
exchange for each $2,000 principal amount of old notes validly
tendered and integral multiples of $1,000 in excess thereof. |
|
Resale |
|
Based upon interpretations by the staff of the SEC set forth in
no-action letters issued to unrelated third parties, we believe
that the exchange notes may be offered for resale, resold or
otherwise transferred by you without compliance with the
registration and prospectus delivery requirements of the
Securities Act, unless you: |
|
|
|
are an affiliate of Merge Healthcare
Incorporated or any guarantor within the meaning of
Rule 405 under the Securities Act;
|
|
|
|
acquired the exchange notes other than in the
ordinary course of your business;
|
|
|
|
have an arrangement or understanding with any person
to engage in the distribution of the exchange notes; or
|
|
|
|
are engaging in or intend to engage in a
distribution of the exchange notes.
|
|
|
|
If you are a broker-dealer and receive exchange notes for your
own account in exchange for old notes that you acquired as a
result of market-making activities or other trading activities,
you must acknowledge that you will deliver this prospectus in
connection with any resale of the exchange notes. See Plan
of Distribution. |
|
|
|
Any holder of old notes who: |
|
|
|
is an affiliate of Merge Healthcare Incorporated or
any guarantor;
|
|
|
|
does not acquire exchange notes in the ordinary
course of its business; or
|
|
|
|
tenders its old notes in the exchange offer with the
intention to participate, or for the purpose of participating,
in a distribution of exchange notes,
|
7
|
|
|
|
|
cannot rely on the position of the staff of the SEC enunciated
in Morgan Stanley & Co. Incorporated (available
June 5, 1991) and Exxon Capital Holdings Corp.
(available May 13, 1988), as interpreted in the SECs
letter to Shearman & Sterling, publicly available
July 2, 1993, or similar no-action letters and, in the
absence of an exemption therefrom, must comply with the
registration and prospectus delivery requirements of the
Securities Act in connection with any resale of the exchange
notes. |
|
Expiration Date |
|
The exchange offer will expire at 5:00 p.m., Eastern time,
on ,
2011, which we refer to as the expiration date, unless we, in
our sole discretion, extend it. |
|
Conditions to Exchange Offer |
|
The exchange offer is subject to certain conditions, some of
which may be waived by us. See The Exchange
Offer Conditions to the Exchange Offer. |
|
Procedure for Tendering Old Notes |
|
If you wish to accept the exchange offer, you must complete,
sign and date the letter of transmittal, or a copy of the letter
of transmittal, in accordance with the instructions contained in
this prospectus and in the letter of transmittal, and mail or
otherwise deliver the letter of transmittal, or the copy,
together with the old notes and any other required
documentation, to the exchange agent at the address set forth in
this prospectus and in the letter of transmittal. |
|
|
|
If you hold old notes through The Depositary Trust Company,
which we refer to as DTC, and wish to participate in the
exchange offer, you must comply with the Automated Tender Offer
Program procedures of DTC by which you will agree to be bound by
the letter of transmittal. |
|
|
|
By signing, or agreeing to be bound by, the letter of
transmittal, you will represent to us that, among other things: |
|
|
|
you are not an affiliate of Merge
Healthcare Incorporated or any guarantor within the meaning of
Rule 405 under the Securities Act;
|
|
|
|
you are acquiring the exchange notes in the ordinary
course of your business;
|
|
|
|
you do not have an arrangement or understanding with
any person to engage in the distribution of the exchange notes;
|
|
|
|
you are not engaging in or intend to engage in a
distribution of the exchange notes; and
|
|
|
|
if you are a broker-dealer that will receive
exchange notes for your own account in exchange for old notes
that were acquired as a result of market-making activities or
other trading activities, that you will comply with the
applicable provisions of the Securities Act (including, but not
limited to, the prospectus delivery requirements thereunder).
|
|
|
|
We will accept for exchange any and all old notes that are
properly tendered in the exchange offer prior to the expiration
date. The exchange notes issued in the exchange offer will be
delivered |
8
|
|
|
|
|
promptly following the expiration date. See The Exchange
Offer Procedures For Tendering. |
|
Special Procedures for Beneficial Owners |
|
If you are the beneficial owner of old notes registered in the
name of a broker, dealer, commercial bank, trust company or
other nominee and wish to tender in the exchange offer, you
should contact the person in whose name your notes are
registered and instruct the registered holder to tender the old
notes on your behalf. If you wish to tender on your own behalf,
you must, prior to completing and executing the letter of
transmittal and delivering your old notes, either make
appropriate arrangements to register ownership of the old notes
in your name or obtain a properly completed bond power from the
registered holder. The transfer of registered ownership may take
considerable time and may not be able to be completed prior to
the expiration date. See The Exchange Offer
Procedures for Tendering. |
|
Guaranteed Delivery Procedures |
|
If you wish to tender your old notes and your old notes are not
immediately available or you cannot deliver your old notes, the
letter of transmittal or any other required documents, or you
cannot comply with the procedures under DTCs Automated
Tender Offer Program for transfer of book-entry interests, prior
to the expiration date, you must tender your old notes according
to the guaranteed delivery procedures set forth in this
prospectus under The Exchange Offer Guaranteed
Delivery Procedures. |
|
Withdrawal Rights |
|
The tender of the old notes pursuant to the exchange offer may
be withdrawn at any time prior to 5:00 p.m., Eastern time,
on the expiration date. |
|
Acceptance of Old Notes and Delivery of Exchange Notes |
|
Subject to customary conditions, we will accept old notes which
are properly tendered in the exchange offer and not withdrawn
prior to the expiration date. The exchange notes will be
delivered promptly following the expiration date. |
|
Effect of Not Tendering |
|
Any old notes that are not tendered or that are tendered but not
accepted will remain subject to the restrictions on transfer.
Since the old notes have not been registered under the federal
securities laws, they bear a legend restricting their transfer
absent registration or the availability of a specific exemption
from registration. Upon completion of the exchange offer, we
will have no further obligations, except under limited
circumstances, to provide for registration of the old notes
under the federal securities laws. |
|
Interest on the Exchange Notes and the Old Notes |
|
Upon issuance, the exchange notes will bear interest equal to
the accrued and unpaid interest on the old notes. Interest on
the old notes accepted for exchange will cease to accrue upon
the issuance of the exchange notes. |
|
United States Federal Income Tax Consequences |
|
The exchange of old notes for exchange notes by tendering
holders should not be a taxable exchange for federal income tax
purposes. See United States Federal Income Tax
Consequences. |
9
|
|
|
Exchange Agent |
|
The Bank of New York Mellon Trust Company, N.A., the
trustee under the indenture, is serving as exchange agent in
connection with the exchange offer. |
|
Use of Proceeds |
|
We will not receive any proceeds from the issuance of exchange
notes pursuant to the exchange offer. |
Summary
of Terms of Exchange Notes
The summary below describes the principal terms of the exchange
notes. Certain of the terms and conditions described below are
subject to important limitations and exceptions. The
Description of the Exchange Notes section of this
prospectus contains a more detailed description of the terms and
conditions of the exchange notes. The exchange notes will have
terms identical in all material respects to the old notes,
except that the exchange notes will not contain terms with
respect to transfer restrictions, registration rights and
additional interest for failure to observe certain obligations
in the registration rights agreement.
|
|
|
Issuer |
|
Merge Healthcare Incorporated |
|
Notes Offered |
|
The $52,000,000 aggregate principal amount of 11.75% Senior
Secured Notes due 2015 that we issued on June 20, 2011 (the
old notes) constitute a further issuance of the
$200,000,000 aggregate principal amount of 11.75% Senior
Secured Notes due 2015 that we issued on April 28, 2010
(the April 2010 notes) and form a single series of
debt securities with the April 2010 notes. Unless the context
requires otherwise, we refer to the old notes, the exchange
notes and the April 2010 notes together as the notes
or Notes. The old notes have identical terms to the
April 2010 notes (as modified by the consent solicitation
described herein), other than the issue date and offering price
and, following the completion of this exchange offer, the
exchange notes will be fungible with the April 2010 notes. The
aggregate principal amount of notes is $252,000,000.
Accordingly, the $52,000,000 aggregate principal amount of
exchange notes constitute approximately one-fifth of the total
voting power of the $252,000,000 of outstanding notes. |
|
Maturity Date |
|
May 1, 2015. |
|
Interest |
|
Interest will be payable in cash on May 1 and November 1 of each
year, beginning November 1, 2011. |
|
Optional Redemption |
|
At any time on or prior to May 1, 2013, we may redeem any
of the notes at a price equal to 100% of the principal amount of
notes to be redeemed plus an applicable make-whole
premium, plus accrued and unpaid interest, if any, to the
redemption date. |
|
|
|
On or after May 1, 2013, we may redeem the notes, in whole
or in part, at the redemption prices described in this
prospectus, plus accrued and unpaid interest, if any, to the
applicable redemption date. |
|
|
|
In addition, prior to May 1, 2013, we may redeem up to 35%
of the aggregate principal amount of the notes at a redemption
price equal to 111.75%, plus accrued and unpaid interest, if
any, to the redemption date, with the net cash proceeds that we
raise in one or more equity offerings. See Description of
the Exchange Notes Optional Redemption. |
10
|
|
|
Note Guarantees |
|
The notes are fully and unconditionally guaranteed on a senior
secured basis by each of our current and future domestic
restricted subsidiaries. In the future, the note guarantees may
be released or terminated under certain circumstances. See
Description of the Exchange Notes Note
Guarantees. |
|
Collateral |
|
The notes and the note guarantees are secured by first priority
security interests, subject to certain exceptions, in
substantially all of our and the guarantors tangible and
intangible assets whether now owned or hereafter acquired or
arising, and wherever located. See Description of the
Exchange Notes Collateral and Security. |
|
Ranking |
|
The notes: |
|
|
|
are our general senior obligations;
|
|
|
|
are secured on a first-priority lien basis by the
Collateral (as defined in Description of the Exchange
Notes Collateral and Security), subject to
certain exceptions;
|
|
|
|
rank equally in right of payment with all of our
existing and future senior indebtedness;
|
|
|
|
rank senior in right of payment to all of our
existing and future subordinated indebtedness;
|
|
|
|
are structurally subordinated to all the existing
and future indebtedness and other liabilities of our
subsidiaries that are not guarantors; and
|
|
|
|
are guaranteed on a senior secured basis by each
guarantor.
|
|
|
|
Each note guarantee is: |
|
|
|
a general senior obligation of each guarantor;
|
|
|
|
secured on a first-priority lien basis by the
Collateral, subject to certain exceptions;
|
|
|
|
senior in right of payment to all future obligations
of such guarantor that are, by their terms, expressly
subordinated in right of payment to such note guarantee; and
|
|
|
|
pari passu in right of payment with all existing and
future unsecured obligations of such guarantor that are not so
subordinated.
|
|
Change of Control |
|
If a change of control occurs, the holders of the notes will
have the right to require us to repurchase their notes, in whole
or in part, at a repurchase price of 101% of the principal
amount, plus accrued and unpaid interest, if any. See
Description of the Exchange Notes Repurchase
at the Option of Holders. |
|
Certain Covenants |
|
The indenture governing the notes contains covenants that, among
other things, limit our ability and the ability of our
restricted subsidiaries to: |
|
|
|
incur additional indebtedness and issue preferred
stock;
|
|
|
|
pay dividends and make distributions in respect of
capital stock;
|
|
|
|
make investments or certain other restricted
payments;
|
11
|
|
|
|
|
sell assets;
|
|
|
|
enter into transactions with stockholders or
affiliates;
|
|
|
|
issue or sell stock of certain subsidiaries;
|
|
|
|
effect a consolidation or merger; and
|
|
|
|
engage in sale-leaseback transactions.
|
|
|
|
These covenants are subject to a number of important limitations
and exceptions, including the suspension thereof. See
Description of the Exchange Notes Certain
Covenants. |
|
No Public Market |
|
The exchange notes will be freely transferable but will be new
securities for which we expect there will not initially be a
market. Accordingly, we cannot assure you whether a market for
the exchange notes will develop or as to the liquidity of any
market. |
|
Qualified Reopening |
|
The old notes are treated by us as having been issued in a
qualified reopening for United States federal income
tax purposes, and the following discussion assumes such
treatment will be respected. Consequently, the old notes are and
the exchange notes will be part of the same issue as the
April 2010 notes. Because the April 2010 notes were
issued with OID for United States federal income tax purposes,
the old notes and exchange notes also have OID. However, as
discussed in further detail below under United States
Federal Income Tax Considerations U.S.
Holders Amortizable Premium, since the initial
offering price of the old notes is greater than their stated
principal amount, investors who purchased old notes at their
initial offering price will not be required to include any OID
in income for United States federal income tax purposes. See
United States Federal Income Tax Considerations. |
|
Risk Factors |
|
You should carefully consider all of the information set forth
or incorporated by reference in this prospectus and, in
particular, should evaluate the specific risk factors set forth
in the section entitled Risk Factors for an
explanation of certain risks of investing in the notes,
including risks related to our business. |
12
SUMMARY
CONSOLIDATED FINANCIAL DATA
The following table sets forth summary consolidated financial
data of Merge Healthcare Incorporated as of the dates and for
the periods indicated. The summary consolidated financial data
as of and for the years ended December 31, 2010 and
December 31, 2009, and for the year ended December 31,
2008, have been derived from our audited consolidated financial
statements incorporated by reference in this prospectus. The
summary consolidated financial data as of December 31, 2008
has been derived from our audited consolidated financial
statements not included or incorporated by reference in this
prospectus. The summary consolidated financial data as of and
for the six months ended June 30, 2011 and 2010 have been
derived from our unaudited consolidated financial statements as
of such dates and for such periods incorporated by reference in
this prospectus and which, in our opinion, reflect all
adjustments, consisting of normal accruals, necessary for a fair
presentation of the information as of the dates and for such
periods presented. Our results of operations for the six months
ended June 30, 2011 may not be indicative of results
that may be expected for the full year.
The below summary consolidated financial data should be read in
conjunction with the Managements Discussion and
Analysis of Financial Condition and Results of Operations
incorporated by reference herein from our Annual Report on
Form 10-K
for the year ended December 31, 2010 and our Quarterly
Reports on
Form 10-Q
for the periods ended March 31, 2011 and June 30,
2011, as well as our consolidated financial statements and
related notes thereto incorporated by reference in this
prospectus.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended
|
|
|
Years Ended
|
|
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2011
|
|
|
2010
|
|
|
2010(1)
|
|
|
2009(2)
|
|
|
2008
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands, except for share and per share data)
|
|
|
Statement of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
$
|
108,264
|
|
|
$
|
48,973
|
|
|
$
|
140,332
|
|
|
$
|
66,841
|
|
|
$
|
56,735
|
|
Operating income (loss)
|
|
|
13,945
|
|
|
|
(13,778
|
)
|
|
|
(8,524
|
)
|
|
|
8,963
|
|
|
|
(21,697
|
)
|
Income (loss) before income taxes
|
|
|
(403
|
)
|
|
|
(18,007
|
)
|
|
|
(25,162
|
)
|
|
|
150
|
|
|
|
(23,743
|
)
|
Income tax expense (benefit)
|
|
|
2,871
|
|
|
|
106
|
|
|
|
(13,646
|
)
|
|
|
(135
|
)
|
|
|
(60
|
)
|
Net income (loss)
|
|
|
(3,274
|
)
|
|
|
(18,113
|
)
|
|
|
(11,516
|
)
|
|
|
285
|
|
|
|
(23,683
|
)
|
Net income (loss) available to common shareholders
|
|
|
(6,427
|
)
|
|
|
(34,057
|
)
|
|
|
(30,592
|
)
|
|
|
285
|
|
|
|
(23,683
|
)
|
Earnings (loss) per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
(0.08
|
)
|
|
$
|
(0.44
|
)
|
|
$
|
(0.38
|
)
|
|
$
|
0.00
|
|
|
$
|
(0.51
|
)
|
Diluted
|
|
|
(0.08
|
)
|
|
|
(0.44
|
)
|
|
|
(0.38
|
)
|
|
|
0.00
|
|
|
|
(0.51
|
)
|
Weighted average shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
84,277,343
|
|
|
|
77,461,669
|
|
|
|
80,231,427
|
|
|
|
60,910,268
|
|
|
|
46,717,546
|
|
Diluted
|
|
|
84,277,343
|
|
|
|
77,461,669
|
|
|
|
80,231,427
|
|
|
|
62,737,821
|
|
|
|
46,717,546
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended
|
|
|
|
|
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2011
|
|
|
2010
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands)
|
|
|
Balance Sheet Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Working capital
|
|
|
45,964
|
|
|
|
27,074
|
|
|
$
|
28,792
|
|
|
$
|
18,231
|
|
|
$
|
8,254
|
|
Total assets
|
|
|
395,619
|
|
|
|
359,704
|
|
|
|
396,388
|
|
|
|
100,249
|
|
|
|
54,737
|
|
Long-term debt obligations
|
|
|
249,065
|
|
|
|
194,708
|
|
|
|
195,077
|
|
|
|
|
|
|
|
14,230
|
|
Shareholders equity
|
|
|
55,356
|
|
|
|
91,807
|
|
|
|
104,806
|
|
|
|
68,137
|
|
|
|
8,841
|
|
|
|
|
(1) |
|
Includes the results of AMICAS, Inc. (now Merge Healthcare
Solutions Inc.) from April 28, 2010, the date of the
business combination. |
|
(2) |
|
Includes the results of etrials and Confirma from July 20,
2009 and September 1, 2009, the respective dates of the
business combinations. |
13
RISK
FACTORS
You should carefully consider the risks described as well as
the other information contained in this prospectus, as well as
well as the other information included in this prospectus and
the risk factors incorporated by reference into this prospectus
from Part I, Item 1A,Risk Factors of our Annual
Report on Form 10-K for the year ended December 31, 2010 and
from our Quarterly Report on Form 10-Q for the period ended
June 30, 2011, before making a decision to participate in
the exchange offer. The risks described below and incorporated
herein by reference are not the only risks facing us. Additional
risks and uncertainties not currently known to us or that we
currently deem to be immaterial may also materially adversely
affect our business, financial condition or results of
operations. Any of such risks could materially adversely affect
our business, financial condition or results of operations. In
such case, you may lose all or part of your original
investment.
Risks
Related to the Notes
We
have a Substantial Amount of Indebtedness, which could Impact
our Ability to Obtain Future Financing or Pursue our Growth
Strategy.
We have substantial indebtedness. As of June 30, 2011, we
would have had approximately $252.0 million of
indebtedness, before taking into account outstanding letters of
credit, subject to borrowing base limitations and other
specified terms and conditions.
Our high level of indebtedness could have important consequences
to you and significant adverse effects on our business,
including the following:
|
|
|
|
|
we must use a substantial portion of our cash flow from
operations to pay interest on our indebtedness, which will
reduce the funds available to us for operations and other
purposes;
|
|
|
|
our ability to obtain additional financing for working capital,
capital expenditures, acquisitions or general corporate purposes
may be impaired;
|
|
|
|
our high level of indebtedness could place us at a competitive
disadvantage compared to our competitors that may have
proportionately less indebtedness;
|
|
|
|
our flexibility in planning for, or reacting to, changes in our
business and the industry in which we operate may be limited;
|
|
|
|
our high level of indebtedness may make us more vulnerable to
economic downturns and adverse developments in our
business; and
|
|
|
|
our ability to fund a change of control offer may be limited.
|
The indenture governing the notes contains, and the instruments
governing any indebtedness we may incur in the future may
contain, restrictive covenants that limit our ability to engage
in activities that may be in our long-term best interests. Our
failure to comply with these covenants could result in an event
of default which, if not cured or waived, could result in the
acceleration of all or a portion of our outstanding indebtedness.
Payments
on our Indebtedness will Require a Significant Amount of Cash.
Our Ability to Meet our Cash Requirements and Service our
Indebtedness is Impacted by many Factors that are Outside of our
Control.
We expect to obtain the funds to pay our expenses and to pay the
amounts due under the notes primarily from our operations. Our
ability to meet our expenses and make these payments thus
depends on our future performance, which will be affected by
financial, business, economic and other factors, many of which
we cannot control. Our business may not generate sufficient cash
flow from operations in the future and our currently anticipated
growth in revenue and cash flow may not be realized, either or
both of which could result in our being unable to repay
indebtedness, including the notes, or to fund other liquidity
needs. If we do not have sufficient cash resources in the
future, we may be required to refinance all or part of our then
existing indebtedness, sell assets or borrow more money. We
cannot assure you that we will be able to accomplish any
14
of these alternatives on terms acceptable to us or at all. In
addition, the terms of existing or future debt agreements may
restrict us from adopting any of these alternatives. Our failure
to generate sufficient cash flow or to achieve any of these
alternatives could materially adversely affect the value of the
notes and our ability to pay the amounts due under the notes.
See Managements Discussion and Analysis of Financial
Condition and Results of Operations Liquidity and
Capital Resources incorporated by reference herein from
our Annual Report on
Form 10-K
for the year ended December 31, 2010 and our Quarterly
Reports on
Form 10-Q
for the periods ended March 31, 2011 and June 30, 2011.
We may
be Able to Incur Substantial Additional Indebtedness that could
Further Exacerbate the Risks Associated with our
Indebtedness.
We may incur substantial additional indebtedness in the future.
Although the indenture governing the notes will contain
restrictions on our incurrence of additional indebtedness, these
restrictions are subject to a number of qualifications and
exceptions, and we could incur substantial additional
indebtedness, including additional secured indebtedness. If we
incur additional indebtedness, the risks described above under
We have a substantial amount of indebtedness,
which could impact our ability to obtain future financing or
pursue our growth strategy and Payments
on our indebtedness will require a significant amount of cash.
Our ability to meet our cash requirements and service our
indebtedness is impacted by many factors that are outside of our
control would intensify.
Restrictive
Covenants in the Indenture may Limit our Current and Future
Operations, Particularly our Ability to Respond to Changes in
our Business or to Pursue our Business Strategies.
The terms of the indenture governing the notes contain, and any
future indebtedness of ours may contain, a number of restrictive
covenants that impose significant operating and financial
restrictions, including restrictions on our ability to take
actions that we believe may be in our interest. The indenture
among other things, limits our ability to:
|
|
|
|
|
incur additional indebtedness and issue preferred stock;
|
|
|
|
pay dividends on or make distributions in respect of capital
stock;
|
|
|
|
make investments or certain other restricted payments;
|
|
|
|
place limits on dividends and enter into other payment
restrictions affecting certain subsidiaries;
|
|
|
|
enter into transactions with stockholders or affiliates;
|
|
|
|
create or incur liens;
|
|
|
|
enter into sale-leaseback transactions;
|
|
|
|
guarantee indebtedness;
|
|
|
|
merge, consolidate or sell substantially all of our
assets; and
|
|
|
|
issue or sell stock of certain subsidiaries.
|
You should read the discussions under the heading
Description of the Exchange Notes Certain
Covenants for further information about these covenants. A
breach of the covenants or restrictions under the indenture,
could result in a default under the notes. Such default, if not
cured or waived, may allow the noteholders to accelerate the
payment of the notes. In the event noteholders accelerate the
repayment of the notes, we cannot assure you that we and our
subsidiaries would have sufficient assets to repay such
indebtedness.
The restrictions contained in the indenture could adversely
affect our ability to:
|
|
|
|
|
finance our operations;
|
|
|
|
make needed capital expenditures;
|
15
|
|
|
|
|
make strategic acquisitions or investments or enter into
alliances;
|
|
|
|
withstand a future downturn in our business or the economy in
general;
|
|
|
|
engage in business activities, including future opportunities,
that may be in our interest; and
|
|
|
|
plan for or react to market conditions or otherwise execute our
business strategies.
|
Our financial results, our substantial indebtedness and our
credit ratings could adversely affect the availability and terms
of our financing.
The
Value of the Collateral Securing the Notes may not be Sufficient
to Satisfy our Obligations Under the Notes.
The notes and the note guarantees are secured by first priority
liens on the collateral described in this prospectus (subject to
permitted liens), equally and ratably with any future first lien
obligations permitted to be incurred pursuant to the indenture.
No appraisal of the fair market value of the collateral securing
the notes has been made in connection with the offering of the
notes. The book value of the collateral should not be relied on
as a measure of realizable value for such assets. The value of
the collateral could be impaired in the future as a result of
changing economic and market conditions, our failure to
successfully implement our business strategy, competition and
other factors. The collateral may include intangible or other
illiquid assets that by their nature may not have a readily
ascertainable market value or may not be readily saleable or, if
saleable, there may be substantial delays in their liquidation.
Additionally, certain of our assets are held by our foreign
subsidiaries and will not be pledged to secure the notes.
In the event of a liquidation, foreclosure, bankruptcy,
reorganization or similar proceeding, the value of the
collateral and the amount that may be received upon a sale of
collateral will depend upon many factors including, among
others, the condition of the collateral and our industry, the
ability to sell the collateral in an orderly sale, market and
economic conditions, the availability of buyers and other
factors. In addition, courts could limit recoverability with
respect to the collateral if they deem a portion of the interest
claim usurious in violation of applicable public policy. As a
result, liquidating the collateral securing the notes may not
produce proceeds in an amount sufficient to pay any amounts due
on the notes. We cannot assure you of the value of the
collateral or that the net proceeds received upon a liquidation,
foreclosure, bankruptcy, reorganization or similar proceeding
would be sufficient to repay all amounts due on the notes (and
any payments in respect of prior liens).
The
Collateral Securing the Notes may be Diluted Under Certain
Circumstances.
The indenture governing the notes permits us to issue additional
senior secured indebtedness, including priority lien
indebtedness and further additional notes, subject to our
compliance with the restrictive covenants in the indenture
governing the notes at the time we issue such additional senior
secured indebtedness. Any further additional notes issued under
the indenture governing the notes would be guaranteed by the
same guarantors and would have the same security interests, with
the same priority, as currently securing the notes. As a result,
the collateral securing the notes would be shared by any further
additional notes we may issue under the applicable indenture,
and an issuance of such additional notes would dilute the value
of the collateral compared to the aggregate principal amount of
notes issued. In addition, the indenture and our other security
documents permit us and certain of our subsidiaries to incur
additional pari passu secured indebtedness and subordinated lien
indebtedness up to respective maximum pari passu secured
indebtedness threshold amounts by issuing additional debt
securities under one or more new indentures or by borrowing
additional amounts under new credit facilities. Any additional
pari passu secured indebtedness or subordinated lien
indebtedness secured by the collateral would dilute the value of
the noteholders rights to the collateral. The proceeds
from the sale of all such collateral may not be sufficient to
satisfy the amounts outstanding under the notes and all other
indebtedness and obligations secured by such liens.
The terms of the indenture also permit us to incur other
permitted liens on the collateral, whether arising on or after
the date the notes are issued. The existence of any permitted
liens could adversely affect the value of the collateral
securing the notes and the note guarantees as well as the
ability to realize or foreclose on
16
such collateral. To the extent we incur any permitted liens, the
liens of the noteholders may not be first priority.
If such proceeds were not sufficient to repay amounts
outstanding under the notes, then noteholders (to the extent not
repaid from the proceeds of the sale of the collateral) would
only have an unsecured claim against our remaining assets.
The
Notes and the Note Guarantees will be Structurally Subordinated
to Indebtedness and other Liabilities of our Non-Guarantor
Subsidiaries.
All of our domestic subsidiaries will guarantee the notes but
none of our foreign subsidiaries will guarantee the notes. The
notes and the note guarantees will be structurally subordinated
to the indebtedness and other liabilities of our non-guarantor
subsidiaries, and noteholders will not have any claim as a
creditor against any such non-guarantor subsidiary. In addition,
subject to certain limitations, the indenture governing the
notes will permit our non-guarantor subsidiaries to incur
additional indebtedness. In the event of a liquidation,
foreclosure, bankruptcy, reorganization or similar proceeding of
any non-guarantor subsidiary, holders of their indebtedness and
their trade creditors will generally be entitled to payment of
their claims from the assets of those entities before any assets
are made available for distribution to us.
Rights
of Noteholders in the Collateral may be Adversely Affected by
the Failure to Perfect Security Interests in
Collateral.
Applicable law requires that a security interest in certain
tangible and intangible assets can only be properly perfected
and its priority retained through certain actions undertaken by
the secured party. The liens on the collateral may not be
perfected with respect to the notes and the note guarantees if
the collateral agent is not able to or does not take the actions
necessary to perfect any such liens. In addition, applicable law
requires that certain property and rights acquired after the
grant of a general security interest can only be perfected at
the time such property and rights are acquired and identified.
There can be no assurance that the collateral agent will
monitor, or that we will inform the collateral agent of, the
future acquisition of property and rights that constitute
collateral, and that the necessary action will be taken to
properly perfect the security interest in such after-acquired
collateral. The collateral agent has no obligation to monitor
the acquisition of additional property or rights that constitute
collateral or the perfection of any security interest therein.
Such failure may result in the loss of the security interest in
the collateral or the priority of the security interest in favor
of the notes and the note guarantees against third parties.
Additionally, the indenture and the security documents entered
into in connection with the notes do not require us to take a
number of actions that might improve the perfection or priority
of the liens of the collateral agent in the collateral. With
limited exceptions, such actions will be limited to (i) the
filing of UCC-1 financing statements in the jurisdiction of
incorporation of us and the guarantors, (ii) the granting
of mortgages over owned real properties to the extent described
under Description of the Exchange Notes
Collateral and Security, (iii) the delivery of stock
certificates of domestic and up to 65% of first-tier foreign
subsidiaries, (iv) the entry into control agreements over
certain deposit accounts and securities accounts, (v) the
filing of a notice with the U.S. Patent and Trademark
Office of the U.S. Copyright Office, and (vi) the
delivery of debt instruments in favor of us or the guarantors.
To the extent that the security interests created by the
security documents with respect to any collateral are not
perfected, the collateral agents rights will be equal to
the rights of general unsecured creditors in the event of a
liquidation, foreclosure, bankruptcy, reorganization or similar
proceeding.
There
are Certain Categories of Property that are Excluded from the
Collateral.
The collateral securing the notes and the note guarantees
excludes certain assets, generally as a result of applicable
laws, or the terms of existing agreements. Property not included
in the collateral will include:
|
|
|
|
|
rights in any property if the grant of a security interest in
such property is prohibited by any law, treaty, rule or
regulation or determination of an arbitrator or a court or other
governmental authority or
|
17
|
|
|
|
|
constitutes a breach or default under or results in the
termination of, or requires any consent not obtained under, any
lease, license or agreement;
|
|
|
|
|
|
property and assets in which a lien may not be granted without
governmental approval or consent;
|
|
|
|
any U.S. Trademark applications filed on the basis of our
or any guarantors
intent-to-use
such mark if the granting of a security interest in such
application would result in the invalidation of such application;
|
|
|
|
property and assets owned by us or any guarantor which are
located outside of the U.S. to the extent a lien on such
property and assets cannot be perfected by the filing of UCC
financing statements in our jurisdictions of organization or
that of such Guarantor;
|
|
|
|
any capital stock of any first-tier foreign subsidiary in excess
of 65% of the capital stock of such foreign subsidiary and any
capital stock of any direct or indirect subsidiaries of a
foreign subsidiary;
|
|
|
|
leasehold interests in real property;
|
|
|
|
motor vehicles and other assets in which a security interest may
be perfected only through compliance with a certificate of title
or similar statute;
|
|
|
|
certain other items agreed by the parties and as more fully set
forth in the security documents;
|
|
|
|
interests in any owned real property with values of
$1.0 million or less; and
|
|
|
|
proceeds and products of any and all of the foregoing excluded
property and assets described above only to the extent that such
proceeds and products would constitute property or assets of the
type described above.
|
Rights
of Noteholders in the Collateral may be Adversely Affected by
Bankruptcy Proceedings.
The right of the collateral agent to repossess and dispose of
the collateral upon the occurrence of an event of default under
the indenture is likely to be significantly impaired by
applicable bankruptcy law if a bankruptcy case were to be
commenced by or against us or any guarantor before, or possibly
after, the collateral agent repossessed and disposed of the
collateral. Upon the commencement of a case under the bankruptcy
code, a secured creditor such as the collateral agent is
prohibited from repossessing its security from a debtor in a
bankruptcy case, or from disposing of security repossessed from
such debtor, without bankruptcy court approval, which may not be
given. Moreover, the bankruptcy code permits the debtor to
continue to retain and use collateral even though the debtor is
in default under the applicable debt instruments, provided that
the secured creditor is given adequate protection.
The meaning of the term adequate protection may vary
according to circumstances, but it is intended in general to
protect the value of the secured creditors interest in the
collateral as of the commencement of the bankruptcy case and may
include cash payments or the granting of additional security if
and at such times as the bankruptcy court in its discretion
determines that the value of the secured creditors
interest in the collateral is declining during the pendency of
the bankruptcy case. A bankruptcy court may determine that a
secured creditor may not require compensation for a diminution
in the value of its collateral if the value of the collateral
exceeds the debt it secures. In view of the broad discretionary
power of a bankruptcy court, it is impossible to predict how
long payments under the notes could be delayed following
commencement of a bankruptcy case; whether or when the
collateral agent could repossess or dispose of the collateral;
or whether or to what extent noteholders would be compensated
for any delay in payment or loss of value of the collateral
through the requirement of adequate protection.
Any disposition of the collateral during a bankruptcy case would
also require permission from the bankruptcy court. Furthermore,
in the event a bankruptcy court determines the value of the
collateral is not sufficient to repay all amounts due on the
notes, the noteholders would hold a secured claim only to the
extent of the value of the collateral to which the noteholders
are entitled and unsecured claims with respect to such
shortfall. The bankruptcy code only permits the payment and
accrual of post-petition interest, costs and attorneys
fees to a secured creditor during a debtors bankruptcy
case to the extent the value of its collateral
18
is determined by the bankruptcy court to exceed the aggregate
outstanding principal amount of the obligations secured by the
collateral.
A
Court could Void our Subsidiaries Guarantees of the Notes
Under Fraudulent Transfer Laws.
Although the note guarantees provide you with a direct claim
against the assets of the subsidiary guarantors, under the
federal bankruptcy laws and comparable provisions of state
fraudulent transfer laws, or bankruptcy laws in other applicable
jurisdictions, a note guarantee could be voided, or claims with
respect to a note guarantee could be subordinated to all other
debts of that guarantor. In addition, a bankruptcy court could
void (i.e., cancel) any payments by that guarantor pursuant to
its note guarantee and require those payments to be returned to
the guarantor or to a fund for the benefit of the other
creditors of the guarantor.
The bankruptcy court might take these actions if it found, among
other things, that when a subsidiary guarantor executed its note
guarantee (or, in some jurisdictions, when it became obligated
to make payments under its note guarantee):
|
|
|
|
|
such subsidiary guarantor received less than reasonably
equivalent value or fair consideration for the incurrence of its
note guarantee; and
|
|
|
|
such subsidiary guarantor:
|
|
|
|
|
|
was (or was rendered) insolvent by the incurrence of the note
guarantee;
|
|
|
|
was engaged or about to engage in a business or transaction for
which its assets constituted unreasonably small capital to carry
on its business;
|
|
|
|
intended to incur, or believed that it would incur, obligations
beyond its ability to pay as those obligations matured; or
|
|
|
|
was a defendant in an action for money damages, or had a
judgment for money damages docketed against it and, in either
case, after final judgment, the judgment was unsatisfied.
|
A bankruptcy court would likely find that a subsidiary guarantor
received less than fair consideration or reasonably equivalent
value for its note guarantee to the extent that it did not
receive any direct or indirect benefits from the issuance of the
notes. A bankruptcy court could also void a note guarantee if it
found that the subsidiary issued its note guarantee with actual
intent to hinder, delay, or defraud creditors.
Although courts in different jurisdictions measure solvency
differently, in general, an entity would be deemed insolvent if
the sum of its debts, including contingent and unliquidated
debts, exceeds the fair value of its assets, or if the present
fair salable value of its assets is less than the amount that
would be required to pay the expected liability on its debts,
including contingent and unliquidated debts, as they become due.
If a court voided a note guarantee, it could require that
noteholders return any amounts previously paid under such note
guarantee. If any note guarantee were voided, noteholders would
retain their rights against us and any other subsidiary
guarantors, although there is no assurance that those
entities assets would be sufficient to pay the notes in
full.
Any
Future Pledge of Collateral Might be Avoidable in
Bankruptcy.
Any future pledge of collateral in favor of the collateral
agent, including pursuant to security documents delivered after
the date of the indenture governing the notes, might be
avoidable by the pledgor (as debtor in possession) or by its
trustee in bankruptcy if certain events or circumstances exist
or occur, including, among others, if the pledgor is insolvent
at the time of the pledge, the pledge permits the noteholders to
receive a greater recovery than if the pledge had not been given
and a bankruptcy proceeding in respect of the pledgor is
commenced within 90 days following the pledge, or, in
certain circumstances, a longer period.
19
The
Collateral is Subject to Casualty Risks.
The indenture governing the notes and the security documents
requires us and the guarantors to maintain adequate insurance or
otherwise insure against risks to the extent customary with
companies in the same or similar business operating in the same
or similar locations. There are, however, certain losses,
including losses resulting from terrorist acts, that may be
either uninsurable or not economically insurable, in whole or in
part. As a result, we cannot assure you that the insurance
proceeds will compensate us fully for our losses. If there is a
total or partial loss of any of the collateral securing the
notes, we cannot assure you that any insurance proceeds received
by us will be sufficient to satisfy all the secured obligations,
including the notes.
There
are Circumstances other than Repayment or Discharge of the Notes
Under which the Collateral Securing the Notes will be Released
Automatically, without Consent of the Trustee or
Noteholders.
Under various circumstances, collateral securing the notes will
be released automatically, including:
|
|
|
|
|
with respect to collateral owned by a guarantor, upon the
release of such guarantor from its note guarantee;
|
|
|
|
upon a disposition of such collateral in a transaction not
prohibited under the indenture;
|
|
|
|
with respect to any particular item of collateral, assuming the
notes do not constitute the largest class of outstanding pari
passu secured obligations at such time, upon release by the
authorized representative for the largest class of outstanding
pari passu secured obligations at such time of the liens on such
item of collateral and the concurrent release of the liens on
such item securing any other pari passu secured
obligations; or
|
|
|
|
if such property or other asset is or becomes an excluded asset
pursuant to the security documents.
|
The indenture governing the notes permits us to designate one or
more of our restricted subsidiaries that is a guarantor as an
unrestricted subsidiary. If we designate a guarantor that is a
subsidiary as an unrestricted subsidiary for purposes of the
indenture, all of the liens on any collateral owned by such
subsidiary or any of its subsidiaries, and any guarantees of the
notes by such subsidiary or any of its subsidiaries, will be
released under the indenture. Designation of an unrestricted
subsidiary will reduce the aggregate value of the collateral
securing the notes to the extent that liens on the assets of the
unrestricted subsidiary and its subsidiaries are released. In
addition, the creditors of the unrestricted subsidiary and its
subsidiaries will have a senior claim on the assets of such
unrestricted subsidiary and its subsidiaries.
Any of these events will reduce the aggregate value of the
collateral securing the notes.
We
will in Most Cases have Control over the Collateral, and the
Sale of Particular Assets by us could Reduce the Pool of Assets
Securing the Notes and the Note Guarantees.
The security documents allow us to remain in possession of,
retain exclusive control over, freely operate, and collect,
invest and dispose of any income from, the collateral securing
the notes and the note guarantees. So long as no default or
event of default under the indenture would result therefrom, we
may, among other things, without any release or consent by the
collateral agent, conduct ordinary course activities with
respect to collateral, such as selling, factoring, abandoning or
otherwise disposing of collateral and making ordinary course
cash payments (including repayments of indebtedness). To the
extent that additional indebtedness and obligations are secured
by the collateral, our control over the collateral may be
diminished.
You
may have Limited Rights to Enforce Remedies Under the Security
Documents, and the Collateral may be Released without your
Consent in Certain Circumstances.
If we issue additional pari passu secured indebtedness, subject
to our compliance with the restrictive covenants in the
indenture governing the notes at the time we issue such
additional senior secured indebtedness, the collateral agent
will enter into an intercreditor agreement with the collateral
agent for the holders of such additional pari passu secured
indebtedness. Under the terms of the intercreditor agreement,
the collateral agent will pursue remedies and take other action
related to the collateral, including the release
20
thereof, pursuant to the direction of the authorized
representative for the holders of the largest class of
outstanding obligations secured by liens on the collateral,
including the notes. There can be no assurance that the notes
will always represent the largest class of obligations secured
by liens on the collateral. Accordingly, noteholders may not
always have the right to control the remedies and the taking of
other actions related to the collateral. In addition, all
collateral sold or otherwise disposed of in accordance with the
terms of the documents governing the pari passu secured
obligations will automatically be released from the lien
securing the notes and the lien securing the other pari passu
secured obligations. Accordingly, any such sale or other
disposition in a transaction that does not violate the asset
disposition covenant of the indenture governing the notes may
result in a release of the collateral subject to such sale or
disposition. See Description of the Exchange
Notes Limitation on Asset Sales. Under the
intercreditor agreement, the collateral agent may not object
following the filing of a bankruptcy petition to any
debtor-in-possession
financing or to the use of the shared collateral to secure that
financing, subject to conditions and limited exceptions, if at
such time the notes are not the largest class of outstanding
obligations secured by liens on the collateral. After such a
filing, the value of the collateral could materially depreciate,
and the noteholders would be unable to raise an objection.
The
Value of the Collateral Securing the Notes may not be Sufficient
to Secure Post-Petition Interest.
In the event of a bankruptcy proceeding against us or any
guarantor, the noteholders will be entitled to post-petition
interest, costs and attorneys fees under the bankruptcy
code to the extent the value of their security interest in the
collateral (which would be determined after taking into
consideration, among other things, any equal ranking or prior
ranking lien claims in the collateral) is greater than their
pre-bankruptcy claim. The noteholders that have a security
interest in the collateral with a value equal to or less than
their pre-bankruptcy claim will not be entitled to post-petition
interest, costs and attorneys fees under the bankruptcy
code. The bankruptcy trustee, the
debtor-in-possession
or competing creditors could possibly assert that the fair
market value of the collateral with respect to the notes on the
date of the bankruptcy filing was less than the then-current
principal amount of the notes. Upon a finding by a bankruptcy
court that the notes are under collateralized, the claims in the
bankruptcy proceeding with respect to the notes would be
bifurcated between a secured claim and an unsecured claim, and
the unsecured claim would not be entitled to the benefits of
security in the collateral. No appraisal of the fair market
value of the collateral securing the notes has been prepared in
connection with the offering of the notes and, therefore, the
value of the collateral agents interest in the collateral
may not equal or exceed the principal amount of the notes. We
cannot assure you that there will be sufficient collateral to
satisfy our and the guarantors obligations under the notes.
We may
not be Able to Fulfill our Repurchase Obligations with Respect
to the Notes Upon a Change of Control or an Asset
Sale.
If we experience certain change of control events, we are
required by the indenture governing the notes to offer to
repurchase all outstanding notes at a repurchase price equal to
101% of the principal amount of notes repurchased, plus accrued
and unpaid interest and special interest, if any, to the
applicable repurchase date. In addition, under certain
circumstances, if we sell assets and fail to apply the net
proceeds therefrom as provided in the indenture, we must offer
to repurchase the notes at a repurchase price equal to 100% of
the principal amount of the notes repurchased, plus accrued and
unpaid interest and special interest, if any, to the applicable
repurchase date. The instruments governing our future
indebtedness may also provide that certain change of control
events or asset sales will constitute events of default
thereunder. Such defaults could result in amounts outstanding
under such other indebtedness becoming immediately due and
payable.
If a change of control event or an asset sale were to occur, we
cannot assure you that we would have sufficient funds to repay
any notes that we would be required to offer to purchase or that
would become immediately due and payable as a result of such
change of control event or asset sale. We may require additional
financing from third parties to fund any such repurchases, and
we cannot assure you that we would be able to obtain additional
financing on satisfactory terms or at all. Our failure to repay
noteholders who tender notes for repurchase following a change
of control event could result in an event of default under the
indenture governing the notes. Any future indebtedness to which
we become a party may also prohibit us from purchasing notes. If
a change of control event or an asset sale occurs at a time when
we are prohibited from
21
purchasing notes, we may have to either seek the consent of the
applicable lenders to the purchase of notes or attempt to
refinance the borrowings that contain such prohibition. Our
failure to obtain such a consent or to refinance such borrowings
may preclude us from purchasing tendered notes and trigger an
event of default under the indenture governing the notes, which
may, in turn, constitute a default under other indebtedness.
Noteholders
may not be Able to Determine when a Change of Control Giving
Rise to Mandatory Repurchase Rights has Occurred Following a
Sale of Substantially All of our Assets and our
Restricted Subsidiaries Assets.
The definition of change of control in the indenture governing
the notes includes a phrase relating to the direct or indirect
sale, transfer, conveyance or other disposition of all or
substantially all of our assets and our restricted
subsidiaries assets. There is no precise established
definition of the phrase substantially all under
applicable law. Accordingly, the ability of a noteholder to
require us to repurchase notes as a result of a sale, transfer,
conveyance, assignment or other disposition of less than all of
our assets and our restricted subsidiaries assets to
another individual, group or entity may be uncertain.
No
Active Trading Market Exists for the Notes and, if an Active
Trading Market for the Notes does not Develop, you may not be
Able to Resell Them.
The notes are a new issue of securities for which there is
currently no public market. We do not intend to file an
application to have the notes listed on any securities exchange
or included for quotation on any automated dealer quotation
system. There is no established public trading market for the
notes, and an active trading market may not develop. If no
active trading market develops, you may not be able to resell
your notes at their fair market value or at all. Future trading
prices of the notes will depend on many factors, including,
among other things, our ability to effect the exchange offer,
prevailing interest rates, our financial condition and results
of operations, the volume of noteholders and the market for
similar securities. The initial purchaser has advised us that it
intends to make a market in the notes, but it is not obligated
to do so. The initial purchaser may discontinue any market
making in the notes at any time, in its sole discretion.
In the past, the market for debt securities has been subject to
disruptions that have caused substantial volatility in the
prices of securities similar to the notes. We cannot assure you
that the market, if any, for the notes will be free from similar
disruptions or that any such disruptions may not adversely
affect the prices at which noteholders may sell their notes.
If a
Bankruptcy Petition were Filed by or Against us, Holders of
Notes may Receive A Lesser Amount for their Claim than they
would have been Entitled to Receive Under the Indenture
Governing the Notes.
If a bankruptcy petition were filed by or against us under the
U.S. Bankruptcy Code, the claim by any holder of the notes
for the principal amount of the notes may be limited to an
amount equal to the sum of:
|
|
|
|
|
the original issue price for the notes; and
|
|
|
|
that portion of the original issue discount that does not
constitute unmatured interest for purposes of the
U.S. Bankruptcy Code.
|
Any original issue discount that was not amortized as of the
date of the bankruptcy filing would constitute unmatured
interest. Accordingly, holders of the notes under these
circumstances may receive a lesser amount than they would be
entitled to receive under the terms of the indenture governing
the notes, even if sufficient funds are available.
22
Risks
Related to our Recently Completed Acquisition of OIS
We may
be unable to Integrate OIS Operations Successfully or to
Achieve Expected Cost Savings and Unanticipated Costs Relating
to the OIS Acquisition could Reduce our Future Earnings Per
Share.
On August 4, 2011, we consummated our acquisition of OIS.
Our earnings, financial condition and prospects after the
acquisition of OIS will depend in part on our ability to
integrate the operations and management of OIS and to continue
to implement OIS business plan. Among the issues that we
could face in such integration are:
|
|
|
|
|
unexpected problems with operations, personnel, technology or
credit;
|
|
|
|
loss of customers and employees of OIS;
|
|
|
|
potential difficulty in working with OIS employees and
customers;
|
|
|
|
the assimilation of OIS operations, sites and
personnel; and
|
|
|
|
instituting and maintaining uniform standards, controls,
procedures and policies.
|
Even if the integration of OIS is successful, it may not result
in the realization of the full benefits of the synergies and
growth opportunities that we currently expect or these benefits
may not be achieved within the anticipated time frame. Any
failure to timely realize these anticipated benefits could have
a material adverse effect on our revenues, expenses and
operating results.
Further, although we anticipate cost savings as a result of the
acquisition, we may not be fully able to realize those savings.
Any cost savings which are realized may be offset by losses in
revenues or other charges to earnings.
We believe that we have reasonably estimated the likely costs of
integrating the operations of OIS into our business and the
incremental costs of operating as a combined company. However,
it is possible that unexpected transaction costs or future
operating expenses, as well as other types of unanticipated
adverse developments, could have a material adverse effect on
our results of operations and financial condition. If unexpected
costs are incurred, the acquisition could have a dilutive effect
on our earnings per share, meaning earnings per share could be
less than if the acquisition had not been completed.
FORWARD-LOOKING
STATEMENTS
This prospectus contains and incorporates by reference
forward-looking statements regarding our anticipated financial
condition, results of operations and business in the future,
including expectations, beliefs, projections, future plans and
strategies and assumptions concerning future results and events.
These forward-looking statements generally may, but do not
necessarily, include words such as believes,
expects, anticipates,
intends, plans, estimates,
may, will, should,
could, predicts, potential,
continues or similar expressions. Forward-looking
statements are not guarantees. They involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed
or implied by the forward-looking statements. Our future results
may differ materially from those expressed in these
forward-looking statements. For a more detailed description of
some of these risks and uncertainties and other factors you
should consider before participating in the exchange offer, see
Risk Factors in this prospectus.
These risks and uncertainties include, but are not limited to
our ability to maintain the technological competitiveness of our
current products, develop new products, successfully market our
products, respond to competitive developments, develop and
maintain partnerships with providers of complementary
technologies, manage our costs and the challenges that may come
with growth of our business, and attract and retain qualified
sales, technical and management employees. We are also affected
by the growth and regulation of the medical technology industry,
including the acceptance of enterprise-wide advanced
visualization by hospitals, clinics, and universities, product
clearances and approvals by the United States Food and Drug
Administration and similar regulatory bodies outside the U.S.,
and reimbursement and regulatory practices by Medicare,
Medicaid, and private third-party payer organizations. We are
also affected by recent downturns in
23
the U.S. and international economies and, as such, may be
further impacted by the lack of credit available to our
customers.
Except as required by applicable law, including the securities
laws of the United States and the rules and regulations of the
SEC, we do not undertake any obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise to reflect actual
results or changes in factors or assumptions affecting such
forward-looking statements.
USE OF
PROCEEDS
We will not receive any proceeds from the issuance of the
exchange notes in the exchange offer. This exchange offer is
intended to satisfy our obligations under the registration
rights agreement, dated as of June 20, 2011, by and among
us, the guarantors party thereto, and the initial purchaser of
the old notes. In return for issuance of the exchange notes, we
will receive in exchange old notes in like principal amount. We
will retire or cancel all of the old notes tendered in the
exchange offer.
On June 20, 2011, we issued and sold the old notes. We used
the proceeds from the offering of the old notes to, among other
things, (i) redeem and retire our Series A Non-Voting Preferred
Stock that we issued in the AMICAS, Inc. (now Merge Healthcare
Solutions Inc.) transaction, (ii) pay the consent payments in
connection with the Solicitation required to permit the issuance
of the old notes being registered for exchange hereby and
(iii) pay related fees and expenses.
24
CAPITALIZATION
The following table sets forth our capitalization as of
June 30, 2011, which includes the following transactions:
|
|
|
|
|
the sale of the old notes and our receipt of approximately
$50.8 million of net proceeds; and
|
|
|
|
the redemption and retirement of our Series A Non-Voting
Preferred Stock, payment of consent payments in connection with
the related Solicitation and payment of related fees and
expenses.
|
This information should be read in conjunction with Use of
Proceeds herein and the sections entitled
Managements Discussion and Analysis of Financial
Condition and Results of Operations incorporated by
reference herein from our Annual Report on
Form 10-K
for the year ended December 31, 2010 and our Quarterly
Reports on
Form 10-Q
for the periods ended March 31, 2011 and June 30,
2011, as well as the historical consolidated financial
statements and related notes thereto of Merge Healthcare
Incorporated included elsewhere and incorporated by reference in
this prospectus.
Capitalization
|
|
|
|
|
|
|
As of
|
|
|
|
June 30, 2011
|
|
|
|
(Unaudited)
|
|
|
|
(In thousands)
|
|
|
Cash and cash equivalents
|
|
$
|
45,234
|
|
|
|
|
|
|
Total long-term debt, less current maturities
|
|
|
249,065
|
|
Total stockholders equity
|
|
|
55,356
|
|
|
|
|
|
|
Total capitalization
|
|
$
|
304,421
|
|
|
|
|
|
|
25
SELECTED
CONSOLIDATED FINANCIAL DATA
The following table sets forth selected historical consolidated
financial data of Merge Healthcare Incorporated as of the dates
and for the periods indicated. The selected historical
consolidated financial data as of and for the years ended
December 31, 2010, and December 31, 2009, and for the
year ended December 31, 2008, have been derived from our
audited historical consolidated financial statements
incorporated by reference into this prospectus. The selected
historical consolidated financial data as of December 31,
2008, and as of and for the years ended December 31, 2007,
and December 31, 2006, have been derived from our audited
historical consolidated financial statements not included or
incorporated by reference into this prospectus. The selected
historical consolidated financial data as of and for the
six months ended June 30, 2011 and 2010 have been
derived from our unaudited consolidated financial statements as
of such dates and for such periods incorporated by reference
into this prospectus; and which, in our opinion, reflect all
adjustments, consisting of normal accruals, necessary for a fair
presentation of the information as of the dates and for such
periods presented. Our results of operations for the
six months ended June 30, 2011 may not be
indicative of results that may be expected for the full year.
The below selected historical consolidated financial data should
be read in conjunction with the Managements
Discussion and Analysis of Financial Condition and Results of
Operations incorporated by reference herein form our
Annual Report on Form 10-K for the year ended December 31,
2010 and our Quarterly Reports on Form 10-Q for the periods
ended March 31, 2011 and June 30, 2011, as well as our
consolidated financial statements and related notes thereto
incorporated by reference into this prospectus.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30,
|
|
|
Years Ended December 31,
|
|
|
|
2011
|
|
|
2010
|
|
|
2010(1)
|
|
|
2009(2)
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(Unaudited)
|
|
|
(In thousands, except for share and per share data)
|
|
|
Statement of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
$
|
108,264
|
|
|
$
|
48,973
|
|
|
$
|
140,332
|
|
|
$
|
66,841
|
|
|
$
|
56,735
|
|
|
$
|
59,572
|
|
|
$
|
74,322
|
|
Operating income (loss)(3)
|
|
|
13,945
|
|
|
|
(13,778
|
)
|
|
|
(8,524
|
)
|
|
|
8,963
|
|
|
|
(21,697
|
)
|
|
|
(171,238
|
)
|
|
|
(252,087
|
)
|
Income (loss) before income taxes
|
|
|
(403
|
)
|
|
|
(18,007
|
)
|
|
|
(25,162
|
)
|
|
|
150
|
|
|
|
(23,743
|
)
|
|
|
(171,808
|
)
|
|
|
(249,473
|
)
|
Income tax expense (benefit)
|
|
|
2,871
|
|
|
|
106
|
|
|
|
(13,646
|
)
|
|
|
(135
|
)
|
|
|
(60
|
)
|
|
|
(240
|
)
|
|
|
9,450
|
|
Net income (loss)
|
|
|
(3,274
|
)
|
|
|
(18,113
|
)
|
|
|
(11,516
|
)
|
|
|
285
|
|
|
|
(23,683
|
)
|
|
|
(171,568
|
)
|
|
|
(258,923
|
)
|
Less: Preferred stock dividends
|
|
|
3,153
|
|
|
|
15,944
|
|
|
|
19,076
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) available to common shareholders
|
|
|
(6,427
|
)
|
|
|
(34,057
|
)
|
|
|
(30,592
|
)
|
|
|
285
|
|
|
|
(23,683
|
)
|
|
|
(171,568
|
)
|
|
|
(258,923
|
)
|
Earnings (loss) per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
(0.08
|
)
|
|
$
|
(0.44
|
)
|
|
$
|
(0.38
|
)
|
|
$
|
0.00
|
|
|
$
|
(0.51
|
)
|
|
$
|
(5.06
|
)
|
|
$
|
(7.68
|
)
|
Diluted
|
|
|
(0.08
|
)
|
|
|
(0.44
|
)
|
|
|
(0.38
|
)
|
|
|
0.00
|
|
|
|
(0.51
|
)
|
|
|
(5.06
|
)
|
|
|
(7.68
|
)
|
Weighted average shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
84,277,343
|
|
|
|
77,461,669
|
|
|
|
80,231,427
|
|
|
|
60,910,268
|
|
|
|
46,717,546
|
|
|
|
33,913,379
|
|
|
|
33,701,735
|
|
Diluted
|
|
|
84,277,343
|
|
|
|
77,461,669
|
|
|
|
80,231,427
|
|
|
|
62,737,821
|
|
|
|
46,717,546
|
|
|
|
33,913,379
|
|
|
|
33,701,735
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2011
|
|
|
2010
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(Unaudited)
|
|
|
(In thousands)
|
|
|
Balance Sheet Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Working capital
|
|
$
|
45,964
|
|
|
$
|
27,074
|
|
|
$
|
28,792
|
|
|
$
|
18,231
|
|
|
$
|
8,254
|
|
|
$
|
878
|
|
|
$
|
27,101
|
|
Total assets
|
|
|
395,619
|
|
|
|
359,704
|
|
|
|
396,388
|
|
|
|
100,249
|
|
|
|
54,737
|
|
|
|
61,635
|
|
|
|
234,875
|
|
Long-term debt obligations
|
|
|
249,065
|
|
|
|
194,708
|
|
|
|
195,077
|
|
|
|
|
|
|
|
14,230
|
|
|
|
|
|
|
|
|
|
Shareholders equity
|
|
|
55,356
|
|
|
|
91,807
|
|
|
|
104,806
|
|
|
|
68,137
|
|
|
|
8,841
|
|
|
|
24,405
|
|
|
|
189,925
|
|
|
|
|
(1) |
|
Includes the results of AMICAS, Inc. (now Merge Healthcare
Solutions Inc.) from April 28, 2010, the date of the
business combination. |
|
(2) |
|
Includes the results of etrials and Confirma from July 20,
2009 and September 1, 2009, the respective dates of the
business combinations. |
|
(3) |
|
For the years ended December 31, 2007 and 2006, we incurred
charges of $122.4 million and $214.1 million,
respectively, related to the impairment of goodwill. |
26
RATIO OF
EARNINGS TO FIXED CHARGES
The following table sets forth the ratio of earnings to fixed
charges of Merge Healthcare Incorporated for the periods
indicated:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30,
|
|
Year Ended December 31,
|
|
|
2011
|
|
2010
|
|
2010
|
|
2009
|
|
2008
|
|
2007
|
|
2006
|
|
Ratio of Earnings to Fixed Charges
|
|
|
NA
|
|
|
|
NA
|
|
|
|
NA
|
|
|
|
1.0
|
|
|
|
NA
|
|
|
|
NA
|
|
|
|
NA
|
|
Dollar amount of deficiency (in thousands)
|
|
$
|
(403
|
)
|
|
$
|
(18,007
|
)
|
|
$
|
(25,162
|
)
|
|
|
NA
|
|
|
$
|
(23,743
|
)
|
|
$
|
(171,808
|
)
|
|
$
|
(249,473
|
)
|
For purposes of computing these ratios, earnings consists of
pre-tax income from continuing operations plus fixed charges.
Fixed charges consist of interest expense (including
amortization of debt issuance premiums, discounts and issuance
costs) and interest portion of rental expense. The ratio is
calculated by dividing earnings by the sum of the fixed charges.
The interest portion of rental expense is estimated at 23% of
rental expense based on net present value analysis.
For further information on the Ratio of Earnings to Fixed
Charges, see Exhibit 12.1, Computation of Ratio of
Earnings to Fixed Charges, filed herewith.
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
Merrick RIS, LLC (Merrick) beneficially owns, as of
August 5, 2011, 37.7% of our outstanding Common Stock
(including 250,000 shares of Common Stock which may be
acquired upon the exercise of stock options which are currently
exercisable or exercisable within sixty (60) days by
Michael W. Ferro, Jr.). Michael W. Ferro, Jr., the
Companys Chairman of the Board, and trusts for the benefit
of Mr. Ferros family members beneficially own a
majority of the equity interests in Merrick. Mr. Ferro also
serves as the chairman and chief executive officer of Merrick.
Accordingly, Mr. Ferro indirectly controls all of the
shares of Common Stock owned by Merrick.
In January of 2009, we entered into a Consulting Agreement with
Merrick which was effective as of January 1, 2009, had a
one (1) year term and which allowed us to take advantage of
certain consulting services offered by Merrick to us. These
services included, but were not limited to, investor relations,
financial analysis and strategic planning. Effective on
January 1, 2010, we and Merrick entered into an amendment
to extend the term of this Consulting Agreement through
December 31, 2011, and modified the payment terms from a
flat fee arrangement per quarter to a per transaction or success
based arrangement. Our Audit Committee considered the amendment
to the Consulting Agreement prior to its execution and approved
its terms. The fees under the Consulting Agreement in 2010 were
approximately $1,050,000.
In addition, as a result of the completion of the acquisition of
AMICAS, Inc. (now Merge Healthcare Solutions Inc.), we paid a
$1.0 million success fee to Merrick in April 2010.
Merrick also subscribed for and purchased 1.8 million
shares of our Common Stock and 10,000 shares of our
Series A Non-Voting Preferred Stock in the private
placement that funded a portion of our acquisition of AMICAS,
Inc. (now Merge Healthcare Solutions Inc.). These shares were
purchased by Merrick at the same purchase price per share of
Common Stock and per share of Series A Non-Voting Preferred
Stock paid by the other investors in the private placement. The
Series A Non-Voting Preferred Stock was redeemed on
June 20, 2011 as described in Prospectus
Summary Recent Developments Consent
Solicitation and Redemption of Series A Non-Voting
Preferred Stock.
On July 30, 2010, we entered into an Asset Purchase
Agreement with Merrick Healthcare Solutions, LLC, a subsidiary
of Merrick Ventures, pursuant to which we acquired substantially
all of the assets related to the development and distribution of
the Olivia Greets system. In consideration of this purchase, we
issued 500,000 shares of our Common Stock to Merrick
Healthcare Solutions, LLC subject to a twelve month lock up.
Merrick also purchased an aggregate principal amount of
$5.0 million of the old notes at the same purchase price
per old note as the other investors who purchased old notes in
the offering of the old notes. Together with the
$5.0 million of April 2010 notes that were previously
purchased by Merrick on April 28, 2010, Merrick now holds
$10.0 million aggregate principal of the notes.
27
THE
EXCHANGE OFFER
Purpose
and Effect
Concurrently with the sale of the old notes on June 20, 2011, we
and the guarantors entered into a registration rights agreement
with the initial purchaser of the old notes, which requires us
to file the registration statement under the Securities Act with
respect to the exchange notes (the exchange offer
registration statement) and, upon the effectiveness of the
exchange offer registration statement, offer to the holders of
old notes who are able to make certain representations the
opportunity to exchange their old notes for a like principal
amount of exchange notes. The exchange notes will be issued
without a restrictive legend and may generally be reoffered and
resold without registration under the Securities Act.
Pursuant to the registration rights agreement, we and the
guarantors agreed, at our cost, for the benefit of the holders
of the notes, to:
|
|
|
|
|
not later than 90 days after the date of original issuance
of the notes, file the exchange offer registration statement
with the SEC with respect to a registered offer to exchange the
notes for new notes of Merge evidencing the same continuing
indebtedness under, and having terms substantially identical in
all material respects to, the old notes (except that the
exchange notes will not contain terms with respect to transfer
restrictions); and
|
|
|
|
use our commercially reasonable efforts to cause the exchange
offer registration statement to be declared effective under the
Securities Act not later than 180 days after the date of
original issuance of the notes.
|
Upon the effectiveness of the exchange offer registration
statement, we will promptly offer the exchange notes in exchange
for surrender of the notes. We will keep the registered exchange
offer open for not less than 20 business days (or longer if
required by applicable law) after the date notice of the
registered exchange offer is mailed to the holders of the notes.
For each note surrendered to us pursuant to the registered
exchange offer, the holder of such note will receive an exchange
note having a principal amount equal to that of the surrendered
note. Interest on each exchange note will accrue from the last
interest payment date on which interest was paid on the note
surrendered in exchange thereof or, if no interest has been paid
on such note, from the date of its original issue.
Under existing SEC interpretations, the exchange notes would be
freely transferable by holders of the notes other than our
affiliates after the registered exchange offer without further
registration under the Securities Act if the holder of the
exchange notes represents that it is acquiring the exchange
notes in the ordinary course of its business, that it has no
arrangement or understanding with any person to participate in
the distribution of the exchange notes and that it is not an
affiliate of us, as such terms are interpreted by the SEC;
provided that broker-dealers (participating
broker-dealers) receiving exchange notes in the registered
exchange offer will have a prospectus delivery requirement with
respect to resales of such exchange notes. The SEC has taken the
position that participating broker-dealers may fulfill their
prospectus delivery requirements with respect to exchange notes
(other than a resale of an unsold allotment from the original
sale of the notes) with the prospectus contained in the exchange
offer registration statement. Under the registration rights
agreement, we will be required to allow participating
broker-dealers and other persons, if any, with similar
prospectus delivery requirements to use the prospectus contained
in the exchange offer registration statement in connection with
the resale of such exchange notes.
A holder of notes (other than certain specified holders) who
wishes to exchange such notes for exchange notes in the
registered exchange offer will be required to represent that any
exchange notes to be received by it will be acquired in the
ordinary course of its business and that at the time of the
commencement of the registered exchange offer it has no
arrangement or understanding with any person to participate in
the distribution (within the meaning of the Securities Act) of
the exchange notes and that it is not an affiliate,
as defined in Rule 405 of the Securities Act, of us or if
it is an affiliate, that it will comply with the registration
and prospectus delivery requirements of the Securities Act to
the extent applicable.
28
In the event that
(i) any change of law or applicable interpretations thereof
by the staff of the SEC do not permit us to effect such a
registered exchange offer,
(ii) for any other reason the registered exchange offer is
not consummated within 210 days after the date of the
original issuance of the notes,
(iii) the initial purchaser so requests with respect to
notes not eligible to be exchanged for exchange notes in the
registered exchange offer,
(iv) any holder of notes (other than the initial purchaser)
is not eligible to participate in the registered exchange
offer, or
(v) in the case of the initial purchaser participates in
the registered exchange offer or otherwise acquires new
securities under the registration rights agreement and, the
initial purchaser does not receive freely tradable new
securities (it being understood that (x) the requirement
that the initial purchaser deliver the prospectus contained in
the exchange offer registration statement containing the
information required by Item 507 or 508 of
Regulation S-K
under the Act in connection with sales of exchange notes shall
not result in such new securities being not freely
tradable and (y) the requirement that a participating
broker-dealer deliver the prospectus contained in the exchange
offer registration statement in connection with sales of
exchange notes shall not result in such exchange notes being not
freely tradable),
we and the guarantors will, at our cost,
(a) as promptly as practicable (but in no event more than
60 days after so required or requested in accordance with
the above), file a registration statement (the shelf
registration statement) covering resales of the notes or
the exchange notes, as the case may be,
(b) use our commercially reasonable efforts to cause the
shelf registration statement to be declared effective under the
Securities Act within 120 days after so required or
requested and
(c) use our commercially reasonable efforts to keep the
shelf registration statement effective until two years after its
effective date.
We will, in the event a shelf registration statement is filed,
among other things, provide to each holder for whom such shelf
registration statement was filed copies of the shelf
registration statement and prospectus which is a part of the
shelf registration statement, notify each such holder when the
shelf registration statement has become effective and take
certain other actions as are required to permit unrestricted
resales of the notes or the exchange notes, as the case may be.
A holder selling such notes or exchange notes pursuant to the
shelf registration statement generally would be required to be
named as a selling security holder in the related prospectus and
to deliver a prospectus to purchasers, will be subject to
certain of the civil liability provisions under the Securities
Act in connection with such sales and will be bound by the
provisions of the registration rights agreement which are
applicable to such holder (including certain indemnification
obligations).
If
(a) either the exchange offer registration statement or the
shelf registration statement has not been filed with the SEC as
required by the registration rights agreement,
(b) either the exchange offer registration statement or the
shelf registration statement has not been declared effective as
required by the registration rights agreement, or
(c) after either the exchange offer registration statement
or the shelf registration statement has been declared effective,
such registration statement thereafter ceases to be effective or
usable (subject to certain exceptions) in connection with
resales of notes or exchange notes in accordance with and during
the periods specified in the registration rights agreement,
(each such event referred to in clauses (a) through (c), a
registration default), we shall pay liquidated
damages (registration default damages) to the
holders of the notes and the exchange notes. Registration
default damages shall accrue at a rate of 0.25%
29
per annum for the first 60 days from and including the date
of a registration default and at a rate of 0.50% thereafter.
Resale of
Exchange Notes
Based on interpretations by the SEC set forth in no-action
letters issued to third parties, we believe that you may resell
or otherwise transfer exchange notes issued in the exchange
offers without complying with the registration and prospectus
delivery provisions of the Securities Act, if: you are not an
affiliate of Merge Healthcare Incorporated or any
guarantor within the meaning of Rule 405 under the
Securities Act; you do not have an arrangement or understanding
with any person to participate in a distribution of the exchange
notes in violation of the provisions of the Securities Act; you
are not engaged in, and do not intend to engage in, a
distribution of the exchange notes; and you are acquiring the
exchange notes in the ordinary course of your business.
If you are our affiliate or an affiliate of any guarantor, or
are engaging in, or intend to engage in, or have any arrangement
or understanding with any person to participate in, a
distribution of the exchange notes, or are not acquiring the
exchange notes in the ordinary course of your business: you
cannot rely on the position of the SEC set forth in Morgan
Stanley & Co. Incorporated (available June 5,
1991) and Exxon Capital Holdings Corp. (available
May 13, 1988), as interpreted in the SECs letter to
Shearman & Sterling, publicly available July 2,
1993, or similar no-action letters; and in the absence of an
exception from the position stated immediately above, you must
comply with the registration and prospectus delivery
requirements of the Securities Act in connection with any resale
of the exchange notes.
This prospectus may be used for an offer to resell, resale or
other transfer of exchange notes only as specifically set forth
in this prospectus. With regard to broker-dealers, only
broker-dealers that acquired the old notes as a result of
market-making activities or other trading activities may
participate in the exchange offer. Each broker-dealer that
receives exchange notes for its own account in exchange for old
notes, where such old notes were acquired by such broker-dealer
as a result of market-making activities or other trading
activities, must acknowledge that it will deliver a prospectus
in connection with any resale of the exchange notes. Please read
Plan of Distribution for more details regarding the
transfer of exchange notes.
Terms of
the Exchange Offer
Upon the terms and subject to the conditions set forth in this
prospectus, we will accept any and all old notes validly
tendered and not validly withdrawn prior to 5:00 p.m.,
Eastern time,
on ,
2011, or such date and time to which we extend the offer. Notes
may be tendered only in denominations of $2,000 and integral
multiples of $1,000 in excess thereof.
The exchange notes will evidence the same debt as the old notes
and will be issued under the terms of, and be entitled to the
benefits of, the indenture relating to the old notes.
As of the date of this prospectus, $200 million in
aggregate principal amount of notes were outstanding, and there
was one registered holder, a nominee of the Depository
Trust Company, or DTC. This prospectus is being sent to
that registered holder and to others believed to have beneficial
interests in the old notes. We intend to conduct the exchange
offer in accordance with the applicable requirements of the
Exchange Act and the rules and regulations of the SEC
promulgated under the Exchange Act.
We will be deemed to have accepted for exchange validly tendered
old notes when, as and if we have given oral or written notice
of the acceptance to The Bank of New York Mellon Trust
Company, N.A., the exchange agent. The exchange agent will act
as agent for the tendering holders for the purpose of receiving
the exchange notes from us and delivering the exchange notes to
holders. If any tendered old notes are not accepted for exchange
because of an invalid tender, the occurrence of certain other
events set forth under the heading Conditions
to the Exchange Offer or otherwise, such unaccepted old
notes will be returned, without expense, to the tendering holder
of those old notes promptly after the expiration date unless the
exchange offer is extended.
30
Holders who tender old notes in the exchange offer will not be
required to pay brokerage commissions or fees or transfer taxes
with respect to the exchange of old notes in the exchange offer.
We will pay all charges and expenses applicable to the exchange
offer, other than certain applicable taxes, underwriting
discounts, if any, and commissions and transfer taxes, if any,
which shall be borne by the holder. See Fees
and Expenses.
Expiration
Date; Extensions; Amendments
The expiration date for the exchange offer shall be
5:00 p.m., Eastern time,
on ,
2011, unless we, in our sole discretion, extend the exchange
offer, in which case the expiration date shall be the latest
date and time to which the exchange offer is extended. In order
to extend the exchange offer, we will notify the exchange agent
of any extension by oral or written notice, followed by
notification by press release or other public announcement to
the registered holders of the outstanding notes no later than
9:00 a.m., Eastern time, on the next business day after the
previously scheduled expiration date. In the event of a material
change to the terms of the exchange offer, we will extend the
offer period if necessary to ensure that at least five business
days remain in the exchange offer following notice of the
material change. We reserve the right, in our sole discretion:
to delay accepting for exchange any old notes (if we amend or
extend the exchange offer), to extend the exchange offer or, if
any of the conditions set forth under
Conditions to the Exchange Offer shall
not have been satisfied, to terminate the exchange offer, by
giving oral or written notice of that delay, extension or
termination to the exchange agent, or to amend the terms of the
exchange offer in any manner.
In the event that we make a fundamental change to the terms of
the exchange offer, we will file a post-effective amendment to
the registration statement of which this prospectus is a part.
Conditions
to the Exchange Offer
Notwithstanding any other provision of the exchange offer, we
will not be required to accept for exchange, or to issue
exchange notes in exchange for, any old notes and may terminate
or amend the exchange offer if at any time before the acceptance
of those old notes for exchange or the exchange of the exchange
notes for those old notes, we determine in our reasonable
discretion that the exchange offer violates applicable law or
any applicable interpretation of the staff of the SEC.
In addition we will not be obligated to accept for exchange the
old notes of any holder that has not made to us: the
representations described under Purpose and
Effect; or any other representations as may be reasonably
necessary under applicable SEC rules, regulations, or
interpretations to make available to us an appropriate form of
registration of the exchange notes under the Securities Act.
We expressly reserve the right at any time or at various times
to extend the period of time during which the exchange offer is
open. Consequently, we may delay acceptance of any old notes by
giving oral or written notice of such extension to their
holders. We will return any old notes that we do not accept for
exchange for any reason without expense to their tendering
holder promptly after the expiration or termination of the
exchange offer.
We expressly reserve the right to amend or terminate the
exchange offer and to reject for exchange any old notes not
previously accepted for exchange, upon the occurrence of any of
the conditions of the exchange offer specified above. We will
give notice by press release or other public announcement of any
extension, amendment, non-acceptance or termination to the
holders of the old notes as promptly as practicable. In the case
of any extension, such notice will be issued no later than
9:00 a.m., Eastern time, on the next business day after the
previously scheduled expiration date. In the event of a material
change to the terms of the exchange offer, we will extend the
offer period if necessary to ensure that at least five business
days remain in the exchange offer following notice of the
material change.
The foregoing conditions are for our sole benefit and may be
asserted by us regardless of the circumstances giving rise to
any such condition or may be waived by us in whole or in part at
any time on or before the expiration of the exchange offer in
our sole discretion. The failure by us at any time to exercise
any of the foregoing rights shall not be deemed a waiver of any
of those rights and each of those rights shall be deemed an
ongoing right which may be asserted at any time on or before the
expiration of the exchange offer.
31
In addition, we will not accept for exchange any old notes
tendered, and no exchange notes will be issued in exchange for
those old notes, if at such time any stop order shall be in
effect with respect to the registration statement of which this
prospectus constitutes a part or the qualification of the
indenture under the Trust Indenture Act of 1939. In any of
those events we are required to use every commercially
reasonable effort to obtain the withdrawal of any stop order at
the earliest practicable date.
Procedures
for Tendering
To tender your old notes in the exchange offer, you must comply
with either of the following: complete, sign and date the letter
of transmittal, or a facsimile of the letter of transmittal,
have the signature(s) on the letter of transmittal guaranteed if
required by the letter of transmittal and mail or deliver such
letter of transmittal or facsimile thereof to the exchange agent
at the address set forth below under Exchange
Agent prior to the expiration date; or comply with
DTCs Automated Tender Offer Program, or ATOP, procedures
described below.
In addition, either: the exchange agent must receive
certificates for old notes along with the letter of transmittal
prior to the expiration date; the exchange agent must receive a
timely confirmation of book-entry transfer of old notes into the
exchange agents account at DTC according to the procedures
for book-entry transfer described below or a properly
transmitted agents message prior to the expiration date;
or you must comply with the guaranteed delivery procedures
described below.
Your tender, if not withdrawn prior to the expiration date,
constitutes an agreement between us and you upon the terms and
subject to the conditions described in this prospectus and in
the letter of transmittal.
The method of delivery of old notes, letter of transmittal, and
all other required documents to the exchange agent is at your
election and risk. We recommend that instead of delivery by
mail, you use an overnight or hand delivery service, properly
insured. In all cases, you should allow sufficient time to
assure timely delivery to the exchange agent before the
expiration date. You should not send letters of transmittal or
certificates representing old notes to us. You may request that
your broker, dealer, commercial bank, trust company or nominee
effect the above transactions for you.
If you are a beneficial owner whose old notes are registered in
the name of a broker, dealer, commercial bank, trust company, or
other nominee and you wish to tender your old notes, you should
promptly contact the registered holder and instruct the
registered holder to tender on your behalf. If you wish to
tender the old notes yourself, you must, prior to completing and
executing the letter of transmittal and delivering your old
notes, either: make appropriate arrangements to register
ownership of the old notes in your name; or obtain a properly
completed bond power from the registered holder of old notes.
The transfer of registered ownership may take considerable time
and may not be able to be completed prior to the expiration date.
Signatures on the letter of transmittal or a notice of
withdrawal, as the case may be, must be guaranteed by a member
firm of a registered national securities exchange or of the
Financial Industry Regulatory Authority, Inc., a commercial bank
or trust company having an office or correspondent in the United
States or another eligible guarantor institution
within the meaning of
Rule 17Ad-15
under the Exchange Act unless the old notes surrendered for
exchange are tendered: by a registered holder of the old notes
who has not completed the box entitled Special Issuance
Instructions or Special Delivery Instructions
on the letter of transmittal; or for the account of an eligible
guarantor institution.
If the letter of transmittal is signed by a person other than
the registered holder of any old notes listed on the old notes,
such old notes must be endorsed or accompanied by a properly
completed bond power. The bond power must be signed by the
registered holder as the registered holders name appears
on the old notes and an eligible guarantor institution must
guarantee the signature on the bond power.
If the letter of transmittal or any certificates representing
old notes, or bond powers are signed by trustees, executors,
administrators, guardians, attorneys-in-fact, officers of
corporations, or others acting in a fiduciary
32
or representative capacity, those persons should also indicate
when signing and, unless waived by us, they should also submit
evidence satisfactory to us of their authority to so act.
If you are a participant that has old notes which are credited
to your DTC account by book-entry and which are held of record
by DTC, you may tender your old notes by book-entry transfer as
if you were the record holder. Because of this, reference herein
to registered or record holders include DTC participants with
old notes credited to their accounts. If you are not a DTC
participant, you may tender your old notes by book-entry
transfer by contacting your broker, dealer or other nominee or
by opening an account with a DTC participant.
Participants in DTCs ATOP program must electronically
transmit their acceptance of the exchange by causing DTC to
transfer the old notes to the exchange agent in accordance with
DTCs ATOP procedures for transfer. DTC will then send an
agents message to the exchange agent. The term
agents message means a message transmitted by
DTC, received by the exchange agent and forming part of the
book-entry confirmation, which states that:
|
|
|
|
|
DTC has received an express acknowledgment from a participant in
its ATOP that is tendering old notes that are the subject of the
book-entry confirmation; the participant has received and agrees
to be bound by the terms and subject to the conditions set forth
in this prospectus; and we may enforce the agreement against
such participant.
|
Your tender, if not withdrawn before the expiration date, will
constitute an agreement between you and us in accordance with
the terms and subject to the conditions described in this
prospectus.
We reserve the right in our sole discretion to purchase or make
offers for any old notes that remain outstanding after the
expiration date or, as set forth under
Conditions to the Exchange Offer, to
terminate the exchange offer and, to the extent permitted by
applicable law, purchase old notes in the open market, in
privately negotiated transactions, or otherwise. The terms of
any such purchases or offers could differ from the terms of the
exchange offer.
Subject to and effective upon the acceptance for exchange and
exchange of exchange notes, a tendering holder of old notes will
be deemed to: have agreed to irrevocably sell, assign, transfer
and exchange, to us all right, title and interest in, to and
under all of the old notes tendered thereby; have represented
and warranted that when such old notes are accepted for exchange
by us, we will acquire good and marketable title thereto, free
and clear of all liens, restrictions, charges and encumbrances
and not subject to any adverse claims; and have irrevocably
appointed the exchange agent the true and lawful agent and
attorney-in-fact of the holder with respect to any tendered old
notes, with full power of substitution to (1) deliver
certificates representing such old notes, or transfer ownership
of such old notes on the account books maintained by DTC
(together, in any such case, with all accompanying evidences of
transfer and authenticity), to us, (2) present and deliver
such old notes for transfer on our books and (3) receive
all benefits and otherwise exercise all rights and incidents of
beneficial ownership with respect to such old notes, all in
accordance with the terms of the exchange offer.
Each broker-dealer that receives exchange notes for its own
account in exchange for old notes, where those old notes were
acquired by such broker-dealer as a result of market-making
activities or other trading activities, must acknowledge that it
will deliver a prospectus in connection with any resale of those
exchange notes. See Plan of Distribution.
Acceptance
of Exchange Notes
In all cases, we will promptly issue exchange notes for old
notes that we have accepted for exchange under the exchange
offer only after the exchange agent timely receives: old notes
or a timely book-entry confirmation of such old notes into the
exchange agents account at the book-entry transfer
facility; and a properly completed and duly executed letter of
transmittal and all other required documents or a properly
transmitted agents message.
33
|
|
|
|
|
By tendering old notes pursuant to the exchange offer, you will
represent to us that, among other things: you are not our
affiliate or an affiliate of any guarantor within the meaning of
Rule 405 under the Securities Act; you are acquiring the
exchange notes in the ordinary course of your business; you do
not have an arrangement or understanding with any person to
participate in a distribution of the exchange notes; you are not
engaging in or intend to engage in a distribution of the
exchange notes; and if you are a broker that will receive
exchange notes for your own account in exchange for old notes
that were acquired as a result of market-making activities or
other trading activities, that you will comply with the
applicable provisions of the Securities Act (including, but not
limited to, the prospectus delivery requirements thereunder).
|
The letter of transmittal states that by so acknowledging and by
delivering a prospectus, a broker-dealer will not be deemed to
admit that it is an underwriter within the meaning
of the Securities Act. See Plan of Distribution.
We will interpret the terms and conditions of the exchange
offer, including the letter of transmittal and the instructions
to the letter of transmittal, and will resolve all questions as
to the validity, form, eligibility, including time of receipt,
and acceptance of old notes tendered for exchange. We reserve
the absolute right to reject any and all tenders of any
particular old notes not properly tendered or to not accept any
particular old notes if the acceptance might, in its or its
counsels judgment, be unlawful. We also reserve the
absolute right to waive any defects or irregularities as to any
particular old notes prior to the expiration date.
Unless waived, any defects or irregularities in connection with
tenders of old notes for exchange must be cured within such
reasonable period of time as we determine. Neither we, the
exchange agent, nor any other person will be under any duty to
give notification of any defect or irregularity with respect to
any tender of old notes for exchange, nor will any of them incur
any liability for any failure to give notification. Any old
notes received by the exchange agent that are not properly
tendered and as to which the irregularities have not been cured
or waived will be returned by the exchange agent to the
tendering holder, unless otherwise provided in the letter of
transmittal, promptly after the expiration date.
Return of
Notes
If we do not accept any tendered old notes for any reason
described in the terms and conditions of the exchange offer or
if you withdraw or submit old notes for a greater principal
amount than you desire to exchange, we will return the
unaccepted, withdrawn or non-exchanged notes without expense to
you as promptly as practicable.
Book-Entry
Transfer
Promptly after the date of this prospectus, the exchange agent
will establish an account with respect to the old notes at DTC,
as the book-entry transfer facility, for purposes of the
exchange offer. Any financial institution that is a participant
in the book-entry transfer facilitys system may make
book-entry delivery of the old notes by causing the book-entry
transfer facility to transfer those old notes into the exchange
agents account at the facility in accordance with the
facilitys procedures for such transfer. To be timely,
book-entry delivery of old notes requires receipt of a
confirmation of a book-entry transfer, a book-entry
confirmation, prior to the expiration date. In addition,
although delivery of old notes may be effected through
book-entry transfer into the exchange agents account at
the book-entry transfer facility, the letter of transmittal or a
manually signed facsimile thereof, together with any required
signature guarantees and any other required documents, or an
agents message in connection with a book-entry transfer,
must, in any case, be delivered or transmitted to and received
by the exchange agent at its address set forth on the cover page
of the letter of transmittal prior to the expiration date to
receive exchange notes for tendered old notes, or the guaranteed
delivery procedure described below must be complied with. Tender
will not be deemed made until such documents are received by the
exchange agent. Delivery of documents to the book-entry transfer
facility does not constitute delivery to the exchange agent.
Holders of old notes who are unable to deliver confirmation of
the book-entry tender of their old notes into the exchange
agents account at the book-entry transfer facility or all
other documents required by the
34
letter of transmittal to the exchange agent on or prior to the
expiration date must tender their old notes according to the
guaranteed delivery procedures described below.
Guaranteed
Delivery Procedures
If you wish to tender your old notes but your old notes are not
immediately available or you cannot deliver your old notes, the
letter of transmittal or any other required documents to the
exchange agent or comply with DTCs ATOP procedures in the
case of old notes, prior to the expiration date, you may still
tender if: the tender is made through an eligible guarantor
institution; prior to the expiration date, the exchange agent
receives from such eligible guarantor institution either a
properly completed and duly executed notice of guaranteed
delivery, by facsimile transmission, mail or hand delivery or a
properly transmitted agents message and notice of
guaranteed delivery, that (1) sets forth your name and
address, the certificate number(s) of such old notes and the
principal amount of old notes tendered; (2) states that the
tender is being made thereby; and (3) guarantees that,
within three New York Stock Exchange trading days after the
expiration date, the letter of transmittal, or facsimile
thereof, together with the old notes or a book-entry
confirmation, and any other documents required by the letter of
transmittal, will be deposited by the eligible guarantor
institution with the exchange agent; and the exchange agent
receives the properly completed and executed letter of
transmittal or facsimile thereof, as well as certificate(s)
representing all tendered old notes in proper form for transfer
or a book-entry confirmation of transfer of the old notes into
the exchange agents account at DTC all other documents
required by the letter of transmittal within three New York
Stock Exchange trading days after the expiration date.
Upon request, the exchange agent will send to you a notice of
guaranteed delivery if you wish to tender your old notes
according to the guaranteed delivery procedures.
Withdrawal
Rights
Except as otherwise provided in this prospectus, you may
withdraw your tender of old notes at any time prior to
5:00 p.m., Eastern time, on the expiration date.
For a withdrawal to be effective: the exchange agent must
receive a written notice, which may be by facsimile or letter,
of withdrawal at its address set forth below under
Exchange Agent; or you must comply with
the DTCs ATOP procedures.
Any notice of withdrawal must: specify the name of the person
who tendered the old notes to be withdrawn; identify the old
notes to be withdrawn, including the certificate numbers and
principal amount of the old notes; and signed by the holder in
the same manner as the original signature on the letter of
transmittal by which such old notes are tendered (including any
required signature guarantees).
If old notes have been tendered pursuant to the procedures for
book-entry transfer described above, any notice of withdrawal
must specify the name and number of the account at the
book-entry transfer facility to be credited with the withdrawn
old notes and otherwise comply with the procedures of the
facility. Any old notes so withdrawn will be deemed not to have
been validly tendered for exchange for purposes of the exchange
offer. Any old notes that have been tendered for exchange but
that are not exchanged for any reason will be returned to their
holder, without cost to the holder, or, in the case of
book-entry transfer, the old notes will be credited to an
account at the book-entry transfer facility, promptly after
withdrawal, rejection of tender or termination of the applicable
exchange offer. Properly withdrawn old notes may be retendered
by following the procedures described under
Procedures for Tendering above at any
time on or prior to the expiration date.
35
Exchange
Agent
The Bank of New York Mellon Trust Company, N.A. has been
appointed as exchange agent for the exchange offer. Questions,
requests for assistance and requests for additional copies of
this prospectus or should be directed to the exchange agent
addressed as follows:
|
|
|
By Registered & Certified Mail:
THE BANK OF NEW YORK MELLON Corporate Trust Operations Reorganization Unit 101 Barclay Street 7 East New York, NY 10286 Attention: [ ]
|
|
By Regular Mail or Overnight Courier:
THE BANK OF NEW YORK MELLON Corporate Trust Operations Reorganization Unit 101 Barclay Street 7 East New York, NY 10286 Attention: [ ]
|
|
|
|
|
|
|
In Person by Hand Only:
THE BANK OF NEW YORK MELLON Corporate Trust Operations Reorganization Unit 101 Barclay Street 7 East New York, NY 10286 Attention: [ ]
|
|
By Facsimile (for Eligible Institutions only):
(212)
298-1915
|
|
|
|
|
|
|
|
|
For Information or Confirmation by Telephone:
(212)
[ ]
|
Fees And
Expenses
We will not make any payments to brokers, dealers or others
soliciting acceptances of the exchange offer. The principal
solicitation is being made by mail; however, additional
solicitations may be made in person or by telephone by our
officers and employees. The estimated cash expenses to be
incurred in connection with the exchange offer will be paid by
us and will include fees and expenses of the exchange agent,
accounting, legal, printing and related fees and expenses.
Transfer
Taxes
We will pay all transfer taxes, if any, applicable to the
transfer and exchange of old notes to us in the exchange offer.
If transfer taxes are imposed for any other reason, the amount
of those transfer taxes, whether imposed on the registered
holder or any other persons, will be payable by the tendering
holder.
DESCRIPTION
OF THE EXCHANGE NOTES
On June 20, 2011, Merge Healthcare Incorporated (the
Company), issued $52,000,000 of 11.75% Senior
Secured Notes due 2015 (the old notes) under an
Indenture, dated as of April 28, 2010, as supplemented by
the First Supplemental Indenture dated June 14, 2011 and
the Second Supplemental Indenture dated June 20, 2011,
between the Company and The Bank of New York Mellon
Trust Company, N.A., as trustee (the Trustee).
There are $200,000,000 in aggregate principal amount of
11.75% Senior Secured Notes due 2015 (the
April 2010 notes) already outstanding under the
Indenture. As a result, the term Closing Date as
used herein refers to April 28, 2010, the date of original
issuance of the April 2010 notes under the Indenture. As used in
this Description of the Exchange Notes, except as
otherwise specified, the term Notes means the
April 2010 notes together with the old notes and the
exchange notes offered in the exchange transaction that is being
registered hereby (the exchange notes). All such
Notes will be treated as a single class for all purposes under
the Indenture. The old notes, however, were issued with a
separate, restricted CUSIP which is expected to be switched to
the same unrestricted CUSIP as the existing notes following
completion of the exchange offer. The terms of the Notes include
those stated in the Indenture and those made part of the
Indenture by reference to the Trust Indenture Act of 1939,
as amended, which is referred to in this prospectus as the
Trust Indenture Act, or TIA.
36
The following is a summary of the material provisions of the
Indenture but does not restate the Indenture in its entirety.
You can find the definitions of certain capitalized terms used
in the following summary under the subheading
Definitions. The definitions used in this
Description of the Exchange Notes may differ from
definitions used elsewhere in this prospectus. We urge you to
read the Indenture because it, and not this description, defines
your rights as holders of the Notes. A copy of the Indenture is
available upon request from the Company. For purposes of this
Description of the Exchange Notes, the term
Company means Merge Healthcare Incorporated, a
Delaware corporation, and its successors under the Indenture, in
each case excluding its subsidiaries.
General
The Notes are secured, senior Indebtedness of the Company,
limited to $252,000,000 aggregate principal amount, of which
$52,000,000 were issued on June 20, 2011 and $200,000,000
were issued on April 28, 2010. The Notes will mature on
May 1, 2015. The Notes will be issuable only in
denominations of $2,000 and integral multiples of $1,000 in
excess of $2,000. Subject to the covenants described below under
Covenants and applicable law, the
Company may issue additional Notes (Additional
Notes) under the Indenture. The Notes, any exchange notes
issued as described under The Exchange Offer, and
any Additional Notes would be treated as a single class for all
purposes under the Indenture.
Each New Note will initially bear interest at the rate per annum
shown on the cover page of this prospectus from the most recent
interest payment date to which interest has been paid on the
Notes. Interest on the old notes will be payable semiannually on
May 1 and November 1, commencing on November 1, 2011.
Interest will be paid to Holders of record at the close of
business on the April 15 and October 15 immediately preceding
the Interest Payment Date. Interest is computed on the basis of
a 360-day
year of twelve
30-day
months. Interest on overdue principal and interest and
Additional Interest, if any, will accrue at a rate that is 1%
higher than the then applicable interest rate on the Notes.
The old notes were offered and sold to qualified institutional
buyers in reliance on Rule 144A under the Securities Act.
Rule 144A Notes initially will be represented by one or
more Notes in registered global form without interest coupons.
The Rule 144A global note will be deposited upon issuance
with the Trustee as custodian for The Depository
Trust Company, also referred to as DTC, and registered in
the name of DTC or its nominee, in each case for credit to an
account of a direct or indirect participant as described below.
No service charge will be made for any registration of transfer
or exchange of Notes, but the Company may require payment of a
sum sufficient to cover any transfer tax or other similar
governmental charge payable in connection therewith.
Ranking
The Notes are:
|
|
|
|
|
general senior obligations of the Company;
|
|
|
|
secured on a first-priority lien basis by the Collateral,
subject to certain Permitted Liens;
|
|
|
|
equal in right of payment with all existing and future senior
Indebtedness of the Company;
|
|
|
|
senior in right of payment to all existing and future
subordinated Indebtedness of the Company;
|
|
|
|
structurally subordinated to all existing and future
Indebtedness and other liabilities of the Companys
subsidiaries that are not Guarantors; and
|
|
|
|
guaranteed on a senior secured basis by each Guarantor.
|
Each Note Guarantee (as defined below) is:
|
|
|
|
|
a general senior obligation of each Guarantor;
|
|
|
|
secured on a first-priority lien basis by the Collateral,
subject to certain Permitted Liens;
|
37
|
|
|
|
|
senior in right of payment to all future obligations of such
Guarantor that are, by their terms, expressly subordinated in
right of payment to such Note Guarantee; and
|
|
|
|
pari passu in right of payment with all existing and future
unsecured obligations of such Guarantor that are not so
subordinated.
|
The Notes are effectively subordinated to all existing and
future obligations, including Indebtedness, of any Subsidiaries
of the Company that do not guarantee the Notes, including any
Unrestricted Subsidiaries. Claims of creditors of these
Subsidiaries, including trade creditors, will generally have
priority as to the assets of these Subsidiaries over the claims
of the Company and the holders of the Companys
Indebtedness, including the Notes.
As of June 30, 2011, after giving effect to the offering of
the old notes, the Company would have had $252.0 million
aggregate principal amount of senior secured Indebtedness
outstanding.
As of the date of the Indenture, all of our Subsidiaries were
Restricted Subsidiaries. However, subject to
compliance with the requirements noted in the definition of
Unrestricted Subsidiary, we will be permitted to
designate Subsidiaries as Unrestricted Subsidiaries.
Our Unrestricted Subsidiaries will not be subject to the
restrictive covenants in the Indenture. Our Unrestricted
Subsidiaries will not guarantee the Notes.
Note
Guarantees
The Companys obligations under the Notes and the Indenture
will be jointly and severally guaranteed (the Note
Guarantees) by each of the Companys current and
future Domestic Restricted Subsidiaries.
Not all of the Companys Subsidiaries will guarantee the
Notes. Unrestricted Subsidiaries and Foreign Restricted
Subsidiaries will not be Guarantors. In the event of a
bankruptcy, liquidation or reorganization of any of these
non-Guarantor Subsidiaries, these non-Guarantor Subsidiaries
will pay the holders of their debts and their trade creditors
before they will be able to distribute any of their assets to
the holders of the Notes. For the quarter ended March 31,
2011, the Companys non-Guarantor Subsidiaries represented
approximately 10.0% of its revenues and had net income of
approximately $0.3 million compared to the Companys
consolidated net loss of approximately $1.6 million for the
same period. In addition, as of March 31, 2011, the
Companys non-Guarantor Subsidiaries held approximately
7.8% of its consolidated assets and had approximately
$32.3 million of liabilities (including trade payables), to
which the Notes and Note Guarantees would have been structurally
subordinated.
The obligations of each Guarantor under its Note Guarantee will
be limited to the maximum amount as will, after giving effect to
all other contingent and fixed liabilities of such Guarantor and
after giving effect to any collections from or payments made by
or on behalf of any other Guarantor in respect of the
obligations of such other Guarantor under its Note Guarantee or
pursuant to its contribution obligations under the Indenture,
result in the obligations of such Guarantor under its Note
Guarantee not constituting a fraudulent conveyance or fraudulent
transfer under federal or state law. Nonetheless, in the event
of the bankruptcy or financial difficulty of a Guarantor, such
Guarantors obligations under its Note Guarantee may be
subject to review and avoidance under state and federal
fraudulent transfer laws. Among other things, such obligations
may be avoided if a court concludes that such obligations were
incurred for less than a reasonably equivalent value or fair
consideration at a time when the Guarantor was insolvent, was
rendered insolvent, or was left with inadequate capital to
conduct its business. A court would likely conclude that a
Guarantor did not receive reasonably equivalent value or fair
consideration to the extent that the aggregate amount of its
liability on its Note Guarantee exceeds the economic benefits it
receives from the issuance of the Note Guarantee. See Risk
Factors Risks Related to the Notes A
court could void our subsidiaries guarantees of the notes
under fraudulent transfer laws.
Each Guarantor that makes a payment for distribution under its
Note Guarantee is entitled to a contribution from each other
Guarantor in a pro rata amount based on adjusted net assets of
each Guarantor.
38
A Subsidiary Guarantor shall be released from its obligations
under its Note Guarantee and its obligations under the Indenture
and the Registration Rights Agreement:
(1) in connection with any sale or other disposition of all
or substantially all of the assets of that Guarantor (including
by way of merger or consolidation) to a Person that is not
(either before or after giving effect to such transaction) the
Company or a Restricted Subsidiary of the Company, if the sale
or other disposition does not violate the covenants set forth
below under Repurchase at the Option of
Holders Asset Sales;
(2) in connection with any sale or other disposition of the
Capital Stock of that Guarantor (including by way of merger or
consolidation) to a Person that is not (either before or after
giving effect to such transaction) the Company or a Restricted
Subsidiary of the Company, such that, immediately after giving
effect to such transaction, such Guarantor would no longer
constitute a Subsidiary of the Company, if the sale or other
disposition does not violate the covenants set forth below under
Repurchase at the Option of Holders Asset
Sales;
(3) if the Company designates any Restricted Subsidiary
that is a Guarantor to be an Unrestricted Subsidiary in
accordance with the applicable provisions of the
Indenture; or
(4) upon legal defeasance or satisfaction and discharge of
the Indenture as provided below under the captions Legal
Defeasance and Covenant Defeasance and Satisfaction
and Discharge.
Collateral
and Security
Collateral
Generally
The Notes, the Note Guarantees, and all other Permitted Pari
Passu Obligations will be secured equally and ratably by
continuing first priority security interests (subject to
Permitted Liens) in substantially all of the tangible and
intangible assets of the Company and the Guarantors, whether now
owned or hereafter acquired or arising, and wherever located,
including, but not limited to, all existing and future Capital
Stock and intercompany debt of any Domestic Subsidiary owned
directly by the Company or any Guarantor and all existing and
future Capital Stock of any first-tier Foreign Subsidiary
owned directly by the Company or any Guarantor (limited in the
case of any such Foreign Subsidiaries, to 65% of the Capital
Stock of such Foreign Subsidiaries), accounts receivable,
deposit accounts, chattel paper, inventory, equipment,
investment property, intellectual property, interests in
commercial tort claims, other general intangibles and certain
owned real property, and all proceeds of the foregoing, subject
to the exceptions discussed in the succeeding paragraph
(collectively, the Collateral).
The Collateral will exclude certain items of property, including
without limitation:
|
|
|
|
|
rights in any property to the extent that and only for as long
as the grant of a security interest in such property (i) is
prohibited by any law, treaty, rule or regulation or
determination of an arbitrator or a court or other governmental
authority applicable to or binding upon the Company or any
Guarantor, or (ii) constitutes a breach or default under or
results in the termination of, or requires any consent not
obtained under, any lease, license or agreement (other than to
the extent that the provisions of any such lease, license or
agreement are ineffective under applicable law or would be
ineffective under
Sections 9-406,
9-407, 9-408 or 9-409 of the Uniform Commercial Code of any
relevant jurisdiction to prevent the attachment of the security
interest granted under the Security Documents);
|
|
|
|
property and assets owned by the Company or any Guarantor in
which a Lien may not be granted without governmental approval or
consent (but only for so long as the Company or the applicable
Guarantor has not obtained such approval or consents); and
|
|
|
|
any United States Trademark applications filed on the basis of
the Companys or any Guarantors
intent-to-use
such mark, but only if and to the extent that the granting of a
security interest in such application would result in the
invalidation of such application, provided that, upon the
submission of evidence of use of such Trademark in interstate
commerce is submitted to the United States Patent and Trademark
Office, such Trademark application shall automatically be
included in the Collateral;
|
39
|
|
|
|
|
any Capital Stock of any first-tier Foreign Restricted
Subsidiary directly owned by the Company or any Guarantor in
excess of 65% of the Capital Stock of such Foreign Restricted
Subsidiary;
|
|
|
|
property and assets owned by the Company or any Guarantor which
are located outside of the United States to the extent a lien on
such property and assets cannot be perfected by the filing of
UCC financing statements in the jurisdictions of organization of
the Company or such Guarantor;
|
|
|
|
any Capital Stock of any direct or indirect Subsidiaries of any
Foreign Subsidiary;
|
|
|
|
any leasehold interest in real property;
|
|
|
|
motor vehicles and other assets in which a security interest may
be perfected only through compliance with a certificate of title
or similar statute;
|
|
|
|
certain other items agreed by the parties and as more fully set
forth in the Security Documents; and
|
|
|
|
proceeds and products of any and all of the foregoing excluded
property and assets described above only to the extent that such
proceeds and products would constitute property or assets of the
type described above.
|
Mortgages and other perfection steps will not be required in
respect of any fee interest in any Real Property having a value
of $1.0 million or less.
As of the date of the issuance of the old notes, there have been
no grants of mortgages or other perfection steps taken with
respect to Real Property, because none of the Real Property
interests of the Company or the Guarantors meets the
aforementioned $1.0 million threshold.
Security
Documents Generally
On or prior to the Closing Date, the Company and the Guarantors
entered into certain Security Documents (including, without
limitation, the Guarantee and Collateral Agreement) with the
Collateral Agent, which documents provided for the grant of
security interests in the Collateral in favor of the Collateral
Agent, for the benefit of the Trustee and the Holders of the
Notes, including the old notes.
The Company will, and will cause each of the Guarantors to, do
or cause to be done all acts and things which may be required,
or which the Collateral Agent from time to time may reasonably
request, to assure and confirm that the Collateral Agent holds,
for the benefit of the Trustee and the Holders of the Notes,
duly created, enforceable and perfected Liens upon the
Collateral as contemplated by the Indenture and the Security
Documents.
The Company and the Guarantors will be able to incur additional
Indebtedness in the future which could share in the Collateral.
Any such Indebtedness may limit the recovery from the
realization of the value of such Collateral available to satisfy
the Holders of the Notes. A representative for the lenders with
respect to such Indebtedness will be required to enter into the
Intercreditor Agreement as Pari Passu Secured Parties. No
Collateral will secure any other Indebtedness unless such
Collateral also secures the Note Obligations. The amount of all
such additional Indebtedness will be limited by the covenants
disclosed under Certain Covenants Limitation
on Indebtedness and Certain Covenants
Limitation on Liens. Under certain circumstances the
amount of such additional Indebtedness could be significant.
No appraisals of any Collateral have been prepared in connection
with the offering of the old notes. The value of the Collateral
at any time is subject to fluctuation based on factors that
include, among others, the condition of the healthcare
information industry, the ability to sell the Collateral in an
orderly sale, general economic conditions, the availability of
suitable buyers and similar factors. By its nature, some or all
of the Collateral may be illiquid and may have no readily
ascertainable market value. We cannot assure you that the fair
market value of the Collateral as of the date of this prospectus
exceeds the principal amount of the Indebtedness secured
thereby. The value of the assets pledged as Collateral for
obligations under the Indenture could be impaired in the future
as a result of changing economic conditions, our failure to
implement our business strategy, competition or other future
trends.
40
We cannot assure you that, in the event of a foreclosure, the
proceeds from the sale of the portion of the Collateral
allocated or allocable to the repayment of the obligations under
the Indenture would be sufficient to satisfy the amounts
outstanding under the Notes. If such proceeds were not
sufficient to repay amounts outstanding under the Notes, the
holders of the Notes (to the extent not repaid from the proceeds
of the sale of the Collateral) would have only an unsecured,
general claim against us and our Guarantors remaining
assets, which claim would rank equal in priority to unsecured
general Indebtedness. In the event that a bankruptcy case is
commenced by or against us, if the value of the Collateral is
less than the amount of principal and accrued and unpaid
interest on the Notes and all other senior secured obligations,
interest may cease to accrue on the Notes from and after the
date the bankruptcy petition is filed.
After-Acquired
Property
Promptly following the acquisition by the Company or any
Guarantor of any After-Acquired Property (but subject to the
applicable limitations in the Security Documents), the Company
or such Guarantor will execute and deliver such security
agreement supplements, mortgages, deeds of trust, security
instruments, financing statements, title insurance, surveys and
certificates and opinions of counsel as are reasonably necessary
to vest in the Collateral Agent a perfected security interest or
other Liens in or on such After-Acquired Property and to have
such After-Acquired Property added to the Collateral, and
thereupon all provisions of the Indenture relating to the
Collateral will be deemed to relate to such After-Acquired
Property to the same extent and with the same force and effect.
Intercreditor
Agreement
If additional secured Indebtedness is issued in the future, the
Company, the Guarantors, the Collateral Agent, and the
Authorized Representative for the holders and the lenders of
such additional secured debt (the Pari Passu Debt
Collateral Agent) will enter into an Intercreditor
Agreement (as the same may be amended from time to time, the
Intercreditor Agreement), with respect to the
Collateral, which Intercreditor Agreement may be amended from
time to time without the consent of the Holders of the Notes to
add additional lenders holding Pari Passu Obligations permitted
to be incurred under the Indenture, the Intercreditor Agreement
and any Pari Passu Agreements then in effect.
Collateral
Agent
By accepting the Notes, each Holder will be deemed to have
irrevocably appointed The Bank of New York Mellon
Trust Company, N.A. as the Collateral Agent, to act as its
agent under the Intercreditor Agreement, the Guarantee and
Collateral Agreement and the other Security Documents, and to
have irrevocably authorized the Collateral Agent to perform the
duties and exercise the rights powers and discretions that are
specifically given to it under the Indenture, the Intercreditor
Agreement, the Guarantee and Collateral Agreement and the other
Security Documents, together with any other incidental rights
power and discretion. Under the terms of the Indenture, the
Collateral Agent may resign on 30 days prior written
notice, and the Collateral Agent may also be removed for cause
and replaced by a replacement collateral agent selected by the
Trustee, in consultation with the Company.
The Collateral Agent holds (directly or through co-trustees,
co-agents, agents or sub agents), and will be entitled to
enforce, all Liens on the Collateral created by the Security
Documents in accordance with the following.
Enforcement
of Security Interests
Under the Intercreditor Agreement, the Applicable Authorized
Representative has the right, under certain circumstances, to
direct the Collateral Agent and each Pari Passu Debt Collateral
Agent to foreclose or take other actions with respect to the
Collateral, and no other party to the Intercreditor Agreement
will have the right to direct any action with respect to the
Collateral. Except as described below, the Applicable Authorized
Representative will be the Authorized Representative of the
Series of Pari Passu Obligations that constitutes the largest
outstanding principal amount of all then-outstanding Pari Passu
Obligations (the Controlling
41
Authorized Representative). Upon the occurrence of the
Non-Controlling Authorized Representative Enforcement Date (as
defined below), the then-Applicable Authorized Representative
will be replaced as Applicable Authorized Representative by the
Authorized Representative of the Series of Pari Passu
Obligations that then constitutes the next largest outstanding
principal amount of all then-outstanding Pari Passu Obligations
with respect to the Collateral (the Major Non-Controlling
Authorized Representative).
The Non-Controlling Authorized Representative Enforcement
Date, with respect to which a Non- Controlling Authorized
Representative becomes the Applicable Authorized Representative
is the date that is 90 days (throughout which
90-day
period the applicable Non-Controlling Authorized Representative
was the Major Non-Controlling Authorized Representative) after
the occurrence of both (a) an event of default that has
occurred and is continuing, as defined in the Indenture or any
other applicable indenture or credit document for that Series of
Pari Passu Obligations, and (b) the Collateral Agents
and each other Authorized Representatives receipt of
written notice from that Authorized Representative certifying
that (i) such Authorized Representative is the Major
Non-Controlling Authorized Representative and that an event of
default, as defined in the Indenture or any other applicable
indenture or credit document for that Series of Pari Passu
Obligations, has occurred and is continuing and (ii) the
Pari Passu Obligations of that Series are currently due and
payable in full (whether as a result of acceleration thereof or
otherwise) in accordance with the Indenture or other applicable
indenture or credit document, as applicable, for that Series of
Pari Passu Obligations; provided that the Non-Controlling
Authorized Representative Enforcement Date will be stayed and
shall not occur and shall be deemed not to have occurred with
respect to any Collateral if (1) at any time the Applicable
Authorized Representative has commenced and is diligently
pursuing any enforcement action with respect to such Collateral
or (2) at any time the Company or the Guarantor that has
granted a security interest in such Collateral is then a debtor
under or with respect to (or otherwise subject to) any
insolvency or liquidation proceeding. If no such stay occurs, or
is deemed to occur, then the Major Non-Controlling Authorized
Representative will become the Applicable Authorized
Representative from and after the occurrence of the
Non-Controlling Authorized Representative Enforcement Date.
Restrictions
on Enforcement of Priority Liens
Subject to the terms of the Intercreditor Agreement, the
Applicable Authorized Representative will have the sole right to
instruct the Collateral Agent and each Pari Passu Debt
Collateral Agent to act or refrain from acting with respect to
the Collateral, and (a) neither Collateral Agent nor any
Pari Passu Debt Collateral Agent will follow any instructions
(other than certain types of instructions to exercise rights
other than enforcement rights) with respect to the Collateral
from any representative of any Non-Controlling Secured Party or
other Pari Passu Secured Party (other than the Applicable
Authorized Representative), and (b) no Authorized
Representative of any Non-Controlling Secured Party or other
Pari Passu Secured Party (other than the Applicable Authorized
Representative) will instruct the Collateral Agent or any Pari
Passu Debt Collateral Agent to commence any judicial or
non-judicial foreclosure proceedings with respect to, seek to
have a trustee, receiver, liquidator or similar official
appointed for or over, attempt any action to take possession of,
exercise any right, remedy or power with respect to, or
otherwise take any action to enforce its interests in or realize
upon, or take any other action available to it in respect of,
the Collateral.
No representative of any Non-Controlling Secured Party may
contest, protest or object to any foreclosure proceeding or
action brought by or at the direction of the Controlling
Authorized Representative in connection with the Intercreditor
Agreement or the exercise of remedies against the Collateral in
accordance with the terms of the Intercreditor Agreement. Each
Authorized Representative will agree that it will not accept any
Lien on any Collateral for the benefit of any series of Pari
Passu Obligations (other than funds deposited for the discharge
or defeasance of any Pari Passu Agreement) unless each other
series of Pari Passu Obligations is also secured by a Lien on
such Collateral. Each of the Pari Passu Secured Parties will
also agree that it will not contest or support any other person
in contesting, in any proceeding (including any insolvency or
liquidation proceeding), the perfection, priority, validity or
enforceability of a Lien held by or on behalf of any of the Pari
Passu Secured Parties in all or any part of the Collateral, or
the provisions of the Intercreditor Agreement.
42
Notwithstanding the foregoing, with respect to any Collateral
for which a third party (other than a Pari Passu Secured Party)
has a lien or security interest that is junior in priority to
the security interest of any Series of Pari Passu Obligations
but senior (as determined by appropriate legal proceedings in
the case of any dispute) to the security interest of any other
Series of Pari Passu Obligations (such third party, an
Intervening Creditor), the value of any Collateral
or proceeds which are allocated to such Intervening Creditor
will be deducted on a ratable basis solely from the Collateral
or proceeds to be distributed in respect of the Series of Pari
Passu Obligations with respect to which such impairment exists.
In addition, the Pari Passu Secured Parties of each Series bear
the risk that a court may deem that the Pari Passu Obligations
of such Series (and not of any other Series) (i) are
unenforceable under applicable law, (ii) are equitably
subordinated to any other obligations or (iii) do not have
an enforceable security interest in any of the Collateral that
secures any other Series of Pari Passu Obligations. In the event
of any such impairment, the rights of the holders of Pari Passu
Obligations of the impaired Series under the Intercreditor
Agreement will be modified to the extent necessary so that the
effects of the impairment are borne solely by such impaired
holders and not the holders of any other Series of Pari Passu
Obligations.
None of the Pari Passu Secured Parties may institute any suit or
assert in any suit, bankruptcy, insolvency or other proceeding
any claim against the Collateral Agent or any other Pari Passu
Secured Party seeking damages from or other relief by way of
specific performance, instructions or otherwise with respect to
any Collateral, except to the extent expressly permitted by the
terms of the Intercreditor Agreement. In addition, none of the
Pari Passu Secured Parties may seek to have any Collateral or
any part thereof marshaled upon any foreclosure or other
disposition of such Collateral. If any Pari Passu Secured Party
obtains possession of any Collateral or realizes any proceeds or
payment in respect thereof, at any time prior to the discharge
of each of the Pari Passu Obligations, then it must hold such
Collateral, proceeds or payment in trust for the other Pari
Passu Secured Parties and promptly transfer such Collateral,
proceeds or payment to the Applicable Authorized Representative
to be distributed in accordance with the Intercreditor Agreement.
The Pari Passu Secured Parties acknowledge that the Pari Passu
Obligations may, subject to the limitations set forth in the
applicable debt documents, be increased, extended, renewed,
replaced, restated, supplemented, restructured, repaid,
refunded, refinanced or otherwise amended or modified from time
to time, all without affecting the priorities set forth in the
Intercreditor Agreement defining the relative rights of the Pari
Passu Secured Parties; provided that the authorized
representative of the holders of such amended or modified
Indebtedness, if not a party to the Intercreditor Agreement,
shall have executed a Joinder Agreement to the Intercreditor
Agreement on behalf of the holders of such Indebtedness.
Release
of Liens on Collateral
The Company and the Guarantors will be entitled to the release
of property and other assets included in the Collateral from the
Liens securing the Pari Passu Obligations under any one or more
of the following circumstances:
|
|
|
|
|
to enable the disposition or other use of such property or
assets to the extent permitted under the Indenture and all other
Secured Credit Documents; and
|
|
|
|
in the case of a Guarantor that is released from its Note
Guarantee and any guarantee under all other Secured Credit
Documents, the release of the property and assets of such
Guarantor.
|
The Liens on the Collateral securing the Notes and the Note
Guarantees will also be released upon (i) the termination
and release of all Liens on Collateral in accordance with the
terms of the Indenture, each Pari Passu Agreement then in
effect, the Intercreditor Agreement, and all other applicable
Pari Passu Security Documents, or (ii) the consent of each
Authorized Representative, the Company and, as applicable,
Holders of the Notes and lenders under the Pari Passu Agreements
and the Guarantors, it being agreed that the termination of the
Collateral pursuant to the preceding clause (i) or
(ii) will be concurrent with the termination of the
Intercreditor Agreement and the other Pari Passu Security
Documents (including the release of all Liens granted
thereunder).
43
Amendment
of Security Documents
The Applicable Authorized Representative may enter into any
amendment to any Pari Passu Security Document, so long as the
Applicable Authorized Representative receives a certificate of
the Company stating that such amendment is permitted by the
terms of the Indenture and each other Secured Credit Document
then in effect. The Applicable Authorized Representative will
give notice to each other Authorized Representative of any
release of Collateral and of any amendment to any Pari Passu
Security Document. The Applicable Authorized Representative may
not enter into any amendment that releases all or substantially
all of the Collateral from the Liens under any Pari Passu
Security Document without the written consent of each Authorized
Representative.
Certain
Covenants with Respect to the Collateral
The Collateral is pledged pursuant to the Security Documents,
which contain provisions relating to the administration of the
Collateral. The following is a summary of some of the covenants
and provisions set forth in the Security Documents and the
Indenture as they relate to the Collateral:
Further Assurances. The Security Documents and
the Indenture provide each Grantor will, at its own expense,
promptly execute and deliver all further instruments and
documents, and take all further action, that may be necessary,
or that Collateral Agent may reasonably request, in order to
perfect any security interest granted or purported to be granted
thereby or to enable the Collateral Agent to exercise and
enforce its rights and remedies under such Security Documents
with respect to any of the Collateral. Under the terms of the
Guarantee and Collateral Agreement, each Grantor authorizes the
filing by the Collateral Agent of financing or continuation
statements, or amendments, and such Grantor will execute and
deliver to the Collateral Agent such other instruments or
notices, as may be necessary or as Collateral Agent may
reasonably request, in order to perfect and preserve the
security interest granted or purported to be granted under the
Guarantee and Collateral Agreement.
Real Property Mortgages and Filings. Each
Grantor agrees that upon the acquisition of any fee interest in
real property in excess of $1.0 million in value it will
promptly notify the Collateral Agent of such acquisition and
will grant to the Collateral Agent, for the benefit of the
Trustee and the Holders of the Notes, a first priority mortgage
(subject to Permitted Liens) on each fee interest in real
property owned by such Grantor and will deliver such other
documentation and opinions, in form and substance satisfactory
to Collateral Agent, in connection with the grant of such
mortgage as the Collateral Agent reasonably requests, including
title insurance policies, financing statements, fixture filings
and environmental audits and such Grantor will pay all recording
costs, intangible taxes and other fees and costs (including
reasonable attorneys fees and expenses) incurred in
connection therewith.
New Subsidiaries. Pursuant to the Indenture
and the Guarantee and Collateral Agreement, any new direct
Domestic Subsidiary (whether by acquisition or creation) of a
Grantor is required to enter into the Guarantee and Collateral
Agreement by executing and delivering a supplement to the
Guarantee and Collateral Agreement in the form attached to the
Guarantee and Collateral Agreement. Upon the execution and
delivery of such supplement by such new Domestic Subsidiary,
such Domestic Subsidiary shall become a Grantor under the
Guarantee and Collateral Agreement, with the same force and
effect as if originally named as a Grantor on the Closing Date.
Certain
Bankruptcy Limitations
The right of the Collateral Agent (acting on behalf of the
Trustee and the Holders of the Notes) to repossess and dispose
of Collateral upon the occurrence of an Event of Default would
be significantly impaired by applicable bankruptcy law in the
event that a bankruptcy case were to be commenced by or against
the Company or any Guarantor prior to and possibly after the
Collateral Agents having repossessed and disposed of the
Collateral. Upon the commencement of a case for relief under
Title 11 of the United States Bankruptcy Code of 1978, as
amended (the Bankruptcy Code), a secured creditor
such as the Collateral Agent is prohibited from repossessing its
security from a debtor in a bankruptcy case, or from disposing
of security repossessed from the debtor, without bankruptcy
court approval.
44
In view of the broad equitable powers of a U.S. bankruptcy
court, it is impossible to predict how long payments under the
Notes could be delayed following commencement of a bankruptcy
case, whether or when the Collateral Agent could repossess or
dispose of the Collateral, the value of the Collateral at the
time of the bankruptcy petition or whether or to what extent
Holders of the Notes would be compensated for any delay in
payment or loss of value of the Collateral. The Bankruptcy Code
permits only the payment
and/or
accrual of post petition interest, costs and attorneys
fees to a secured creditor during a debtors bankruptcy
case to the extent the value of the Collateral is determined by
the bankruptcy court to exceed the aggregate outstanding
principal amount of the obligations secured by the Collateral.
Furthermore, in the event a domestic or foreign bankruptcy court
determines that the value of the Collateral is not sufficient to
repay all amounts due on the Notes, the Holders of the Notes
would hold secured claims to the extent of the value of the
Collateral to which the Holders of the Notes are entitled, and
unsecured claims with respect to such shortfall.
Optional
Redemption
The Company may redeem the Notes at any time on or after
May 1, 2013. The redemption price for the Notes (expressed
as a percentage of principal amount), will be as follows, plus
accrued and unpaid interest and Additional Interest, if any, to
the redemption date:
|
|
|
|
|
If Redeemed During the
|
|
Redemption
|
12-Month Period Commencing May 1,
|
|
Price
|
|
2013
|
|
|
105.875
|
%
|
2014
|
|
|
100.000
|
%
|
In addition, at any time prior to May 1, 2013, the Company
may redeem up to 35% of the principal amount of the Notes with
the Net Cash Proceeds of one or more sales of its Equity
Interests (other than Disqualified Stock) at a redemption price
of 111.75% of their principal amount, plus accrued interest and
Additional Interest, if any, to the redemption date;
provided that at least 65% of the aggregate principal
amount of Notes originally issued (including any Additional
Notes) remains outstanding after each such redemption and notice
of any such redemption is mailed within 90 days of each
such sale of Equity Interests.
At any time on or prior to May 1, 2013, the Notes may also
be redeemed, in whole or in part, at the option of the
Company, at a redemption price equal to 100% of the principal
amount thereof plus the Applicable Premium as of, and accrued
and unpaid interest and Additional Interest, if any, to, the
redemption date.
The Company may acquire Notes by means other than a redemption,
whether pursuant to an issuer tender offer, open market purchase
or otherwise, so long as the acquisition does not otherwise
violate the terms of the Indenture.
Notice
of Redemption
The Company will give not less than 30 days nor more
than 60 days notice of any redemption. If less than
all of the Notes are to be redeemed, subject to DTC procedures,
selection of the Notes for redemption will be made by the
Trustee:
|
|
|
|
|
in compliance with the requirements of the principal national
securities exchange, if any, on which the Notes are listed, or,
|
|
|
|
if the Notes are not listed on a national securities exchange,
pro rata, by lot or by such other method as the Trustee in its
sole discretion shall deem to be fair and appropriate, unless
otherwise required by law.
|
However, no Notes of a principal amount of $2,000 or less shall
be redeemed in part. If any Note is to be redeemed in part only,
the notice of redemption relating to such Note will state the
portion of the principal amount to be redeemed. A new Note in
principal amount equal to the unredeemed portion will be issued
upon cancellation of the original Note.
45
Mandatory
Redemption; Sinking Fund
The Company will not be required to make any mandatory
redemption or sinking fund payments with respect to the Notes.
Repurchase
at the Option of Holders
Change
of Control
If a Change of Control occurs, each holder of Notes will have
the right to require the Company to repurchase all or any part
(equal to $2,000 or an integral multiple of $1,000) of that
holders Notes pursuant to a Change of Control Offer on the
terms set forth in the Indenture. In the Change of Control
Offer, the Company will offer a Change of Control Payment in
cash equal to 101% of the aggregate principal amount of notes
repurchased plus accrued and unpaid interest and Additional
Interest, if any, on the Notes repurchased to the date of
purchase, subject to the rights of holders of Notes on the
relevant record date to receive interest due on the relevant
interest payment date. Within 20 days following any Change
of Control, the Company will mail a notice to each holder and
the Trustee describing the transaction or transactions that
constitute the Change of Control and offering to repurchase
Notes on the Change of Control Payment Date specified in the
notice, which date will be no earlier than 30 days and no
later than 60 days from the date such notice is mailed,
pursuant to the procedures required by the Indenture and
described in such notice.
The Company will comply with the requirements of
Rule 14e-1
under the Exchange Act and any other securities laws and
regulations thereunder to the extent those laws and regulations
are applicable in connection with the repurchase of the Notes as
a result of a Change of Control. To the extent that the
provisions of any securities laws or regulations conflict with
the Change of Control provisions of the indenture, the Company
will comply with the applicable securities laws and regulations
and will not be deemed to have breached its obligations under
the Change of Control provisions of the indenture by virtue of
such compliance.
On the Change of Control Payment Date, the Company will, to the
extent lawful:
(1) accept for payment all Notes or portions of Notes
properly tendered pursuant to the Change of Control Offer;
(2) deposit with the paying agent an amount equal to the
Change of Control Payment in respect of all Notes or portions of
Notes properly tendered; and
(3) deliver or cause to be delivered to the Trustee the
Notes properly accepted together with an officers
certificate stating the aggregate principal amount of Notes or
portions of Notes being purchased by the Company.
The paying agent will promptly mail to each Holder of Notes
properly tendered the Change of Control Payment for such Notes,
and the Trustee will promptly authenticate and mail (or cause to
be transferred by book entry) to each Holder a new Note equal in
principal amount to any unpurchased portion of the Notes
surrendered, if any. The Company will publicly announce the
results of the Change of Control Offer on or as soon as
practicable after the Change of Control Payment Date.
The Company will not be required to make a Change of Control
Offer upon a Change of Control if (1) a third party makes
the Change of Control Offer in the manner, at the times and
otherwise in compliance with the requirements set forth in the
Indenture applicable to a Change of Control Offer made by the
Company and purchases all Notes properly tendered and not
withdrawn under the Change of Control Offer, or (2) notice
of redemption has been given pursuant to the Indenture as
described above under the caption Optional
Redemption, unless and until there is a default in payment
of the applicable redemption price. Notwithstanding anything to
the contrary herein, a Change of Control Offer may be made in
advance of a Change of Control, conditional upon such Change of
Control, if a definitive agreement is in place for the Change of
Control at the time of making of the Change of Control Offer.
The provisions described above that require the Company to make
a Change of Control Offer following a Change of Control will be
applicable whether or not any other provisions of the Indenture
are applicable.
46
Except as described above with respect to a Change of Control,
the Indenture does not contain provisions that permit the
Holders of the Notes to require that the Company repurchase or
redeem the Notes in the event of a takeover, recapitalization or
similar transaction.
If a Change of Control Offer is made, we cannot assure you that
the Company will have available funds sufficient to pay the
Change of Control purchase price for all the Notes that might be
delivered by Holders seeking to accept the Change of Control
Offer. In the event the Company is required to purchase Notes
pursuant to a Change of Control Offer, the Company expects that
it would seek third-party financing to the extent it does not
have available funds to meet its purchase obligations. However,
we cannot assure you that the Company would be able to obtain
such financing. See Risk Factors Risks Related
to the Notes We may not be able to fulfill our
repurchase obligations with respect to the notes upon a change
of control or an asset sale.
The Companys future senior Indebtedness may prohibit
events that would constitute a Change of Control. If the Company
were to experience a change of control that triggers a default
under such other senior Indebtedness, the Company could seek a
waiver of such default or seek to refinance such other senior
Indebtedness. In the event that the Company does not obtain such
a waiver or refinance such senior Indebtedness, such default
could result in amounts outstanding under such other senior
Indebtedness to be declared due and payable. In addition, the
exercise by the Holders of Notes of their right to require the
Company to repurchase the Notes could cause a default under such
other senior Indebtedness, even if the occurrence of the Change
of Control itself does not, due to the financial effect of such
repurchases on the Company.
The definition of Change of Control includes a phrase relating
to the direct or indirect sale, lease, transfer, conveyance or
other disposition of all or substantially all of the
properties or assets of the Company and its Subsidiaries taken
as a whole. Although there is a limited body of case law
interpreting the phrase substantially all, there is
no precise established definition of the phrase under applicable
law. Accordingly, the ability of a holder of Notes to require
the Company to repurchase its Notes as a result of a sale,
lease, transfer, conveyance or other disposition of less than
all of the assets of the Company and its Subsidiaries taken as a
whole to another Person or group may be uncertain.
Asset
Sales
The Company will not, and will not permit any Restricted
Subsidiary to, consummate any Asset Sale, unless:
(1) the consideration received by the Company or such
Restricted Subsidiary is at least equal to the Fair Market Value
of the assets sold or disposed of and, if the Fair Market Value
of the assets or Equity Interests issued or sold or otherwise
disposed of is greater than $10.0 million, the Asset Sale
is approved by the Companys Board of Directors; and
(2) at least 75% of the consideration received consists of:
(a) cash or Temporary Cash Investments, or
(b) Designated Non-Cash Consideration received by the
Company or any Guarantor in such Asset Sale having an aggregate
Fair Market Value (when taken together with all other
Designatured Non-Cash Consideration received pursuant to this
clause (c)) that does not exceed 10% of the total assets of the
Company and the Guarantors, on a consolidated basis, at the time
of receipt of such Designated Non-Cash Consideration, with the
Fair Market Value of each item of Designated Non-Cash
Consideration being measured at the time it was received and
without giving effect to subsequent changes in value.
For purposes of this provision, any securities, notes or other
obligations received by the Company or any such Restricted
Subsidiary that are converted by the Company or such Restricted
Subsidiary into cash within 30 days after receipt (to the
extent of the cash received in such conversion) shall be deemed
to be cash.
47
Within 365 days after the receipt of any Net Proceeds from
an Asset Sale, the Company (or the applicable Restricted
Subsidiary, as the case may be) may apply such Net Proceeds at
its option:
(1) to repay Indebtedness under any Credit Facility of the
Company or any Restricted Subsidiary, in each case owing to a
Person other than the Company or any Affiliate of the
Company; or
(2) to invest (or enter into a definitive agreement
committing to invest) in Replacement Assets or capital
expenditures (provided that if any such commitment
terminates for any reason, the Company shall, within
45 days after such termination, apply such Net Cash
Proceeds in accordance with the provisions of this or the
following paragraph, unless a replacement commitment has been
entered into within such 45 day period); or
(3) to make one or more offers to the Holders of the Notes
(and, at the option of the Company, the holders of Pari Passu
Indebtedness) to purchase Notes (and such other Pari Passu
Indebtedness) pursuant to and subject to the conditions
applicable to an Asset Sale Offer described below; or
(4) to acquire (or enter into a definitive commitment to
acquire) all or substantially all of the assets of, or any
capital stock of another Permitted Business, if, after giving
effect to such acquisition of capital stock, the Permitted
Business is or becomes a Restricted Subsidiary (provided
that if any such commitment terminates for any reason, the
Company shall, within 45 days after such termination, apply
such Net Cash Proceeds in accordance with the provisions of this
or the following paragraph, unless a replacement commitment has
been entered into within such 45 day period); or
(5) any combination of the foregoing.
Any Net Cash Proceeds from Asset Sales that are not applied or
invested as provided in the preceding paragraph of this covenant
will constitute Excess Proceeds. If, as of the first
day of any calendar month, the aggregate amount of Excess
Proceeds not theretofore subject to an Asset Sale Offer pursuant
to this covenant totals at least $20.0 million, the Company
must commence, not later than the fifteenth Business Day of such
month, and consummate an Asset Sale Offer from the Holders (and
if required by the terms of any Indebtedness that is pari passu
with the Notes (Pari Passu Indebtedness), from the
holders of such Pari Passu Indebtedness) on a pro rata basis an
aggregate principal amount of Notes (and Pari Passu
Indebtedness) equal to the Excess Proceeds on such date, at a
purchase price equal to 100% of their principal amount, plus, in
each case, accrued interest (if any) to the Payment Date.
Pending the final application of any such Net Cash Proceeds, the
Company or any of its Restricted Subsidiaries may temporarily
reduce revolving credit borrowings or otherwise invest such Net
Cash Proceeds in any manner that is not prohibited by the terms
of the Indenture. If any Excess Proceeds remain after the
consummation of any Asset Sale Offer, the Company may use such
Excess Proceeds for any other purpose not otherwise prohibited
by the Indenture. Upon completion of each Asset Sale Offer, the
amount of Excess Proceeds will reset to zero.
The Company will comply with the requirements of
Rule 14e-1
under the Exchange Act and any other securities laws and
regulations thereunder to the extent those laws and regulations
are applicable in connection with each repurchase of Notes
pursuant to an Asset Sale Offer. To the extent that the
provisions of any securities laws or regulations conflict with
the Asset Sale provisions of the Indenture, the Company will
comply with the applicable securities laws and regulations and
will not be deemed to have breached its obligations under the
Asset Sale provisions of the indenture by virtue of such
compliance.
Certain
Covenants
Overview
In the Indenture, the Company has agreed to covenants that limit
its and its Restricted Subsidiaries ability, among other
things, to (subject to certain express exceptions):
|
|
|
|
|
incur additional Indebtedness and issue preferred stock;
|
|
|
|
pay dividends and make distributions in respect of capital stock;
|
|
|
|
make investments or certain other restricted payments;
|
48
|
|
|
|
|
place limits on dividends and enter into other payment
restrictions affecting certain subsidiaries;
|
|
|
|
engage in sale-leaseback transactions;
|
|
|
|
enter into transactions with stockholders or affiliates;
|
|
|
|
guarantee debt;
|
|
|
|
sell assets;
|
|
|
|
create liens;
|
|
|
|
issue or sell stock of certain subsidiaries; and
|
|
|
|
merge or consolidate.
|
Limitation
on Indebtedness
The Company will not, and will not permit any Restricted
Subsidiary to, create, incur, assume or Guarantee the payment of
any Indebtedness (including Acquired Indebtedness) other than
Permitted Indebtedness and the Company will not issue any
Disqualified Stock and will not permit any of its Restricted
Subsidiaries to issue any Disqualified Stock or preferred stock
to any Person other than the Company or its Wholly Owned
Restricted Subsidiaries unless, after giving effect to the
transaction, its Fixed Charge Coverage Ratio for the four full
fiscal quarters immediately preceding the transaction for which
internal financial statements are available immediately
preceding the date of such transaction, taken as a single
period, is 2.0 to 1 or greater, determined on a pro forma basis
(including a pro forma application of the net proceeds
therefrom) as if the additional Indebtedness had been incurred
or the Disqualified Stock (or the preferred stock, if
applicable) had been issued, as the case may be, at the
beginning of such four-quarter period.
The first paragraph of this covenant will not prohibit the
incurrence of any of the following items of Indebtedness
(collectively, Permitted Indebtedness):
(1) Indebtedness under Credit Facilities outstanding at any
time in an aggregate principal amount not to exceed
$5.0 million;
(2) additional Indebtedness of the Company and its
Restricted Subsidiaries in an aggregate principal amount
outstanding at any time not to exceed $10.0 million;
(3) Indebtedness of the Company or any of its Restricted
Subsidiaries outstanding on the Closing Date;
(4) the incurrence by the Company or any of its Restricted
Subsidiaries of Permitted Refinancing Indebtedness in exchange
for, or the net proceeds of which are used to renew, refund,
refinance, replace, defease or discharge any Indebtedness (other
than Intercompany Debt Obligations) that was permitted by the
Indenture to be incurred under the first paragraph of this
covenant or clauses (3), (4) or (7) of this paragraph;
(5) Intercompany Debt Obligations between or among the
Company and any of its Wholly Owned Restricted Subsidiaries;
provided that any Intercompany Debt Obligations of the Company
incurred after the Closing Date other than in connection with
Refinancing Indebtedness must be evidenced by an intercompany
note; provided further that (i) any subsequent issuance or
transfer of any Equity Interests that results in such
Indebtedness being held by a Person other than the Company or a
Restricted Subsidiary and (ii) any sale or other transfer
of such Indebtedness to a Person other than the Company or a
Restricted Subsidiary shall each be deemed to be an incurrence
of Indebtedness by the obligor if and to the extent that it is
the Company or a continuing Restricted Subsidiary of the Company;
(6) the incurrence by the Company or any of its Restricted
Subsidiaries of Indebtedness represented by Capital Lease
Obligations, mortgage financings or purchase money obligations,
in each case, incurred for the purpose of financing all or any
part of the purchase price or cost of design, construction,
installation or improvement of property, plant or equipment used
in the business of the Company or any
49
of its Restricted Subsidiaries, in an aggregate principal
amount, including all Permitted Refinancing Indebtedness
incurred to renew, refund, refinance, replace, defease or
discharge any Indebtedness incurred pursuant to this clause (6),
not to exceed $10.0 million;
(7) Indebtedness under (a) the Notes and the Note
Guarantees issued on the Closing Date, (b) the exchange
notes and the Note Guarantees in respect thereof to be issued
pursuant to the Registration Rights Agreement and
(c) Indebtedness under (i) the old notes and the
related Note Guarantees issued after the Closing Date and
(ii) the exchange notes and Note Guarantees in respect
thereof to be issued pursuant to a Registration Rights
Agreement, in the aggregate principal amount not to exceed
$52.0 million;
(8) Indebtedness represented by Guarantees by the Company
or its Restricted Subsidiaries of Indebtedness otherwise
permitted to be incurred;
(9) Hedging Obligations incurred by the Company or any of
its Restricted Subsidiaries in the ordinary course of business;
(10) Indebtedness of the Company or any Restricted
Subsidiary consisting of Guarantees, indemnities, or obligations
in respect of purchase price adjustments, earnout or similar
obligations, in connection with the acquisition or disposition
of assets (other than Guarantees of Indebtedness by any Person
acquiring such assets for the purpose of financing such
acquisition), so long as the amount does not exceed the gross
proceeds actually received by the Company in connection with
such disposition;
(11) Indebtedness of the Company or any Restricted
Subsidiary constituting reimbursement obligations with respect
to letters of credit issued in the ordinary course of business;
(12) Indebtedness of the Company or any of its Restricted
Subsidiaries in respect to performance bonds, bankers
acceptances, workers compensation claims, surety or appeal bonds
payment obligations in connection with self-insurance or similar
obligations;
(13) Indebtedness of the Company or any of its Restricted
Subsidiaries arising from the honoring by a bank or other
financial institution of a check, draft or similar instrument
inadvertently drawn against insufficient funds, so long as such
Indebtedness is promptly extinguished; and
(14) Indebtedness of Foreign Restricted Subsidiaries so
long as the aggregate principal amount outstanding shall not
exceed $5.0 million (or the currency equivalent thereof).
For purposes of determining compliance with this covenant if an
item of Indebtedness meets the criteria of more than one of the
categories of Permitted Indebtedness or may be incurred under
the Fixed Charge Coverage Ratio, the Company may classify (and
from time to time may reclassify) the Indebtedness in its sole
discretion.
Notwithstanding any other provision of this Limitation on
Indebtedness covenant, the maximum amount of Indebtedness
that may be incurred pursuant to this Limitation on
Indebtedness covenant will not be deemed to be exceeded,
with respect to any outstanding Indebtedness, due solely to the
result of fluctuations in the exchange rates of currencies
between the dates such non-dollar Indebtedness was incurred and
the measurement date for purposes of this provision.
The Company will not incur any Indebtedness if such Indebtedness
is subordinate in right of payment to any other Indebtedness
unless such Indebtedness is also subordinate in right of payment
to the Notes to the same extent. For purposes of the foregoing,
no Indebtedness will be deemed to be subordinated in right of
payment to any other Indebtedness solely by virtue of being
unsecured, by virtue of being secured by different collateral or
by virtue of the fact that the holders of any secured
Indebtedness have entered into intercreditor agreements giving
one or more of such holders priority over the other holders in
the collateral held by them.
50
Limitation
on Restricted Payments
The Company will not, and will not permit any Restricted
Subsidiary, directly or indirectly, to make any Restricted
Payment unless, at the time and after giving effect to the
proposed Restricted Payment, the following conditions are met:
(1) no Default or Event of Default under the Indenture
shall have occurred and be continuing (or would result
therefrom);
(2) at the time of and after giving effect to any proposed
Restricted Payment, the Company would be able to incur at least
$1.00 of Indebtedness under the Fixed Charge Coverage Ratio
described above under Limitation on
Indebtedness; and
(3) such payment, along with the aggregate amount of all
Restricted Payments declared or made on or after the Closing
Date may not exceed the sum of
(a) 50% of the Companys total Consolidated Net Income
accrued on a cumulative basis during the period from the
beginning of the first fiscal quarter which begins after the
Closing Date and ending on the last day of its last fiscal
quarter ending prior to the date of the proposed Restricted
Payment for which internal financial statements are available at
the time of such Restricted Payment (or if such aggregate
cumulative Consolidated Net Income is a loss, minus 100% of such
loss); plus
(b) 100% of the aggregate Net Cash Proceeds received by the
Company on or after the Closing Date (i) as capital
contributions or (ii) from the issuance and sale of
(x) Equity Interests of the Company to any Person or entity
other than a Subsidiary of the Company, excluding the issuance
or sale of Disqualified Stock and the Series A Non-Voting
Preferred Stock or (y) any other securities of the Company,
upon the conversion or exchange of such securities into Equity
Interests of the Company, other than Disqualified Stock; plus
(c) to the extent that any Restricted Investment that was
made after the Closing Date is sold for cash or repaid (whether
through interest payments, principal payments, dividends or
other distributions), the amount received in cash from such sale
or repayment; plus
(d) to the extent that any Restricted Investment was made
in an Unrestricted Subsidiary or other entity after the Closing
Date and such Unrestricted Subsidiary or other entity is
redesignated as or becomes a Restricted Subsidiary, the lesser
of (i) the Fair Market Value of the Investment in such
Subsidiary on the date of such redesignation and (ii) the
initial amount of such Restricted Investment.
The provisions of the preceding paragraph shall not prohibit the
following:
(a) the payment of any dividend, within 60 days after
it was declared, if at the date it was declared, the payment
would have been permitted;
(b) the making of any Restricted Payment or the redemption,
repurchase, retirement, defeasance or other acquisition of any
Equity Interests of the Company (or Indebtedness that is
subordinated to the Notes or any Subsidiary Guarantee) by
conversion into, in exchange for, or out of the net proceeds of
the substantially concurrent sale (other than to a Subsidiary of
the Company) of, any Equity Interests of the Company (other than
any Disqualified Stock); provided that, in each such
case, the amount of any such net cash proceeds that are so
utilized shall be excluded from clause (3)(b) of the preceding
paragraph and clause (e) of this paragraph;
(c) the payment, redemption, repurchase, defeasance or
other acquisition or retirement for value of Indebtedness that
is subordinated to the Notes or any Subsidiary Guarantee,
including premium, if any, and accrued interest, with the
proceeds of, or in exchange for, a substantially concurrent
incurrence of Permitted Refinancing Indebtedness;
51
(d) the payment of any dividend (or, in the case of any
partnership or limited liability company, any similar
distribution) by a Restricted Subsidiary of the Company to the
holders of its Equity Interests to the extent such payments are
made on a pro rata basis;
(e) so long as no Default or Event of Default shall have
occurred and be continuing (or would result therefrom), the
repurchase, redemption or other acquisition or retirement for
value of any Equity Interests of the Company held by any current
or former director, officer, employee or agent of the Company
(or any of its Subsidiaries) pursuant to any management equity
subscription agreement, stock option agreement or other employee
benefit plan or arrangement; provided that the aggregate
price paid for all such repurchased, redeemed, acquired or
retired Equity Interests shall not exceed $1.0 million in
any twelve-month period; provided further, that the
Company may carry over and make in subsequent twelve-month
periods, in addition to the amounts permitted for such
twelve-month period, any unutilized capacity under this
clause (e) attributable to the immediately preceding
twelve-month period; provided, further, that such amount
in any twelve-month period may be increased by an amount not to
exceed the cash proceeds from the sale of Equity Interests of
the Company (other than Disqualified Stock) to members of
management, directors or consultants of the Company or any of
its Subsidiaries that occurs after the date of the Indenture to
the extent the cash proceeds from the sale of such Equity
Interests have not otherwise been applied to the making of
Restricted Payments pursuant to clause (3)(b) of the preceding
paragraph or clause (b) of this paragraph; and in addition,
cancellation of Indebtedness owing to the Company from any
current or former officer, director or employee (or any
permitted transferees thereof) of the Company or any of its
Restricted Subsidiaries (or any direct or indirect parent
company thereof), in connection with a repurchase of Equity
Interests of the Company from such Persons will not be deemed to
constitute a Restricted Payment for purposes of this covenant or
any other provisions of the indenture;
(f) the purchase of Equity Interests of the Company deemed
to occur upon the exercise of stock options or warrants if such
Equity Interests represent all or a portion of the exercise
price of (or taxes in respect of the exercise of) such options
or warrants;
(g) cash payments in lieu of the issuance of fractional
shares;
(h) the distribution, by dividend or otherwise, of Equity
Interests in any Unrestricted Subsidiary;
(i) so long as no Default or Event of Default has occurred
and is continuing, within 120 days after completion of any
offer to repurchase Notes pursuant to the covenant described
above under the captions Repurchase at the
Option of Holders Asset Sales or
Repurchase at the Option of
Holders Change of Control (including the
purchase of all Notes tendered), any purchase or redemption of
any subordinated Indebtedness or any Indebtedness of the Company
or any Guarantor that is contractually subordinated to the Notes
or to any Note Guarantee, in each case, that is required to be
repurchased or redeemed pursuant to the terms thereof as a
result of such Asset Sale or such Change of Control;
(j) the redemption, repurchase, defeasance or other
acquisition or retirement of the Series A Non-Voting
Preferred Stock which is redeemed, repurchased, defeased,
acquired or retired with proceeds from the old notes; and
(k) so long as no Default or Event of Default shall have
occurred and be continuing (or would result therefrom), any
Restricted Payment which, together with all other Restricted
Payments made pursuant to this clause (j) on or after the
Closing Date, does not exceed $5.0 million.
In determining the aggregate amount of Restricted Payments made
subsequent to the Closing Date in accordance with
clause (3) above, amounts expended pursuant to clauses (a),
(e), and (k) shall be included in such calculation. If a
Restricted Payment is not made in cash, its value, if in excess
of $5.0 million, must be determined by the Companys
Board of Directors as evidenced by a resolution of the Board of
Directors.
52
Dividend
and Other Payment Restrictions Affecting Restricted
Subsidiaries
The Company will not, and will not permit any of its Restricted
Subsidiaries to, directly or indirectly, create or agree to any
encumbrance or restriction on the ability of any Restricted
Subsidiary to (1) pay dividends or make any other
distributions on its Equity Interests to the Company or any of
the Companys Restricted Subsidiaries, or with respect to
any other interest or participation in, or measured by, its
profits, or pay any Indebtedness owed to the Company or any of
the Companys Restricted Subsidiaries; or (2) make
loans or advances to the Company or any of the Companys
Restricted Subsidiaries.
However, the preceding restrictions will not apply to
encumbrances or restrictions existing under or by reason of:
(1) those in existence on the Closing Date in the Indenture
or any other agreements in effect on the Closing Date, and any
amendments, modifications, restatements, supplements,
extensions, increases, refinancings, renewals, refundings or
replacements of such agreements; provided that the
encumbrances and restrictions in any such amendments,
modifications, restatements, supplements, extensions, increases,
refinancings, renewals, refundings or replacements are not
materially less favorable, taken as a whole (as determined by
the Company in good faith), to the Holders than those
encumbrances or restrictions that are then in effect and that
are being amended, modified, restated, supplemented, extended,
increased, refinanced, renewed, refunded or replaced;
(2) the Indenture, the Notes, the Note Guarantees and the
other Security Documents;
(3) applicable law, rules, regulations or orders;
(4) any agreement or instrument (including Acquired
Indebtedness) applicable to or binding on a Person acquired by
the Company or any of its Restricted Subsidiaries as in effect
at the time of such acquisition (except to the extent such
agreement or instrument was entered into in connection with or
in contemplation of such acquisition), which encumbrance or
restriction is not applicable to any Person, or the properties
or assets of any Person, other than the Person, or the property
or assets of the Person, so acquired, provided that, in
the case of such acquired Persons Indebtedness, such
Indebtedness was permitted to be incurred by the terms of the
Notes, and any amendments, modifications, restatements,
supplements, extensions, increases, refinancings, renewals,
refundings or replacements of such agreements, provided
further that the encumbrances and restrictions in any such
amendments, modifications, restatements, supplements,
extensions, increases, refinancings, renewals, refundings or
replacements are not materially less favorable, taken as a whole
(as determined by the Company in good faith), to the Holders
than those encumbrances or restrictions that are then in effect
and that are being amended, modified, restatements,
supplemented, extended, increased, refinanced, renewed, refunded
or replaced;
(5) restrictions on the ability of any Foreign Restricted
Subsidiary to make dividends or distributions resulting from the
operation of payment defaults and reasonable financial covenants
(as determined in good faith by the Company) contained in
documents governing Indebtedness of Foreign Restricted
Subsidiaries permitted to be incurred under the provisions of
the covenant described above under the caption
Limitation on Indebtedness, provided
that, such Indebtedness does not to exceed
$50.0 million in the aggregate at any time outstanding;
(6) any agreement for the sale or other disposition of a
Restricted Subsidiary that restricts distributions by such
Restricted Subsidiary pending its sale or other disposition;
(7) provisions with respect to the disposition or
distribution of assets or property in joint venture agreements,
asset sale agreements, sale-leaseback agreements, stock sale
agreements and other similar agreements (including agreements
entered into in connection with a Restricted Investment) entered
into in the ordinary course of business or with the approval of
the Companys Board of Directors;
(8) restrictions on cash or other deposits or net worth
under contracts entered into in the ordinary course of business;
53
(9) encumbrances and restrictions in Indebtedness
refinancing other Indebtedness provided that the encumbrances
and restrictions contained in the new Indebtedness are not
materially less favorable, taken as a whole (as determined by
the Company in good faith), to the Holders, than those contained
in the Indebtedness being refinanced;
(10) encumbrances on and agreements or instruments relating
to any property, asset or business acquired by the Company or a
Restricted Subsidiary as in effect at the time of such
acquisition, which encumbrances or restrictions are not
applicable to any other properties, assets or businesses of the
Company or its Restricted Subsidiaries and were not incurred in
contemplation of such acquisition;
(11) customary restrictions imposed on the transfer of, or
in licenses related to, copyrights, patents or other
intellectual property and contained in agreements entered into
in the ordinary course of business;
(12) any restriction contained in mortgages, pledges or
other agreements securing Indebtedness of the Company or any
Restricted Subsidiary to the extent such restriction restricts
the transfer of the property subject to such mortgages, pledges
or other security agreements;
(13) restrictions imposed by an agreement to sell or
otherwise dispose of assets or Equity Interests to any person
pending the closing of such sale or other disposition; and
(14) customary non-assignment provisions and restrictions
on
sub-letting
contained in contracts, leases or licenses entered into in the
ordinary course of business.
Nothing contained in this Dividend and Other Payment
Restrictions Affecting Restricted Subsidiaries covenant
shall prevent the Company or any Restricted Subsidiary from
(1) creating, incurring, assuming or suffering to exist any
Liens otherwise permitted in the Limitation on Liens
covenant or (2) restricting the sale or other disposition
of property or assets of the Company or any of its Restricted
Subsidiaries that secure Indebtedness of the Company or any of
its Restricted Subsidiaries.
Limitation
on Guarantees by Restricted Subsidiaries
The Company will not permit any Restricted Subsidiary that is a
Domestic Restricted Subsidiary, directly or indirectly, by way
of the pledge of any intercompany note or otherwise, to assume,
guarantee or in any other manner become liable with respect to
any Indebtedness of the Company, unless, in any such case:
(1) within 30 days thereafter, such Domestic
Restricted Subsidiary executes and delivers a supplemental
indenture to the Indenture, providing a Note Guarantee of
payment of the Notes by such Domestic Restricted Subsidiary if
not previously delivered; and
(2) if such assumption, guarantee or other liability of
such Domestic Restricted Subsidiary is provided in respect of
Indebtedness that is expressly subordinated to the Notes, the
guarantee or other instrument provided by such Domestic
Restricted Subsidiary in respect of such subordinated
Indebtedness shall be subordinated to the Guarantee pursuant to
subordination provisions that are substantially the same as
those contained in the instrument pursuant to which such
subordinated Indebtedness is issued.
Notwithstanding the foregoing, any such Note Guarantee by a
Domestic Restricted Subsidiary of the Notes shall provide by its
terms that it shall be automatically and unconditionally
released and discharged, without any further action required on
the part of the Trustee or any Holder, upon:
(1) the unconditional release of such Domestic Restricted
Subsidiary from its liability in respect of the Indebtedness in
connection with which such Note Guarantee was executed and
delivered pursuant to the preceding paragraph; or
(2) any sale or other disposition (by merger or otherwise)
to any Person that is not a Restricted Subsidiary of the Company
of the Companys Equity Interests, such that immediately
after giving effect to such transaction, such Domestic
Restricted Subsidiary would no longer constitute a Subsidiary of
the Company, or any sale or other disposition of all or
substantially all of the assets of, such Domestic Restricted
Subsidiary; provided that: (a) such sale or
disposition of such Equity Interests or assets is otherwise in
compliance with the terms of the Indenture; and (b) such
assumption, guarantee or other
54
liability of such Domestic Restricted Subsidiary has been
released by the holders of the other Indebtedness so guaranteed.
Transactions
with Affiliates of the Company
The Company will not, and will not permit any Restricted
Subsidiary to, directly or indirectly enter into any transaction
or series of related transactions (including, without
limitation, the sale, purchase, exchange or lease of assets,
property or services) with any Affiliate of the Company
involving aggregate payments or consideration in excess of
$1.0 million unless the following conditions are met:
(1) the transaction or series of transactions must be on
terms which are as favorable to the Company or the Restricted
Subsidiary, taken as a whole, as would be available in a
comparable transaction with an unrelated third party;
(2) if the transaction or series of transactions involves
aggregate payments of $10.0 million or more, then the
transaction or series of transactions must be approved by the
Companys Board of Directors, including the approval of a
majority of directors who are not Affiliates of the Company in
connection with the transaction or transactions being
approved; and
(3) if the transaction or series of transactions involves
aggregate payments of $15.0 million or more, then the
Company must deliver to the Trustee an opinion as to the
fairness from a financial point of view to the Company and its
Subsidiaries, taken as a whole, of such transaction or series of
transactions issued by an accounting, appraisal or investment
banking firm of national standing.
However, this provision does not apply to:
(1) any employment or compensation agreement (whether based
in cash or securities), stock option plan, stock ownership plan
or employee benefit plan, officer or director indemnification
agreement or any similar arrangement entered into by the Company
or any of its Restricted Subsidiaries in the ordinary course of
business and payments pursuant thereto;
(2) loans and advances to employees of the Company or any
Subsidiary in the ordinary course of business not otherwise
prohibited pursuant to the terms of the Notes;
(3) Restricted Payments that are permitted by the terms of
the Notes described under the covenant Limitation on
Restricted Payments or Permitted Investments;
(4) issuances of Equity Interests (other than Disqualified
Stock) of the Company by the Company and the granting or
performance of registration rights;
(5) any transaction between or among the Company and one or
more Restricted Subsidiaries of the Company or among one or more
Restricted Subsidiaries of the Company;
(6) if such transaction is with any Person solely in its
capacity as a holder of Indebtedness or Equity Interests of the
Company or any of its Restricted Subsidiaries, if such person is
treated no more favorably than any other holder of Indebtedness
or Equity Interest of the Company; provided such Person
owns less than 10% of such Indebtedness or Equity Interests;
(7) payment of reasonable and customary fees and
reimbursements of expenses (pursuant to indemnity arrangements
or otherwise) of officers, directors, employees or consultants
of the Company or any of its Restricted Subsidiaries;
(8) transactions with customers, clients, suppliers, or
purchasers or sellers of goods or services that do not, directly
or indirectly, own Equity Interests in the Company and in which
the Company does not, directly or indirectly, own Equity
Interests, in each case, in the ordinary course of business and
otherwise in compliance with the terms of the Indenture and
which are on terms that are no less favorable to the Company or
the relevant Restricted Subsidiary that those that would have
been obtained in a comparable arms length transaction with
a person that is not an Affiliate of the Company;
55
(9) any agreement between any Person and an Affiliate of
such Person existing at the time such Person is acquired by or
merged into the Company or any of the Companys Restricted
Subsidiaries; provided that such agreement was not entered into
contemplation of such acquisition or merger;
(10) any agreement as in effect on the Closing Date or any
amendment thereto so long as the amendment is not materially
more disadvantageous to the Holders, taken as a whole, than the
agreement existing on Closing Date (as determined in good faith
by the Company); and
(11) issuances of old notes to any Affiliate on terms which
are as favorable to the Issuer and the Restricted Subsidiaries,
taken as a whole, as is available in a simultaneous or
comparable issuance of old notes with an unrelated third party.
Limitation
on Liens
The Company will not, and will not permit any Restricted
Subsidiary to, create, assume, incur or suffer to exist any Lien
upon any of their assets now owned or hereafter acquired, except
for Permitted Liens.
Limitation
on Sale-Leaseback Transactions
The Company will not, and will not permit any of its Restricted
Subsidiaries to, enter into any sale and leaseback transaction;
provided that the Company and any Restricted Subsidiary
may enter into a sale and leaseback transaction if:
(i) the Company or such Restricted Subsidiary could have
(a) incurred Indebtedness in an amount equal to the
Attributable Debt relating to such sale and leaseback
transaction pursuant to the first paragraph of the covenant
described above under the caption Limitation
on Indebtedness and (b) incurred a Lien to secure
such Indebtedness pursuant to the covenant described above under
the caption Limitation on Liens;
(ii) the gross cash proceeds of such sale and leaseback
transaction are at least equal to the Fair Market Value of the
property that is the subject of such sale and leaseback
transaction; and
(iii) the transfer of assets in such sale and leaseback
transaction is permitted by, and the Company applies the
proceeds of such transaction in compliance with, the covenant
described above under the caption Repurchase at the Option
of Holders Asset Sales.
The foregoing restriction does not apply to any sale-leaseback
transaction if:
(1) the lease is for a period, including renewal rights, of
not in excess of three years; or
(2) the transaction is solely between the Company and one
or more Wholly Owned Restricted Subsidiaries or solely between
Wholly Owned Restricted Subsidiaries; or
(3) the property that is the subject of the sale leaseback
transaction is the Hartland Property.
Business
Activities
The Company will not, and will not permit any of its Restricted
Subsidiaries to, engage in any business other than Permitted
Businesses, except to such extent as would not be material to
the Company and its Restricted Subsidiaries taken as a whole.
Payments
for Consent
The Company will not, and will not permit any of its Restricted
Subsidiaries to, directly or indirectly, pay or cause to be paid
any consideration to or for the benefit of any holder of Notes
for or as an inducement to any consent, waiver or amendment of
any of the terms or provisions of the Indenture or the Notes
unless such consideration is offered to be paid and is paid to
all holders of the Notes that consent, waive or agree to amend
such terms and provisions in the time frame set forth in the
solicitation documents relating to such consent, waiver or
agreement.
56
Consolidation,
Merger and Sale of Assets
The Company will agree not to consolidate or merge with or into
any other entity, or sell, lease or convey all or substantially
all of its assets, to any other entity in any one or more
transactions unless the following conditions are met:
(1) the resulting, surviving or transferee Person (the
Surviving Entity) is organized under the laws of the
United States of America or any state thereof or the District of
Columbia, and the Surviving Entity (if not the Company) shall
expressly assume, by an indenture supplemental thereto, executed
and delivered to the Trustee, in form satisfactory to the
Trustee, all of the Companys obligations under the Notes
and the Indenture;
(2) immediately after giving effect to the transaction (and
treating any Indebtedness which becomes an obligation of the
Surviving Entity or any Restricted Subsidiary as a result of
such transaction as having been incurred by such Surviving
Entity or such Restricted Subsidiary at the time of such
transaction), no Default or Event of Default under the Indenture
shall have occurred and be continuing;
(3) immediately after giving effect to the transaction (and
treating any Indebtedness which becomes an obligation of the
Surviving Entity or any Restricted Subsidiary as a result of
such transaction as having been incurred by such Surviving
Entity or such Restricted Subsidiary at the time of such
transaction), either (a) the Surviving Entity would be able
to incur at least $1.00 of Indebtedness under the Fixed Charge
Coverage Ratio described above under Limitation on
Indebtedness, determined on a pro forma basis as if such
transaction had occurred at the beginning of the immediately
preceding four-quarter period; or (b) the Fixed Charge
Coverage Ratio for the Surviving Entity, determined on a pro
forma basis (including Pro Forma Cost Savings) as if such
transaction had occurred at the beginning of the immediately
preceding four-quarter period, would be greater than the actual
Fixed Charge Coverage Ratio for the Company for the most
recently completed four-quarter period prior to the
transaction; and
(4) the Company must deliver to the Trustee an
Officers Certificate and Opinion of Counsel, in each
stating that such consolidation, merger or transfer and such
supplemental indenture complies with this provision and that all
conditions precedent provided for herein relating to such
transaction have been complied with.
If the Company is not the Surviving Entity and the transaction
meets the above conditions, the Surviving Entity will be
substituted for the Company and after that the Company will no
longer have any obligations under the Indenture or the Notes
except in the case of a conveyance, transfer or lease to an
Affiliate of the Company or a lease of substantially all of the
assets of the Company.
Notwithstanding the foregoing, if the Company effects a
consolidation, merger or sale, conveyance, assignment, transfer,
lease or other disposition of substantially all of its assets,
the condition set forth in clause (3) of the paragraph
above shall not apply to a transaction involving a Surviving
Entity which is otherwise subject to the foregoing provisions
if: (A) the consolidation or merger, or any sale,
assignment, transfer, conveyance, lease or other disposition of
assets is between or among the Company and its Restricted
Subsidiaries; or (B) the merger was affected solely in
connection with a reincorporation of the Company.
SEC
Reports and Reports to Holders
Whether or not required by the rules and regulations of the SEC,
so long as any Notes are outstanding, the Company will furnish
to the Holders of Notes and the Trustee or make available to the
Holders of Notes, within the time periods specified in the
SECs rules and regulations:
(1) all quarterly and annual reports that would be required
to be filed with the SEC on
Forms 10-Q
and 10-K if
the Company were required to file such reports; and
(2) all current reports that would be required to be filed
with the SEC on
Form 8-K
if the Company were required to file such reports.
57
All such reports will be prepared in all material respects in
accordance with all of the rules and regulations applicable to
such reports. Each annual report on
Form 10-K
will include a report on the Companys consolidated
financial statements by the Companys certified independent
accountants. In addition, the Company will file a copy of each
of the reports referred to in clauses (1) and
(2) above with the SEC for public availability within the
time periods specified in the rules and regulations applicable
to such reports (unless the SEC will not accept such a filing)
and will post the reports on its website within those time
periods.
If, at any time after consummation of the exchange offer
contemplated by the Registration Rights Agreement, the Company
is no longer subject to the periodic reporting requirements of
the Exchange Act for any reason, the Company will nevertheless
continue filing the reports specified in the preceding
paragraphs of this covenant with the SEC within the time periods
specified above unless the SEC will not accept such a filing.
The Company will not take any action for the purpose of causing
the SEC not to accept any such filings. If, notwithstanding the
foregoing, the SEC will not accept the Companys filings
for any reason, the Company will post the reports referred to in
the preceding paragraphs on its website within the time periods
that would apply if the Company were required to file those
reports with the SEC.
If the Company has designated any of its Subsidiaries as
Unrestricted Subsidiaries, then the quarterly and annual
financial information required by the preceding paragraphs will
include a reasonably detailed presentation, either on the face
of the financial statements or in the footnotes thereto, and in
Managements Discussion and Analysis of Financial Condition
and Results of Operations, of the financial condition and
results of operations of the Company and its Restricted
Subsidiaries separate from the financial condition and results
of operations of the Unrestricted Subsidiaries of the Company.
In addition, the Company and the Guarantors agree that, for so
long as any Notes remain outstanding, if at any time they are
not required to file with the SEC the reports required by the
preceding paragraphs, they will furnish to the Holders of Notes
and to securities analysts and prospective investors, upon their
request, the information required to be delivered pursuant to
Rule 144A(d)(4) under the Securities Act.
Events of
Default
The following events will be defined as Events of
Default in the Indenture:
(a) default in the payment of any installment of interest
on any Notes for 30 days after becoming due;
(b) default in the payment of the principal of (or premium,
if any, on) any Notes when due;
(c) default in the performance of any other covenant
contained in the terms of the Notes or the Indenture for a
period of 60 days (or 90 days in the case of a failure
to comply with the reporting obligations under the caption
Financial Reports) after written notice
of such failure, requiring the Company to remedy the same, shall
have been given to the Company by the Trustee or to the Company
and the Trustee by the holders of 25% in aggregate principal
amount of the Notes then-outstanding;
(d) default under any mortgage, indenture or instrument
under which there may be issued or by which there may be secured
or evidenced any Indebtedness for money borrowed by the Company
or any of its Restricted Subsidiaries (or the payment of which
is guaranteed by the Company or any of its Restricted
Subsidiaries), whether such Indebtedness or Guarantee now
exists, or is created after the date of the Indenture, if that
default:
(A) is caused by a failure to pay principal of, or interest
or premium, if any, on, such Indebtedness prior to the
expiration of the grace period provided in such Indebtedness on
the date of such default (a Payment Default); or
(B) results in the acceleration of such Indebtedness prior
to its express maturity,
58
and, in each case, the principal amount of any such
Indebtedness, together with the principal amount of any other
such Indebtedness under which there has been a Payment Default
or the maturity of which has been so accelerated, aggregates
$10.0 million or more;
(e) one or more judgments, orders or decrees for the
payment of money in excess of $10.0 million, either
individually or in the aggregate, shall be entered against the
Company or any Restricted Subsidiaries and shall not be
discharged, paid, stayed, subject to a negotiated settlement or
subject to insurance, there shall have been a period of
60 days during which a stay of enforcement of such judgment
or order, by reason of an appeal or otherwise, shall not be in
effect;
(f) a court having jurisdiction in the premises enters a
decree or order for (A) relief in respect of the Company or
any Significant Subsidiary in an involuntary case under any
applicable bankruptcy, insolvency or other similar law now or
hereafter in effect, (B) appointment of a receiver,
liquidator, assignee, custodian, trustee, sequestrator or
similar official of the Company or any Significant Subsidiary or
for all or substantially all of the property and assets of the
Company or any Significant Subsidiary or (C) the winding up
or liquidation of the affairs of the Company or any Significant
Subsidiary and, in each case, such decree or order shall remain
unstayed and in effect for a period of 90 consecutive days;
(g) the Company or any Significant Subsidiary
(A) commences a voluntary case under any applicable
bankruptcy, insolvency or other similar law now or hereafter in
effect, or consents to the entry of an order for relief in an
involuntary case under any such law, (B) consents to the
appointment of or taking possession by a receiver, liquidator,
assignee, custodian, trustee, sequestrator or similar official
of the Company or any Significant Subsidiary or for all or
substantially all of the property and assets of the Company or
any Significant Subsidiary or (C) effects any general
assignment for the benefit of creditors;
(h) default in the performance or breach of the provisions
of the Indenture applicable to mergers, consolidations and
transfers of all or substantially all of the assets of the
Company or the failure by the Company to make or consummate an
Asset Sale Offer in accordance with the Repurchase at the
Option of Holders Asset Sales or a Change of
Control Offer in accordance with the Repurchase at the
Option of Holders Change of Control covenant;
(i) (A) any security interest created by any
Collateral Document ceases to be in full force and effect
(except as permitted by the terms of the Indenture or the
Security Documents) or (B) the breach or repudiation by the
Company or any of its Restricted Subsidiaries of any of their
obligations under any Collateral Document; provided that, in the
case of clauses (A) and (B), such cessation, breach or
repudiation, individually or in the aggregate, results in
Collateral having a Fair Market Value in excess of
$10.0 million not being subject to a valid, perfected
security interest and does not result from any unauthorized
action or inaction by the Collateral Agent; or
(j) except as permitted by the Indenture, any Note
Guarantee is held in any judicial proceeding to be unenforceable
or invalid or ceases for any reason to be in full force and
effect, or any Guarantor, or any Person acting on behalf of any
Guarantor, denies or disaffirms its obligations under its Note
Guarantee.
If an Event of Default (other than an Event of Default specified
in clause (f) or (g) that occurs with respect to the
Company) occurs and is continuing under the Indenture, the
Trustee or the Holders of at least 25% in aggregate principal
amount of the Notes, then-outstanding, by written notice to the
Company (and to the Trustee if such notice is given by the
Holders), may declare the principal of, premium, if any, and
accrued interest on the Notes to be immediately due and payable.
Upon a declaration of acceleration, such principal of, premium,
if any, and accrued interest shall be immediately due and
payable. If an Event of Default specified in clause (f) or
(g) above occurs with respect to the Company, the principal
of, premium, if any, and accrued interest on the Notes
then-outstanding shall automatically become and be immediately
due and payable without any declaration or other act on the part
of the Trustee or any Holder. The Holders of at least a majority
in principal amount of the outstanding Notes by written notice
to the Company and to the Trustee, may waive all past defaults
and rescind and annul a declaration of acceleration and its
consequences if (x) all existing Events of Default, other
than the nonpayment of the principal of, premium, if any, and
interest on the Notes that have become due solely by such
declaration of acceleration, have been cured or waived and
(y) the
59
rescission would not conflict with any judgment or decree of a
court of competent jurisdiction. For information as to the
waiver of defaults, see Modification and Waiver.
The Holders of at least a majority in aggregate principal amount
of the outstanding Notes may direct the time, method and place
of conducting any proceeding for any remedy available to the
Trustee or exercising any trust or power conferred on the
Trustee. However, the Trustee may refuse to follow any direction
that conflicts with law or the Indenture, that may involve the
Trustee in personal liability, or that the Trustee determines in
good faith may be unduly prejudicial to the rights of Holders of
Notes not joining in the giving of such direction and may take
any other action it deems proper that is not inconsistent with
any such direction received from Holders of Notes. A Holder may
not pursue any remedy with respect to the Indenture or the Notes
unless:
(1) the Holder gives the Trustee written notice of a
continuing Event of Default;
(2) the Holders of at least 25% in aggregate principal
amount of outstanding Notes make a written request to the
Trustee to pursue the remedy;
(3) such Holder or Holders offer the Trustee indemnity
satisfactory to the Trustee against any costs, liability or
expense;
(4) the Trustee does not comply with the request within
60 days after receipt of the request and the offer of
indemnity; and
(5) during such
60-day
period, the Holders of a majority in aggregate principal amount
of the outstanding Notes do not give the Trustee a direction
that is inconsistent with the request.
However, such limitations do not apply to the right of any
Holder of a Note to receive payment of the principal of,
premium, if any, or interest on, such Note or to bring suit for
the enforcement of any such payment, on or after the due date
expressed in the Notes, which right shall not be impaired or
affected without the consent of the Holder.
Officers of the Company must certify, on or before a date not
more than 120 days after the end of each fiscal year, that
a review has been conducted of the activities of the Company and
its Restricted Subsidiaries and the Companys and its
Restricted Subsidiaries performance under the Indenture
and that, to their knowledge, the Company has fulfilled all
obligations thereunder, or, if there has been a default in the
fulfillment of any such obligation, specifying each such default
and the nature and status thereof. The Company will also be
obligated to notify the Trustee of any default or defaults in
the performance of any covenants or agreements under the
Indenture.
Legal
Defeasance and Covenant Defeasance
The Company may at any time, at the option of its Board of
Directors evidenced by a resolution set forth in an
officers certificate, elect to have all of its obligations
discharged with respect to the outstanding Notes and all
obligations of the Guarantors discharged with respect to their
Note Guarantees (Legal Defeasance) except for:
(1) the rights of holders of outstanding Notes to receive
payments in respect of the principal of, or interest or premium
and Additional Interest, if any, on, such Notes when such
payments are due from the trust referred to below;
(2) the Companys obligations with respect to the
Notes concerning issuing temporary notes, registration of Notes,
mutilated, destroyed, lost or stolen Notes and the maintenance
of an office or agency for payment and money for security
payments held in trust;
(3) the rights, powers, trusts, duties and immunities of
the Trustee, and the Companys and the Guarantors
obligations in connection therewith; and
(4) the Legal Defeasance and Covenant Defeasance provisions
of the Indenture.
60
In addition, the Company may, at its option and at any time,
elect to have the obligations of the Company and the Guarantors
released with respect to certain covenants (including its
obligation to make Change of Control Offers and Asset Sale
Offers) that are described in the Indenture (Covenant
Defeasance) and thereafter any omission to comply with
those covenants will not constitute a Default or Event of
Default with respect to the Notes. In the event Covenant
Defeasance occurs, certain events (not including non-payment,
bankruptcy, receivership, rehabilitation and insolvency events)
described under Events of Default will no longer
constitute an Event of Default with respect to the Notes.
In order to exercise either Legal Defeasance or Covenant
Defeasance:
(1) the Company must irrevocably deposit with the Trustee,
in trust, for the benefit of the holders of the Notes, cash in
U.S. dollars, non-callable Government Securities, or a
combination of cash in U.S. dollars and non-callable
Government Securities, in amounts as will be sufficient, in the
opinion of a nationally recognized investment bank, appraisal
firm or firm of independent public accountants, to pay the
principal of, or interest and premium and Liquidated Damages, if
any, on, the outstanding Notes on the stated date for payment
thereof or on the applicable redemption date, as the case may
be, and the Company must specify whether the Notes are being
defeased to such stated date for payment or to a particular
redemption date;
(2) in the case of Legal Defeasance, the Company must
deliver to the Trustee an opinion of counsel reasonably
acceptable to the Trustee confirming that (a) the Company
has received from, or there has been published by, the Internal
Revenue Service a ruling or (b) since the date of the
Indenture, there has been a change in the applicable United
States federal income tax law, in either case to the effect
that, and based thereon such opinion of counsel will confirm
that, the holders of the outstanding Notes will not recognize
income, gain or loss for United States federal income tax
purposes as a result of such Legal Defeasance and will be
subject to United States federal income tax on the same amounts,
in the same manner and at the same times as would have been the
case if such Legal Defeasance had not occurred;
(3) in the case of Covenant Defeasance, the Company must
deliver to the Trustee an opinion of counsel reasonably
acceptable to the Trustee confirming that the holders of the
outstanding Notes will not recognize income, gain or loss for
United States federal income tax purposes as a result of such
Covenant Defeasance and will be subject to United States federal
income tax on the same amounts, in the same manner and at the
same times as would have been the case if such Covenant
Defeasance had not occurred;
(4) no Default or Event of Default has occurred and is
continuing on the date of such deposit (other than a Default or
Event of Default resulting from the borrowing of funds to be
applied to such deposit) and the deposit will not result in a
breach or violation of, or constitute a default under, any other
instrument to which the Company or any Guarantor is a party or
by which the Company or any Guarantor is bound;
(5) such Legal Defeasance or Covenant Defeasance will not
result in a breach or violation of, or constitute a default
under, any material agreement or instrument (other than the
Indenture) to which the Company or any of its Subsidiaries is a
party or by which the Company or any of its Subsidiaries is
bound;
(6) the Company must deliver to the Trustee an
officers certificate stating that the deposit was not made
by the Company with the intent of preferring the holders of
Notes over the other creditors of the Company with the intent of
defeating, hindering, delaying or defrauding any creditors of
the Company or others; and
(7) the Company must deliver to the Trustee an
officers certificate and an opinion of counsel, each
stating that all conditions precedent relating to the Legal
Defeasance or the Covenant Defeasance have been complied with.
61
Satisfaction
and Discharge
The Indenture will be discharged and will cease to be of further
effect as to all Notes issued thereunder, when:
(1) either:
(a) all Notes that have been authenticated, except lost,
stolen or destroyed Notes that have been replaced or paid and
Notes for whose payment money has been deposited in trust and
thereafter repaid to the Company, have been delivered to the
Trustee for cancellation; or
(b) all Notes that have not been delivered to the Trustee
for cancellation have become due and payable by reason of the
mailing of a notice of redemption or otherwise or will become
due and payable within one year and the Company or any Guarantor
has irrevocably deposited or caused to be deposited with the
Trustee as trust funds in trust solely for the benefit of the
holders, cash in U.S. dollars, non-callable Government
Securities, or a combination of cash in U.S. dollars and
non-callable Government Securities, in amounts as will be
sufficient, without consideration of any reinvestment of
interest, to pay and discharge the entire Indebtedness on the
Notes not delivered to the Trustee for cancellation for
principal, premium and Liquidated Damages, if any, and accrued
interest to the date of maturity or redemption;
(2) no Default or Event of Default has occurred and is
continuing on the date of the deposit (other than a Default or
Event of Default resulting from the borrowing of funds to be
applied to such deposit and the grant on any lien securing such
borrowing) and the deposit will not result in a breach or
violation of, or constitute a default under, any other
instrument to which the Company or any Guarantor is a party or
by which the Company or any Guarantor is bound;
(3) the Company or any Guarantor has paid or caused to be
paid all sums payable by it under the Indenture; and
(4) the Company has delivered irrevocable instructions to
the Trustee under the Indenture to apply the deposited money
toward the payment of the Notes at maturity or on the redemption
date, as the case may be.
In addition, the Company must deliver an officers
certificate and an opinion of counsel to the Trustee stating
that all conditions precedent to satisfaction and discharge have
been satisfied.
Modification
and Waiver
The Indenture may be amended, without the consent of any Holder,
to:
(1) cure any ambiguity, defect, mistake or inconsistency in
the Indenture;
(2) comply with the provisions described under
Consolidation, Merger and Sale of Assets or
Limitation on Guarantees by Restricted Subsidiaries;
(3) comply with any requirements of the SEC in connection
with the qualification of the Indenture under the
Trust Indenture Act;
(4) evidence and provide for the acceptance of appointment
by a successor Trustee;
(5) make any change that, in the good faith opinion of the
Board of Directors, does not materially and adversely affect the
rights of any Holder;
(6) enter into additional or supplemental Security
Documents;
(7) make, complete or confirm any Note Guarantee or any
grant of Collateral permitted or required by the Indenture or
any of the Security Documents or release Collateral in
accordance with the terms of the Indenture and the Security
Documents;
(8) provide for uncertificated Notes in addition to or in
replacement of certificated Notes;
62
(9) evidence the succession of another Person to the
Company or any Guarantor and the assumption by any such
successor of the covenants of the Company of such Guarantor to
the Indenture, the Guarantees and the Security Documents and in
the Notes;
(10) add to the covenants of the Company for the benefit of
the Holders, or to surrender any right or power conferred upon
the Company;
(11) to add additional Events of Default;
(12) to provide for or confirm the issuance of additional
notes in accordance with the terms of the Indenture;
(13) add to the Collateral securing the Notes, to add a
Guarantor or to release a Guarantor in accordance with the terms
of the Indenture; or
(14) conform the text of the Indenture, the Notes or the
Security Documents to any provision of this Description of
the Exchange Notes.
Modifications and amendments of the Indenture may be made by the
Company and the Trustee with the consent of the Holders of not
less than a majority in aggregate principal amount of the
outstanding Notes; provided, however, that no such
modification or amendment may, without the consent of each
Holder affected thereby:
(1) change the Stated Maturity of the principal of, or any
installment of interest on, any Note;
(2) reduce the principal amount of, or premium, if any, or
interest on, any Note;
(3) change the optional redemption dates or optional
redemption prices of the Notes from that stated under the
caption Optional Redemption;
(4) change the place or currency of payment of principal
of, or premium, if any, or interest on, any Note;
(5) impair the right to institute suit for the enforcement
of any payment on or after the Stated Maturity (or, in the case
of a redemption, on or after the Redemption Date) of any
Note;
(6) waive a default in the payment of principal of,
premium, if any, or interest on the Notes; or
(7) reduce the percentage or aggregate principal amount of
outstanding Notes the consent of whose Holders is necessary for
waiver of compliance with certain provisions of the Indenture or
for waiver of certain defaults.
In addition, without the consent of at least two-thirds in
aggregate principal amount of Notes then-outstanding, an
amendment or waiver may not modify any Collateral Document
relating to the Notes or the provisions of the Indenture dealing
with the Security Documents that has the effect of releasing all
or substantially all of the Collateral, except as otherwise
permitted by the Indenture or the Security Documents.
No
Personal Liability of Incorporators, Stockholders, Officers,
Directors, or Employees
No recourse for the payment of the principal of, premium, if
any, or interest on any of the Notes or for any claim based
thereon or otherwise in respect thereof, and no recourse under
or upon any obligation, covenant or agreement of the Company in
the Indenture, or in any of the Notes or because of the creation
of any Indebtedness represented thereby, shall be had against
any incorporator, stockholder, officer, director, employee or
controlling person of the Company or of any successor Person
thereof. Each Holder, by accepting the Notes, waives and
releases all such liability. The waiver and release are part of
the consideration for the issuance of the Notes. Such waiver may
not be effective to waive liabilities under the federal
securities laws.
Concerning
the Trustee
Except during the continuance of an Event of Default, the
Trustee will not be liable, except for the performance of such
duties as are specifically set forth in the Indenture. If an
Event of Default has occurred
63
and is continuing, the Trustee will use the same degree of care
and skill in its exercise of the rights and powers vested in it
under the Indenture as a prudent person would exercise under the
circumstances in the conduct of such persons own affairs.
The Indenture and provisions of the Trust Indenture Act of
1939, as amended, incorporated by reference therein contain
limitations on the rights of the Trustee, should it become a
creditor of the Company, to obtain payment of claims in certain
cases or to realize on certain property received by it in
respect of any such claims, as security or otherwise. The
Trustee is permitted to engage in other transactions;
provided, however, that if it acquires any
conflicting interest, as defined by the Trust Indenture Act
of 1939, it must eliminate such conflict or resign, as provided
in the Trust Indenture Act of 1939.
Neither the Trustee nor the Collateral Agent shall be
responsible for or make any representation as to the existence,
genuineness, value or protection of any Collateral, for the
legality, effectiveness or sufficiency of any Security Document,
or for the creation, perfection, priority, sufficiency or
protection of any Liens securing the Notes and Note Obligations.
Neither the Trustee nor the Collateral Agent shall be
responsible for filing any financing or continuation statements
or recording any documents or instruments in any public office
at any time or times or otherwise perfecting or maintaining the
perfection of any Lien or security interest in the Collateral.
Governing
Law
The Indenture is, and the old notes are, governed by, and
construed in accordance with, the laws of the State of New York.
Book-Entry;
Delivery and Form
The old notes were offered and sold to qualified institutional
buyers in reliance on Rule 144A under the Securities Act.
Old notes also may be offered and sold in reliance on
Regulation S. In addition, Notes may subsequently be
transferred to institutional accredited investors within the
meaning of subparagraph (a)(1), (2), (3) or (7) of
Rule 501 under the Securities Act in transactions exempt
from registration under the Securities Act not made in reliance
on Rule 144A or Regulation S under the Securities Act.
Rule 144A Notes initially will be represented by one or
more Notes in registered, global form without interest coupons.
The Rule 144A global note will be deposited upon issuance
with the Trustee as custodian for The Depository
Trust Company, also referred to as DTC, and registered in
the name of DTC or its nominee, in each case for credit to an
account of a direct or indirect participant as described below.
Regulation S Notes initially will be represented by one or
more Notes in registered, global form without interest coupons.
The Regulation S global note will be deposited upon
issuance with the Trustee as custodian for DTC, and registered
in the name of a nominee of DTC, in each case for credit to the
accounts of Euroclear System and Clearstream Banking, S.A. of
Luxembourg. On or prior to the 40th day after the later of
the commencement of the offering of the old notes and the issue
date of the old notes (such period through and including such
40th day, the Restricted Period), beneficial
interests in the Regulation S Note may be held only through
Euroclear or Clearstream, as indirect participants in DTC,
unless transferred to a person that takes delivery in the form
of an interest in the corresponding Rule 144A global note
in accordance with the certification requirements described
below. Beneficial interests in the Rule 144A global note
may not be exchanged for beneficial interests in the
Regulation S global note at any time except in the limited
circumstances described below. See Exchanges
Between Regulation S Notes and Rule 144A Notes and
Other Notes.
Except as set forth below, the global notes may be transferred,
in whole but not in part, only to another nominee of DTC or to a
successor of DTC or its nominee. Beneficial interests in the
global notes may be exchanged for Notes in certificated form as
described below. See Exchange of Book-Entry
Notes for Certificated Notes.
Global notes and Notes held by institutional accredited
investors will be subject to certain restrictions on transfer
and will bear a restrictive legend. In addition, transfer of
beneficial interests in the global notes will
64
be subject to the applicable rules and procedures of DTC and its
direct or indirect participants (including, if applicable, those
of Euroclear and Clearstream), which may change from time to
time.
The Notes may be presented for registration of transfer and
exchange at the offices of the registrar.
Depositary
Procedures
DTC has advised the Company that DTC is a limited-purpose trust
company created to hold securities for its participating
organizations and to facilitate the clearance and settlement of
transactions in those securities between the participants
through electronic book-entry changes in accounts of the
participants. The participants include securities brokers and
dealers (including the initial purchasers), banks, trust
companies, clearing corporations and certain other
organizations. Access to DTCs system is also available to
other entities such as banks, brokers, dealers and trust
companies that clear through or maintain a custodial
relationship with a participant, either directly or indirectly.
Persons who are not participants may beneficially own securities
held by or on behalf of DTC only through the participants or the
indirect participants. The ownership interest and transfer of
ownership interest of each actual purchaser of each security
held by or on behalf of DTC are recorded on the records of the
participants and the indirect participants.
DTC has also advised the Company that, pursuant to procedures
established by it,
(1) upon deposit of the global notes, DTC will credit the
accounts of participants designated by the beneficiaries with
portions of the principal amount of the global notes, and
(2) ownership of such interests in the global notes will be
shown on, and the transfer of ownership thereof will be effected
only through, records maintained by DTC (with respect to the
participants) or by the participants and the indirect
participants (with respect to other owners of beneficial
interests in the global notes).
Investors in the Rule 144A global note may hold their
interests therein directly through DTC if they are participants
in such system, or indirectly through organizations (including
Euroclear and Clearstream) which are participants in such
system. Investors in the Regulation S global note must
initially hold their interests therein through Euroclear or
Clearstream if they are accountholders in such systems or
indirectly through organizations which are accountholders in
such systems. After the expiration of the Restricted Period (but
not earlier), investors may also hold interests in the
Regulation S global note through organizations other than
Euroclear and Clearstream that are participants in the DTC
system. Euroclear and Clearstream will hold interests in the
Regulation S global note on behalf of their participants
through their respective depositories, which in turn will hold
such interests in the Regulation S global note
customers securities accounts in their respective names on
the books of DTC. Morgan Guaranty Trust Company of New
York, Brussels office, will initially act as depository for
Euroclear, and Citibank, N.A., will initially act as depository
for Clearstream. All interests in a global note, including those
held through Euroclear or Clearstream, may be subject to the
procedures and requirements of DTC. Those interests held through
Euroclear or Clearstream may also be subject to the procedures
and requirements of such system.
The laws of some states require that certain persons take
physical delivery in definitive form of securities that they
own. Consequently, the ability to transfer beneficial interests
in a global note to such persons may be limited to that extent.
Because DTC can act only on behalf of the participants, which in
turn act on behalf of the indirect participants and certain
banks, the ability of a person having beneficial interests in a
global note to pledge such interests to persons or entities that
do not participate in the DTC system or otherwise take actions
in respect of such interests, may be affected by the lack of a
physical certificate evidencing such interests. For certain
other restrictions on the transferability of the Notes, see
Exchange of Book-Entry Notes for Certificated Notes
and Exchanges Between Regulation S Notes and
Rule 144A Notes and Other Notes.
Except as described below, owners of interests in the global
notes will not have Notes registered in their names, will not
receive physical delivery of Notes in certificated form and will
not be considered the registered owners or holders thereof under
the Indenture for any purpose.
65
Payments in respect of the principal of (and premium, if any)
and interest on a global note registered in the name of DTC or
its nominee will be payable to DTC or its nominee in its
capacity as the registered holder under the Indenture. Under the
terms of the Indenture, the Company and the Trustee, will treat
the persons in whose names the Notes, including the global
notes, are registered as the owners thereof for the purpose of
receiving such payments and for any and all other purposes
whatsoever. Consequently, none of the Company, the placement
agents, the Trustee nor any agent of the Company, the placement
agents or the Trustee has or will have any responsibility or
liability for (1) any aspect or accuracy of DTCs
records or any participants or indirect participants
records relating to the beneficial ownership or (2) any
other matter relating to the actions and practices of DTC or any
of the participants or the indirect participants.
The Company understands that DTCs current practice, upon
receipt of any payment in respect of securities such as the
Notes (including principal and interest), is to credit the
accounts of the relevant participants with the payment on the
payment date, in amounts proportionate to their respective
holdings in principal amount of beneficial interests in the
relevant security as shown on the records of DTC. Payments by
the participants and the indirect participants to the beneficial
owners of Notes will be governed by standing instructions and
customary practices and will not be the responsibility of DTC,
the Trustee or the Company. None of the Company nor the Trustee
will be liable for any delay by DTC or any of the participants
in identifying the beneficial owners of the Notes, and the
Company and the Trustee may conclusively rely on and will be
protected in relying on instructions from DTC or its nominee as
the registered owner of the global notes for all purposes.
Except for trades involving only Euroclear and Clearstream
participants, interests in the global notes will trade in
DTCs
same-day
funds settlement system and secondary market trading activity in
such interests will therefore settle in immediately available
funds, subject in all cases to the rules and procedures of DTC
and the participants.
Transfers between participants in DTC will be effected in
accordance with DTCs procedures and will be settled in
same-day
funds. Transfers between accountholders in Euroclear and
Clearstream will be effected in the ordinary way in accordance
with their respective rules and operating procedures.
Subject to compliance with the transfer restrictions applicable
to the Notes described herein, cross-market transfers between
the accountholders in DTC on the one hand and directly or
indirectly through Euroclear or Clearstream accountholders, on
the other hand, will be effected through DTC in accordance with
DTCs rules on behalf of Euroclear or Clearstream, as the
case may be, by its respective depository; however, such
cross-market transactions will require delivery of instructions
to Euroclear or Clearstream, as the case may be, by the
counterparty in such system in accordance with the rules and
procedures and within the established deadlines (Brussels time)
of such system. Euroclear or Clearstream, as the case may be,
will, if the transaction meets its settlement requirements,
deliver instructions to its respective depository to take action
to effect final settlement on its behalf by delivering or
receiving interests in the relevant global note in DTC, and
making or receiving payment in accordance with normal procedures
for same-day
funds settlement applicable to DTC. Euroclear or Clearstream
accountholders may not deliver instructions directly to the
depositories for Euroclear or Clearstream.
Because of time zone differences, the securities account of a
Euroclear or Clearstream accountholder purchasing an interest in
a global note from an accountholder in DTC will be credited, and
any such crediting will be reported to the relevant Euroclear or
Clearstream participant, during the securities settlement
processing day (which must be a business day for Euroclear or
Clearstream) immediately following the settlement date of DTC.
Cash received in Euroclear or Clearstream as a result of sales
of interests in a global note by or through a Euroclear or
Clearstream accountholder to a participant in DTC will be
received with value on the settlement date of DTC but will be
available in the relevant Euroclear or Clearstream cash account
only as of the business day for Euroclear or Clearstream
following DTCs settlement date.
The Company understands that DTC will take any action permitted
to be taken by a holder of Notes only at the direction of one or
more participants in whose account with DTC interests in the
global notes are credited and only in respect of such portion of
the aggregate principal amount at maturity of the notes as to
which such participant or participants has or have given such
direction. However, if any of the events
66
described under Exchange of Book-Entry Notes for
Certificated Notes occurs, DTC reserves the right to
exchange the global notes for (in the case of a Rule 144A
global note) legended notes in certificated form and to
distribute such notes to its participants.
The information in this section concerning DTC, Euroclear and
Clearstream and their book-entry systems has been obtained from
sources that the Company believes to be reliable, but the
Company takes no responsibility for the accuracy thereof.
Although DTC, Euroclear and Clearstream have agreed to the
foregoing procedures to facilitate transfers of interests in the
Regulation S global note and in the Rule 144A global
note among accountholders in DTC and accountholders of Euroclear
and Clearstream, they are under no obligation to perform or to
continue to perform such procedures, and such procedures may be
discontinued at any time. None of the Company, the placement
agents or the Trustee nor any agent of the Company, the
placement agents or the Trustee will have any responsibility for
the performance by DTC, Euroclear or Clearstream or their
respective participants, indirect participants or accountholders
of their respective obligations under the rules and procedures
governing their operations.
Exchange
of Book-Entry Notes for Certificated Notes
A global note is exchangeable for definitive Notes in registered
certificated form if:
(1) DTC (A) notifies the Company that it is unwilling
or unable to continue as depository for the global note and the
Company thereupon fails to appoint a successor depository or
(B) has ceased to be a clearing agency registered under the
Exchange Act;
(2) the Company, at its option, notifies the Trustee in
writing that it elects to cause the issuance of the Notes in
certificated form (DTC has advised the Company that, in such
event, under its current practices, DTC would notify its
participants of the Companys request, but will only
withdraw beneficial interests from a global note at the request
of each DTC participant); or
(3) there shall have occurred and be continuing a Default
or an Event of Default with respect to the Notes.
Holders of an interest in a global note may receive certificated
Notes, which may bear the legend relevant to it in accordance
with DTCs rules and procedures in addition to those
provided for under the Indenture. Certificated notes delivered
in exchange for any global note or beneficial interests therein
will be registered in the names, and issued in any approved
denominations, requested by or on behalf of DTC (in accordance
with its customary procedures) and will bear, in the case of a
restricted global note, a restrictive legend unless the Company
determines otherwise in compliance with applicable law.
Exchanges
Between Regulation S Notes and Rule 144A Notes and
Other Notes
Prior to the expiration of the restricted period, a beneficial
interest in a Regulation S global note may be transferred
to a person who takes delivery in the form of an interest in the
corresponding Rule 144A global note only upon receipt by
the Trustee of a written certification from the transferor to
the effect that such transfer is being made (1) (A) to a
person whom the transferor reasonably believes is a qualified
institutional buyer in a transaction meeting the requirements of
Rule 144A or (B) pursuant to another exemption from
the registration requirements under the Securities Act which is
accompanied by an Opinion of Counsel regarding the availability
of such exemption, and (2) in accordance with all
applicable securities laws of any state of the United States or
any other jurisdiction.
Beneficial interests in the Rule 144A global note may be
transferred to a person who takes delivery in the form of an
interest in the Regulation S global note, whether before or
after the expiration of the restricted period, only if the
transferor first delivers to the Trustee a written certificate
to the effect that such transfer is being made in accordance
with Rule 903 or 904 of Regulation S or Rule 144
under the Securities Act (if
67
available) and that, if such transfer occurs prior to the
expiration of the restricted period, the interest transferred
will be held immediately thereafter through Euroclear or
Clearstream, Luxembourg.
Beneficial interests in a global note may be transferred to a
person who takes delivery in the form of an accredited investor
certificated Note only upon compliance with the procedures set
forth in Notice to Investors in the offering
memorandum under which such Notes were sold.
Any beneficial interest in one of the global notes that is
transferred to a person who takes delivery in the form of an
interest in another global note will, upon transfer, cease to be
an interest in such global note and become an interest in such
other global note and, accordingly, will thereafter be subject
to all transfer restrictions and other procedures applicable to
beneficial interests in such other global note for as long as it
remains such an interest.
Transfers involving an exchange of a beneficial interest in the
Regulation S global note for a beneficial interest in the
Rule 144A global note or vice versa will be effected in DTC
by means of an instruction originated by DTC through the DTC
Deposit/Withdrawal as Custodian system. Accordingly, in
connection with such transfer, upon notice from DTC through the
Deposit/Withdrawal as Custodian system, appropriate adjustments
will be made to reflect a decrease in the principal amount of
the Regulation S global note and a corresponding increase
in the principal amount of the Rule 144A global note or
vice versa, as applicable.
Definitions
Set forth below are defined terms used in the covenants and
other provisions of the Indenture. Reference is made to the
Indenture for other capitalized terms used in this
Description of the Exchange Notes for which no
definition is provided.
Acquired Indebtedness means Indebtedness of a
Person (1) existing at the time such Person becomes a
Restricted Subsidiary or (2) assumed in connection with an
acquisition of such Persons assets.
Affiliate of any specified individual or
entity, means (i) any other individual or entity who
directly or indirectly controls or is controlled by or is under
direct or indirect common control with the specified individual
or entity or (ii) any individual or entity that
beneficially owns 10% or more of the voting power of the
Companys Equity Interests (exclusive of any individual or
entity that is permitted to report such ownership pursuant to
Schedule 13G under the Securities Exchange Act of 1934).
For the purposes of this definition, control of an
entity means having the power to direct the management and
policies of the entity directly or indirectly, whether through
the ownership of voting securities, by contract or otherwise.
After-Acquired Property means any property of
any Company or any Guarantor acquired after the Closing Date of
a type that secures the obligations under the Indenture, the
Notes, the Security Documents and other Pari Passu Secured
Obligations.
Applicable Authorized Representative means
(i) until the occurrence of the Non-Controlling Authorized
Representative Enforcement Date (if any), the Controlling
Authorized Representative and (ii) from and after the
occurrence of the Non-Controlling Authorized Representative
Enforcement Date, the Major Non-Controlling Authorized
Representative.
Applicable Premium means, with respect to any
Note on any redemption date, the excess of (A) the present
value at such redemption date of (1) the redemption price
of such Note at May 1, 2013 (such redemption price being
set forth in the table above) plus (2) all required
interest payments due on such Note through May 1, 2013
(excluding accrued but unpaid interest to the redemption date),
computed using a discount rate equal to the Treasury Rate on
such redemption date plus 50 basis points over (B) the
then-outstanding principal amount of such Note.
Asset Sale means:
(1) the sale, conveyance or other disposition of any
assets, other than sales, leases,
sub-leases
or other dispositions of inventory or other assets in the
ordinary course of business; provided that the sale,
conveyance or other disposition of all or substantially all of
the assets of the Company and its
68
Subsidiaries taken as a whole will be governed by the provisions
of the terms of the Indenture described above under the caption
Repurchase at the Option of Holders Change of
Control
and/or the
provisions described above under the caption
Consolidation, Merger and Sale of Assets and not by
the provisions of the Repurchase at the Option of
Holders Asset Sales covenant; or
(2) the issuance of Equity Interests by any of the
Companys Restricted Subsidiaries or the sale of Equity
Interests in any of its Restricted Subsidiaries, other than such
an issuance or sale to the Company or one or more of its
Restricted Subsidiaries (other than directors qualifying
shares or shares required by applicable law to be held by a
person other than the Company or a Restricted Subsidiary).
Notwithstanding the preceding, the following items shall not be
deemed to be Asset Sales:
(1) any single transaction or series of related
transactions that involves assets having a Fair Market Value of
less than $3.0 million or in which the Company receives
aggregate consideration of less than $3.0 million;
(2) a transfer of assets between or among the Company and
any one or more of its Subsidiary Guarantors;
(3) an issuance or transfer of Equity Interests by a
Restricted Subsidiary to the Company or to another Restricted
Subsidiary;
(4) a Restricted Payment that is permitted by the covenant
described above under the caption Certain
Covenants Limitation on Restricted Payments or
a Permitted Investment;
(5) sales, disposals or replacement of obsolete, damaged or
worn-out assets (including the abandonment or other disposition
of intellectual property that is, in the reasonable judgment of
the Company, no longer economically practicable to maintain or
useful to the conduct of the business of the Company and its
Restricted Subsidiaries taken as a whole);
(6) licenses and sublicenses by the Company and its
Restricted Subsidiaries of software or intellectual property in
the ordinary course of business;
(7) the surrender or waiver of contract rights or the
settlement, release, or surrender of contract, tort or other
claims;
(8) the granting of Liens not prohibited by the covenant
described above under the caption Liens;
(9) the sale or other disposition of cash or Temporary Cash
Investments;
(10) the sale or discount of accounts receivable in the
ordinary course of business;
(11) dispositions resulting in insurance proceeds or
condemnation awards;
(12) so long as no Event of Default has occurred and is
continuing, the sale of the Hartland Property, provided
that, if the aggregate proceeds from such sale are greater
than of $7.5 million, any excess shall be deemed to be
Excess Proceeds; and
(13) the sale of Permitted Investments (other than sales of
Equity Interests of any of Restricted Subsidiaries) made by the
Company or any Restricted Subsidiary after the date of the
Indenture, if such Permitted Investments were (a) received
in exchange for, or purchased out of the net cash proceeds of
the substantially concurrent sale (other than to a Subsidiary of
the Company) of, Equity Interests of the Company (other than
Disqualified Stock) or (b) received in the form of, or were
purchased from the proceeds of, a substantially concurrent
contribution of common equity capital to the Company.
Asset Sale Offer has the meaning assigned to
that term in the Indenture.
Attributable Debt means in respect of a sale
and leaseback transaction means, as of the time of
determination, the present value (discounted at the rate per
annum equal to the rate of interest implicit in the lease
involved in such sale and leaseback transaction, as determined
in good faith by the Company) of the obligation of the lessee
thereunder for rental payments (excluding, however, any amounts
required to be paid
69
by such lessee, whether or not designated as rent or additional
rent, on account of maintenance and repairs, insurance, taxes,
assessments, water rates or similar charges or any amounts
required to be paid by such lessee thereunder contingent upon
the amount of sales or similar contingent amounts) during the
remaining term of such lease (including any period for which
such lease has been extended or may, at the option of the
lessor, be extended). In the case of any lease which is
terminable by the lessee upon the payment of a penalty, such
rental payments shall also include the amount of such penalty,
but no rental payments shall be considered as required to be
paid under such lease subsequent to the first date upon which it
may be so terminated.
Authorized Representative means (i) with
respect to the Holders of the Notes and the Note Obligations,
the Collateral Agent and (ii) in the case of any Series of
Pari Passu Obligations (and the Pari Passu Secured Parties
thereunder) that become subject to the Intercreditor Agreement
after the Closing Date, the Authorized Representative named for
such Series in the Intercreditor Agreement or the applicable
Joinder Agreement.
Average Life means, at any date of
determination with respect to any debt security, the quotient
obtained by dividing (1) the sum of the products of
(a) the number of years from such date of determination to
the dates of each successive scheduled principal payment of such
debt security and (b) the amount of such principal payment
by (2) the sum of all such principal payments.
Board of Directors means, with respect to any
Person, the Board of Directors, Board of Managers or similar
governing body of such Person or any duly authorized committee
of such Board of Directors.
Capital Lease Obligation means, at the time
any determination thereof is to be made, the amount of the
liability in respect of a capital lease that would at that time
be required to be capitalized on a balance sheet in accordance
with GAAP.
Change of Control means an event or series of
events by which any of the following occurs:
(1) any Person, other than Merrick, Michael
Ferro or their respective controlled Affiliates, is or becomes
the beneficial owner directly or indirectly, of more
than 50% of the total voting power of all outstanding classes of
voting capital stock of the Company;
(2) the direct or indirect sale, transfer, conveyance or
other disposition (other than by way of merger or
consolidation), in one or a series of related transactions, of
all or substantially all of the properties or assets of the
Company and its Restricted Subsidiaries, taken as a whole, to
any Person;
(3) the adoption of a plan relating to the liquidation or
dissolution of the Company; or
(4) on any date, a majority of the Companys Board of
Directors does not consist of Persons (a) who were
directors at the Closing Date (Continuing Directors)
or (b) whose election or nomination as directors was
approved by at least a majority of the directors then in office
who are Continuing Directors or whose election or nomination was
previously so approved. In the definition of Change of Control,
Person has the same meaning given to it in
Sections 13(d) and 14(d) of the Exchange Act, and
beneficial owner or beneficially owned
have the same meaning given to these terms in Rules
l3d-3 and
l3d-5 under
the Exchange Act, except that a Person is deemed to have
beneficial ownership of all shares that Person has
the right to acquire, whether the right is exercisable
immediately or only after the passage of time.
Change of Control Offer has the meaning
assigned to that term in the Indenture.
Closing Date means April 28, 2010, the
date on which the April 2010 notes were originally issued
under the Indenture.
Collateral has the meaning set forth under
Collateral and Security Collateral
Generally.
Collateral Agent means The Bank of New York
Mellon Trust Company, N.A., in its capacity as
Collateral Agent under the Guarantee and Collateral
Agreement, the Indenture and the other Security Documents, and
any successor thereto in such capacity.
70
Consolidated Cash Flow means, with respect to
any Person for any period, the Consolidated Net Income of such
Person for such period plus without duplication:
(1) an amount equal to any provision for taxes based on
income or profits of such Person and its Restricted Subsidiaries
for such period, to the extent that such provision for taxes was
deducted in computing such Consolidated Net Income; plus
(2) Fixed Charges of such Person and its Restricted
Subsidiaries to the extent deducted in computing such
Consolidated Net Income; plus
(3) depreciation, amortization (including amortization of
goodwill and other intangibles but excluding amortization of
prepaid cash expenses that were paid in a prior period) and
other non-cash expenses, charges or accruals of such Person and
its Restricted Subsidiaries (excluding such non-cash expense to
the extent it represents an accrual or reserve for cash payments
in any future period) for such period to the extent that such
depreciation, amortization and other non-cash expenses,
write-downs, charges or accruals were deducted in computing such
Consolidated Net Income; minus
(4) non-cash items increasing such Consolidated Net Income
for such period, other than items that were accrued in the
ordinary course of business.
Consolidated Net Income means, with respect
to any Person for any period, the aggregate of the Net Income of
such Person and its Restricted Subsidiaries for such period, on
a consolidated basis, determined in accordance with GAAP;
provided that: (1) the Net Income (but not loss) of
any Person that is not a Restricted Subsidiary or that is
accounted for by the equity method of accounting shall be
included only to the extent of the amount of dividends or
distributions paid in cash to the specified Person or a
Restricted Subsidiary thereof; (2) the negative impact to
revenue as a result of the non-cash write down of deferred
revenue required by purchase accounting and the cumulative
effect of a change in accounting principles, any extraordinary
gains or losses and any gains or losses realized in connection
with an asset sale (including disposals of discontinued
operations) shall be excluded; and (3) solely for the
purposes of determining Consolidated Cash Flow, any net
after-tax income or loss from discontinued operations shall be
excluded.
Notwithstanding the foregoing, there shall be excluded from
Consolidated Net Income that portion, if any, of the Net Income
of any Restricted Subsidiary that is not permitted, directly or
indirectly, to be paid by way of dividend, distribution or loan
to stockholders of such Subsidiary by operation of the terms of
its charter or any agreement, instrument, judgment, decree,
order, statute, rule or governmental regulation applicable to
that Subsidiary or its stockholders.
Consolidated Net Tangible Assets means, with
respect to any Person, the total amount of assets of such Person
and its Restricted Subsidiaries (less applicable depreciation,
amortization and other valuation reserves), after deducting
therefrom (1) all current liabilities of such Person and
its Restricted Subsidiaries (excluding intercompany items) and
(2) all goodwill, trade names, trademarks, patents,
unamortized debt discount and expense and other like
intangibles, all as set forth on the most recent quarterly or
annual consolidated balance sheet of such Person and its
Restricted Subsidiaries, prepared in conformity with GAAP.
Controlling Authorized Representative has the
meaning set forth under Intercreditor
Agreement Enforcement of Security Interests.
Controlling Secured Parties means the Series
of Pari Passu Secured Parties whose Authorized Representative is
the Controlling Authorized Representative.
Credit Facilities means one or more debt
facilities, commercial paper facilities or indentures, in each
case with banks or other institutional lenders or a trustee
providing for revolving credit loans, term loans, receivables
financing (including through the sale of receivables to such
lenders or to special purpose entities formed to borrow from
such lenders against such receivables), letters of credit or
similar obligations or issuances of notes, in each case, as
amended, restated, modified, renewed, refunded, replaced or
refinanced in whole or in part from time to time.
71
Default means any event that is, or after
notice or passage of time or both would be, an Event of Default.
Designated Non-Cash Consideration means the
Fair Market Value of non-cash consideration received by the
Company or any Guarantor in connection with an Asset Sale that
is so designated as Designated Non-Cash Consideration pursuant
to an Officers Certificate setting forth the basis of such
valuation executed by the principal financial officers of the
Company, less the amount of cash received in connection with a
subsequent sale of, or collection on, such Designated Non-Cash
Consideration.
Disqualified Stock means any Equity Interests
that, by its terms (or by the terms of any security into which
it is convertible, or for which it is exchangeable, in each case
at the option of the holder thereof), or upon the happening of
any event, matures or is mandatorily redeemable, pursuant to a
sinking fund obligation or otherwise, or redeemable at the
option of the holder thereof, in whole or in part, on or prior
to the date that is 91 days after the date on which the
Notes are or become due. Notwithstanding the preceding sentence,
any Equity Interests that would constitute Disqualified Stock
solely because the holders thereof have the right to require the
Company to repurchase such Equity Interests upon the occurrence
of a Change of Control or an Asset Sale shall not constitute
Disqualified Stock if the terms of such Equity Interests provide
that the Company may not repurchase or redeem any such Equity
Interests pursuant to such provisions until after the Company
complies with the covenants described above under the captions
Repurchase at the Option of Holders Change of
Control or Repurchase at the Option of
Holders Asset Sales.
Domestic Restricted Subsidiary means
(i) each Restricted Subsidiary of the Company organized or
existing under the laws of the United States, any state thereof
or the District of Columbia and (ii) any other Restricted
Subsidiary that guarantees any Indebtedness under any Credit
Facility.
Equity Interests means capital stock, limited
liability company interests, partnership interests or other
equity interests or equity securities, and all warrants, options
or other rights to acquire such securities (but excluding any
debt security that is convertible into, or exchangeable for,
such equity interests or equity securities).
Exchange Act means the Securities Exchange
Act of 1934, as amended, or any successor statute or statutes
thereto.
Fair Market Value means the price that would
be paid in an arms-length transaction between an informed
and willing seller under no compulsion to sell and an informed
and willing buyer under no compulsion to buy; provided
that any transaction involving consideration of
$10.0 million or more, the Fair Market Value shall be
determined in good faith by the Board of Directors, whose
determination shall be conclusive if evidenced by a Board
Resolution.
Fixed Charge Coverage Ratio means with
respect to any specified Person for any period, the ratio of the
Consolidated Cash Flow of such Person and its Restricted
Subsidiaries for such period to the Fixed Charges of such Person
for such period. In the event that the specified Person or any
of its Restricted Subsidiaries incurs, assumes, Guarantees,
redeems, repays or acquires any Indebtedness or issues, redeems
or acquires preferred stock subsequent to the commencement of
the period for which the Fixed Charge Coverage Ratio is being
calculated but prior to the date on which the event for which
the calculation of the Fixed Charge Coverage Ratio is made (the
Calculation Date), then the Fixed Charge Coverage
Ratio shall be calculated giving pro forma effect to such
incurrence, assumption, Guarantee, redemption, repayment or
acquisition of Indebtedness, or such issuance, redemption or
acquisition of preferred stock, as if the same had occurred at
the beginning of the applicable four-quarter reference period.
Fixed Charges means, with respect to any
Person for any period, the sum, without duplication, of
(1) the consolidated interest expense of such Person and
its Restricted Subsidiaries for such period, whether paid or
accrued; including, without limitation, amortization of debt
issuance costs and original issue discount, non-cash interest
payments, the interest component of any deferred payment
obligations, the interest component of all payments associated
with Capital Lease Obligations, commissions, discounts and other
fees and charges incurred in respect of letter of credit or
bankers acceptance financings and net payments, if any,
pursuant to Hedging Obligations; plus (2) the consolidated
interest of such Person and its Restricted
72
Subsidiaries that was capitalized during such period; plus
(3) the imputed interest with respect to Attributable Debt
created after the Closing Date; plus (4) the aggregate
amount of interest in respect of Indebtedness that is Guaranteed
or secured by the assets of the Company or its Restricted
Subsidiaries; plus (5) the product of (a) all dividend
payments made in cash or in Disqualified Stock, on any series of
preferred stock of such Person or any of its Restricted
Subsidiaries times (b) a fraction, the numerator of which
is one and the denominator of which is one minus the then
current combined federal, state and local statutory tax rate of
such Person, expressed as a decimal, in each case, on a
consolidated basis and in accordance with GAAP.
In addition, for purposes of calculating the Fixed Charge
Coverage Ratio (1) acquisitions that have been made by the
specified Person or any of its Restricted Subsidiaries,
including through the purchase of assets or stock, mergers,
liquidations or consolidations and including any related
financing transactions, during the four-quarter reference period
or subsequent to such reference period and on or prior to the
Calculation Date shall be calculated on a pro forma basis
(including Pro Forma Cost Savings) as if they had occurred on
the first day of the four-quarter reference period; (2) the
Consolidated Cash Flow attributable to discontinued operations,
as determined in accordance with GAAP, and operations or
businesses disposed of prior to the Calculation Date, shall be
excluded; and (3) the Fixed Charges attributable to
discontinued operations, as determined in accordance with GAAP,
and operations or businesses disposed of prior to the
Calculation Date, shall be excluded, but only to the extent that
the obligations giving rise to such Fixed Charges will not be
obligations of the specified Person or any of its Subsidiaries
following the Calculation Date.
Foreign Restricted Subsidiary means any
Restricted Subsidiary of the Company other than a Domestic
Restricted Subsidiary
GAAP means generally accepted accounting
principles in the United States of America as in effect as of
the Closing Date, including, without limitation, those set forth
in the opinions and pronouncements of the Accounting Principles
Board of the American Institute of Certified Public Accountants
and statements and pronouncements of the Financial Accounting
Standards Board or in such other statements by such other entity
as approved by a significant segment of the accounting
profession.
Government Securities means securities that
are (1) direct obligations of the United States of America
for the payment of which its full faith and credit is pledged or
(2) obligations of a Person controlled or supervised by and
acting as an agency or instrumentality of the United States of
America the timely payment of which is unconditionally
guaranteed as a full faith and credit obligation by the United
States of America, which, in either case, are not callable or
redeemable at the option of the issuer thereof at any time prior
to the Stated Maturity of the Notes, and shall also include a
depository receipt issued by a bank or trust company as
custodian with respect to any such Government Security or a
specific payment of interest on or principal of any such
Government Security held by such custodian for the account of
the holder of a depository receipt; provided that (except as
required by law) such custodian is not authorized to make any
deduction from the amount payable to the holder of such
depository receipt from any amount received by the custodian in
respect of the Government Security or the specific payment of
interest on or principal of the Government Security evidenced by
such depository receipt.
Guarantee means any obligation, contingent or
otherwise, of any Person directly or indirectly guaranteeing any
Indebtedness of any other Person and, without limiting the
generality of the foregoing, any obligation, direct or indirect,
contingent or otherwise, of such Person (1) to purchase or
pay (or advance or supply funds for the purchase or payment of)
such Indebtedness of such other Person (whether arising by
virtue of partnership arrangements, or by agreements to
keep-well, to purchase assets, goods, securities or services
(unless such purchase arrangements are on arms-length
terms and are entered into in the ordinary course of business),
to
take-or-pay,
or to maintain financial statement conditions or otherwise) or
(2) entered into for purposes of assuring in any other
manner the obligee of such Indebtedness of the payment thereof
or to protect such obligee against loss in respect thereof (in
whole or in part); provided that the term
Guarantee shall not include endorsements for
collection or deposit in the ordinary course of business. The
term Guarantee used as a verb has a corresponding
meaning.
73
Guarantee and Collateral Agreement means that
certain Guarantee and Collateral Agreement, dated as of the
Closing Date, made by and among the Company, the Guarantors and
the Collateral Agent, as amended, modified, renewed, restated or
replaced, in whole or in part, from time to time, in accordance
with its terms.
Guarantors means each Domestic Restricted
Subsidiary of the Company on the Closing Date, and each other
Person that is required to, or at the election of the Company
does, become a Guarantor by the terms of the Indenture after the
Closing Date, in each case, until such Person is released from
its Note Guarantee in accordance with the terms of the Indenture.
Hedging Obligations means, with respect to
any Person, the net obligations of such Person under
(1) interest rate swap agreements, interest rate cap
agreements and interest rate collar agreements; and
(2) other agreements or arrangements designed to protect
against fluctuations in interest rates, currency exchange rates
or specific financial and other similar risks (including
commodity risks).
Indebtedness means, with respect to any
specified Person, any indebtedness of such Person, contingent or
otherwise, in respect of:
(1) borrowed money;
(2) bonds, notes, debentures or similar instruments or
letters of credit (or reimbursement agreements in respect
thereof), but excluding obligations with respect to letters of
credit (including trade letters of credit) or similar
obligations (such as bank Guarantees), entered into in the
ordinary course of business of such Person (and not for borrowed
money) to the extent such letters of credit or similar
obligations are not drawn upon or, if drawn upon, to the extent
such drawing is reimbursed no later than the fifth Business Day
following receipt by such Person of a demand for reimbursement;
(3) bankers acceptances;
(4) Capital Lease Obligations and Attributable Debt;
(5) the balance deferred and unpaid of the purchase price
of any property, except any such balance that constitutes an
accrued expense or trade payable; or
(6) any Hedging Obligations, other than Hedging Obligations
incurred in the ordinary course of business for the purpose of
fixing or hedging interest rate risk, foreign currency risk or
specific financial and other similar risks (including commodity
risks) and not for speculative purposes;
if and to the extent any of the preceding (other than letters of
credit and Hedging Obligations) would appear as a liability upon
a balance sheet of the specified Person prepared in accordance
with GAAP.
In addition, the term Indebtedness includes all
Indebtedness of others secured by a Lien on any asset of the
specified Person (whether or not such Indebtedness is assumed by
the specified Person) and, to the extent not otherwise included,
the Guarantee by such Person of any Indebtedness of any other
Person.
The amount of any Indebtedness outstanding as of any date shall
be:
(1) the accreted value thereof, in the case of any
Indebtedness issued at a discount to par;
(2) with respect to any Hedging Obligations, the net amount
payable if such agreements terminated at that time due to
default by such Person;
(3) in respect of Indebtedness of another Person secured by
a Lien on the assets of the specified Person, the lesser of:
(a) the Fair Market Value of such assets at the date of
determination; and
(b) the amount of the Indebtedness of the other
Person; or
(4) except as provided above, the principal amount or
liquidation preference thereof, in the case of any other
Indebtedness.
Indenture Documents means the Notes, the
Indenture and the Note Guarantees.
74
Intercompany Debt Obligations means any
Indebtedness of the Company or any of its Restricted
Subsidiaries which is owed to the Company or any of its Wholly
Owned Restricted Subsidiaries.
Intercreditor Agreement has the meaning set
forth under section entitled Intercreditor Agreement
in this Description of the Exchange Notes.
Intercreditor Event of Default means an
Event of Default under and as defined in the
Indenture or any other Pari Passu Agreement.
Intervening Creditor has the meaning set
forth under Intercreditor Agreement
Restrictions on Enforcement of Priority Liens.
Investment Grade means (1) BBB- or
above, in the case of S&P (or its equivalent under any
successor Rating Categories of S&P) and Baa3 or above, in
the case of Moodys (or its equivalent under any successor
Rating Categories of Moodys), or (2) the equivalent
in respect of the Rating Categories of any other Rating
Agencies, in each case, without regard to outlook.
Investments means, with respect to any
Person, all investments by such Person in other Persons
(including Affiliates) in the forms of direct or indirect loans
(including Guarantees of Indebtedness or other obligations),
advances or capital contributions (excluding commission, travel
and similar advances to officers and employees made in the
ordinary course of business), purchases or other acquisitions
for consideration of Indebtedness, Equity Interests or other
securities, to the extent that such items are or would be
classified as investments on a balance sheet prepared in
accordance with GAAP. Investments shall also include
(1) the designation of a Restricted Subsidiary as an
Unrestricted Subsidiary and (2) the retention of the Equity
Interests (or any other Investment) by the Company or any of its
Restricted Subsidiaries, of (or in) any Person that has ceased
to be a Restricted Subsidiary. For purposes of the definition of
Unrestricted Subsidiary and the Limitation on
Restricted Payments covenant, the amount of or a reduction
in an Investment shall be equal to the Fair Market Value thereof
at the time such Investment is made or reduced.
Joinder Agreement means an agreement in form
and substance substantially similar to Exhibit A to the
Intercreditor Agreement, pursuant to which an additional Series
of Pari Passu Obligations become a party to the Intercreditor
Agreement, in accordance with the applicable terms thereof.
Lien means any mortgage, lien, pledge,
security interest, conditional sale or other title retention
agreement, charge or other security interest or encumbrance of
any kind, whether or not filed, recorded or otherwise perfected
under applicable law, including any conditional sale or other
title retention agreement or any lease in the nature thereof;
any option or other agreement to sell or give a security
interest therein and any filing of, or agreement to file, any
financing statement under the Uniform Commercial Code (or
equivalent statutes of any jurisdiction).
Major Non-Controlling Authorized Representative
has the meaning set forth under Intercreditor
Agreement Enforcement of Security Interests.
Merrick means Merrick RIS, LLC.
Moodys means Moodys Investors
Service, Inc. and its successors.
Net Cash Proceeds means:
(a) with respect to any Asset Sale, means the aggregate
cash proceeds received by the Company or any of its Restricted
Subsidiaries (including, without limitation, any cash received
upon the sale or other disposition of any non-cash consideration
received in any Asset Sale), net of the direct costs relating to
such Asset Sale, including, without limitation, legal,
accounting and investment banking fees, and sales commissions,
and any relocation expenses incurred as a result thereof, taxes
paid or payable as a result thereof, in each case after taking
into account any available tax credits or deductions, any tax
sharing arrangements and amounts used to repay Indebtedness
secured by a Lien on the asset or assets that were the subject
of such Asset Sale and appropriate amounts to be provided by the
Company or any Restricted Subsidiary as a reserve against any
liabilities associated with such Asset Sale, including, without
limitation, pension and other post-employment benefit
liabilities, liabilities related to environmental
75
matters and liabilities under any indemnification obligations
associated with such Asset Sale, all as determined in conformity
with GAAP; and
(b) with respect to any issuance or sale of Equity
Interests, the proceeds of such issuance or sale in the form of
cash or cash equivalents, including payments in respect of
deferred payment obligations (to the extent corresponding to the
principal, but not interest, component thereof) when received in
the form of cash or cash equivalents and proceeds from the
conversion of other property received when converted to cash or
cash equivalents, net of attorneys fees, accountants
fees, underwriters or placement agents fees,
discounts or commissions and brokerage, consultant and other
fees incurred in connection with such issuance or sale and net
of taxes paid or payable as a result thereof.
Net Income means, with respect to any Person,
the net income (loss) of such Person and its Restricted
Subsidiaries, determined in accordance with GAAP and before any
reduction in respect of preferred stock dividends.
Non-Controlling Authorized Representative Enforcement
Date has the meaning set forth under
Intercreditor Agreement Enforcement of
Security Interests.
Non-Controlling Secured Parties means the
Pari Passu Secured Parties that are not Controlling Secured
Parties.
Note Documents means Indenture Documents.
Note Obligations means all Obligations in
respect of the Notes or arising under the Indenture Documents.
Note Obligations shall include all interest accrued (or which
would, absent the commencement of an insolvency or liquidation
proceeding, accrue) after the commencement of an insolvency or
liquidation proceeding in accordance with and at the rate
specified in the relevant Indenture Document whether or not the
claim for such interest is allowed as a claim in such insolvency
or liquidation proceeding.
Obligations means any principal, interest,
penalties, fees, indemnifications, reimbursements, damages and
other liabilities payable under the documentation governing any
Indebtedness.
Pari Passu Agreement means any loan
agreement, credit agreement, indenture or other agreement
entered into by the Company after the Closing Date, if any,
pursuant to which the Company or any of its Subsidiaries will
incur Pari Passu Obligations.
Pari Passu Debt means (a) any
Indebtedness of the Company that ranks equally in right of
payment with the Notes or (b) any Indebtedness of a
Guarantor that ranks equally in right of payment with such
Guarantors Note Guarantee.
Pari Passu Debt Collateral Agent has the
meaning set forth in the Intercreditor Agreement.
Pari Passu Obligations means, collectively,
Note Obligations and each other Series of Permitted Pari Passu
Obligations.
Pari Passu Secured Parties means,
collectively, the Collateral Agent, the Notes Secured Parties
(as defined below in the definition of Series), any
secured parties holding any other Pari Passu Obligations, and
each agent and trustee for such holders.
Pari Passu Security Documents means each
security agreement, pledge agreement, deed of trust, mortgage
and other agreement entered into in favor of any Pari Passu Debt
Collateral Agent for purposes of securing the Pari Passu
Obligations and each financing statement and other document or
instrument delivered to create, perfect or continue the Liens
thereby created.
Permitted Business means the provision of
technology services to the healthcare industry businesses and
related activities and services including any business conducted
or proposed to be conducted by the Company and its Restricted
Subsidiaries on the Closing Date as described in this
prospectus, including businesses engaged in by Amicas, Inc. and
its Subsidiaries, and other businesses related, ancillary or
complementary thereto and reasonable expansions or extensions
thereof.
76
Permitted Investments means, for any Person,
Investments made on or after the Closing Date consisting of:
(1) Investments by the Company, or by a Restricted
Subsidiary thereof, in the Company or a Guarantor or in a
Person, if as a result of such Investment (a) such Person
becomes a Guarantor of the Company or (b) such Person is
merged, consolidated or amalgamated with or into, or transfers
or conveys substantially all of its assets to, or is liquidated
into, the Company or any Guarantor;
(2) Temporary Cash Investments;
(3) an Investment that is made as a result of the receipt
of non-cash consideration from an Asset Sale that was made
pursuant to, and in compliance with, the covenant
Repurchase at the Option of Holders Asset
Sales;
(4) Investments existing on the Closing Date;
(5) Investments of the Company or any Restricted Subsidiary
in connection with Hedging Obligations that are incurred for the
purpose of fixing or hedging interest rate risk or foreign
currency risk and not for speculative purposes;
(6) Investments consisting of endorsements for collection
or deposit in the ordinary course of business;
(7) Investments in suppliers or customers that are received
in bankruptcy, receivership or similar proceedings or as a
result of foreclosure on a secured Investment in a third party
received in exchange for or cancellation of an existing
obligation of such supplier or customer to the Company or a
Restricted Subsidiary or received from the compromise or
resolution of litigation, arbitration or other disputes;
(8) Investments solely in exchange for, or out of the net
cash proceeds received from, the issuance of Equity Interests
(other than Disqualified Stock) of the Company;
(9) deposits required by government agencies, public
utilities or suppliers in the ordinary course of business;
(10) prepaid expenses incurred in the ordinary course of
business;
(11) extensions of trade credit in the ordinary course of
business recorded as accounts receivable;
(12) loans or advances to employees made in the ordinary
course of business of the Company or any Restricted Subsidiary
of the Company;
(13) repurchases of the Notes;
(14) any guarantee of Indebtedness permitted to be incurred
by the covenant entitled Certain
Covenants Limitation on Indebtedness other
than a guarantee of Indebtedness of an Affiliate of the Company
that is not a Restricted Subsidiary of the Company;
(15) Investments acquired after the Closing Date as a
result of the acquisition by the Company or any Restricted
Subsidiary of the Company of another Person, including by way of
a merger, amalgamation or consolidation with or into the Company
or any of its Restricted Subsidiaries in a transaction that is
not prohibited by the covenant described above under the caption
Merger, Consolidation or Sale of Assets
after the Closing Date to the extent that such Investments were
not made in contemplation of such acquisition, merger,
amalgamation or consolidation and were in existence on the date
of such acquisition, merger, amalgamation or consolidation;
(16) Investments consisting of the licensing or
contribution of intellectual property pursuant to joint
marketing arrangements with other Persons; and
(17) Investments (other than Investments specified in
clauses (1) through (16) above) in an aggregate
amount, as valued at the time each such Investment is made, not
to exceed 5.0% of Consolidated Net Tangible Assets at any time
after the Closing Date.
77
Permitted Liens means Liens that fit into any
of the following categories:
(1) any Liens existing on the Closing Date;
(2) Liens on assets acquired after the Closing Date that
were existing at the time of the acquisition by the Company or
any Restricted Subsidiary thereof; provided such Liens
were in existence prior to the contemplation of such acquisition
and do not extend to any other assets;
(3) Liens to secure Indebtedness permitted by
clause (6) of the definition of Permitted
Indebtedness covering only the assets acquired with or
financed by such Indebtedness;
(4) Liens securing Indebtedness (including Hedging
Obligations with respect thereto) in an aggregate amount not to
exceed $5.0 million; provided that such Liens are pari
passu with or junior to the Notes;
(5) Liens on an entity or its assets existing at the time
the entity becomes a Restricted Subsidiary or is merged with the
Company or any of its Restricted Subsidiaries or assumed in
connection with the acquisition of its assets; provided
that such Liens were in existence prior to the contemplation
of such acquisition or merger and do not extend to any assets
other than those of the Person that becomes a Restricted
Subsidiary or is merged with the Company;
(6) statutory liens of landlords and carriers,
warehousemens, mechanics, suppliers,
materialmens, repairmens or other like Liens arising
in the ordinary course of business;
(7) judgment Liens and other similar Liens not giving rise
to an Event of Default so long as such Lien is adequately bonded
and any appropriate legal proceedings which may have been duly
initiated for the review of such judgment shall not have been
finally terminated or the period within which such proceedings
may be initiated shall not have expired;
(8) Liens securing Intercompany Debt Obligations;
(9) Liens for taxes, assessments or governmental charges
not yet due and payable or being contested in good faith,
provided that any reserve or other appropriate provision
as shall be required in conformity with GAAP shall have been
made therefor;
(10) Liens on foreign bank accounts in accordance with
customary banking practice;
(11) licenses, entitlements, servitudes, easements,
rights-of-way,
restrictions, reservations, covenants, conditions, utility
agreements, minor imperfections on title, minor survey defects
and other similar encumbrances on the use of any real property
that were not incurred in connection with Indebtedness and do
not, in the aggregate, materially diminish the value of such
properties or materially interfere with their use in the
operation of the business of the Company or any of its
Restricted Subsidiaries;
(12) Liens incurred or pledges or deposits made in the
ordinary course of business in connection with workers
compensation, unemployment insurance and other social security
legislation;
(13) deposits and other Liens to secure letters of credit
and bank Guarantees and the performance of bids, trade contracts
(other than for borrowed money), leases, statutory obligations,
surety and appeal bonds, performance bonds and other similar
obligations incurred in the ordinary course of business;
(14) Liens created for the benefit of (or to secure) the
April 2010 notes, the related Note Guarantees, and any
other Indebtedness incurred under clause (7) of the
definition of Permitted Indebtedness;
(15) Liens to secure Hedging Obligations incurred in the
ordinary course of business for the purpose of fixing or hedging
interest rate risk, foreign currency risk or financial and other
similar risks (including commodity risks); provided that with
respect to Hedging Obligations with respect to Indebtedness such
Liens do not extend to property or assets other than the
property or assets securing such Indebtedness;
(16) Liens in favor of customs and revenue authorities or
freight forwarders or handlers to secure payment of custom
duties incurred in the ordinary course of business;
78
(17) leases, subleases or licenses and sublicenses granted
to others that do not materially interfere with the ordinary
course of business of the Company and its Restricted
Subsidiaries;
(18) Liens arising from the filing of Uniform Commercial
Code financing statements regarding leases;
(19) Liens in favor of the Company or a Restricted
Subsidiary;
(20) Liens securing Permitted Refinancing Indebtedness;
provided that (a) such Liens shall be limited to all or
part of the same property and assets that secured or, under the
written agreements pursuant to which the original Liens arose,
could secure the original Liens (plus improvements and
accessions to such property or proceeds or distributions
thereof) and (b) the Indebtedness secured by such Liens at
such time is not increased to any amount greater than the sum of
(i) the outstanding principal amount or, if greater,
committed amount of the Indebtedness at the time the original
Lien became a Permitted Lien and (ii) an amount necessary
to pay any fees and expenses, including premiums, related to
such refinancing, refunding, extension, renewal or replacement;
(21) Liens of a collection bank arising under
Section 4-210
of the New York Uniform Commercial Code on items in the course
of collection in favor of banking institutions arising as a
matter of law encumbering deposits (including the right of
set-off) within general parameters customary in the banking
industry;
(22) bankers Liens, rights of setoff, Liens arising
out of judgments or awards not constituting an Event of Default
and notices of lis pendens and associated rights related
to litigation being contested in good faith by appropriate
proceedings and for which adequate reserves have been made;
(23) any pledge of the Capital Stock of an Unrestricted
Subsidiary to secure Indebtedness of such Unrestricted
Subsidiary;
(24) deposits made in the ordinary course of business to
secure liability to insurance carriers;
(25) Liens arising out of conditional sale, title
retention, consignment or similar arrangements, or that are
contractual rights of set-off, relating to the sale or purchase
of goods entered into by the Company or any of its Restricted
Subsidiaries in the ordinary course of business;
(26) any encumbrance or restriction (including put and call
arrangements) with respect to Capital Stock of any
non-majority-owned joint venture or similar arrangement pursuant
to any joint venture or similar agreement permitted under the
Indenture;
(27) Liens on cash, Cash Equivalents or other property
arising in connection with the defeasance, discharge or
redemption of Indebtedness;
(28) Liens on specific items of inventory or other goods
(and the proceeds thereof) of any Person securing such
Persons obligations in respect of bankers
acceptances issued or created in the ordinary course of business
for the account of such Person to facilitate the purchase,
shipment or storage of such inventory or other goods;
(29) Liens on assets pursuant to merger agreements, stock
or asset purchase agreements and similar agreements in respect
of the disposition of such assets;
(30) Liens on Capital Stock issued by, or any property or
assets of, any Foreign Subsidiary securing Indebtedness incurred
by such Foreign Subsidiary or another Foreign Subsidiary that
directly or indirectly owns such Capital Stock;
(31) Liens upon assets of the Company or any Restricted
Subsidiary subject to any Sale and Leaseback Transaction
permitted by the Indenture; and
(32) Liens not otherwise permitted by clauses (1)
through (31) above which at any time secure Indebtedness or
other obligations in an amount up to the greater of
$5.0 million.
79
Permitted Pari Passu Obligations means any
obligation under any Additional Notes or any other Indebtedness
(whether or not consisting of Additional Notes) equally and
ratably secured on a first-lien basis with the Notes by Liens on
the Collateral; provided that any such Lien, as of the
date of incurrence of such Permitted Pari Passu Obligations, was
permitted to be incurred under clause (4) of the definition
of Permitted Liens.
Permitted Refinancing Indebtedness means any
Indebtedness of the Company or any of its Restricted
Subsidiaries issued in exchange for, or the net proceeds of
which are used to renew, refund, refinance, replace, defease or
discharge other Indebtedness of the Company or any of its
Restricted Subsidiaries (other than Intercompany Debt
Obligations); provided that:
(1) the principal amount (or accreted value, if applicable)
of such Permitted Refinancing Indebtedness does not exceed the
principal amount (or accreted value, if applicable) of the
Indebtedness renewed, refunded, refinanced, replaced, defeased
or discharged (plus all accrued interest on the Indebtedness and
the amount of all fees and expenses, including premiums,
incurred in connection therewith);
(2) such Permitted Refinancing Indebtedness does not mature
prior to the Stated Maturity of the Indebtedness to be
refinanced or refunded, and the Average Life of such Permitted
Refinancing Indebtedness, determined as of the date of
incurrence of such Permitted Refinancing Indebtedness, is at
least equal to the remaining Average Life of the Indebtedness to
be refinanced or refunded;
(3) if the Indebtedness being renewed, refunded,
refinanced, replaced, defeased or discharged is subordinated in
right of payment to the Notes, such Permitted Refinancing
Indebtedness is subordinated in right of payment to, the Notes
on terms at least as favorable to the Holders of Notes as those
contained in the documentation governing the Indebtedness being
renewed, refunded, refinanced, replaced, defeased or
discharged; and
(4) such Indebtedness is incurred either by the Company or
by the Restricted Subsidiary who is the obligor on the
Indebtedness being renewed, refunded, refinanced, replaced,
defeased or discharged.
Person means an individual, a corporation, a
partnership, a limited liability company, a joint venture, an
association, a trust, an unincorporated organization or any
other entity or organization, including a government or
political subdivision or an agency or instrumentality thereof.
Pro Forma Cost Savings means, with respect to
any period, the reduction in net costs and related adjustments
that are directly attributable to an acquisition that occurred
during the four-quarter period or after the end of the
four-quarter period and on or prior to the Calculation Date, and
calculated on a basis that is consistent with
Regulation S-X
under the Securities Act as in effect and applied as of the date
of the Indenture and are described in a certificate delivered to
the Trustee from the Companys Chief Financial Officer that
outlines the specific actions taken and the net cost savings
achieved or to be achieved from each such action.
Rating Agencies means (1) S&P and
Moodys or (2) if S&P or Moodys or both of
them are not making ratings publicly available with respect to
the Notes for reasons outside of the control of the Company, a
nationally recognized U.S. rating agency or agencies, as
the case may be, selected by the Company, which will be
substituted for S&P or Moodys or both, as the case
may be.
Replacement Assets means, on any date,
property or assets (other than current assets) of a nature or
type or that are used in a business (or an Investment in a
company having property or assets of a nature or type, or
engaged in a business) similar or related or complementary to
the nature or type of the property and assets of, or the
business of, the Company and its Restricted Subsidiaries
existing on such date.
Restricted Investment means an Investment
made after the Closing Date other than Permitted Investments.
Restricted Payment means the Company or any
of its Restricted Subsidiaries, directly or indirectly, does any
of the following: (1) either (a) declares or pays any
dividend on or makes any distribution in respect of its Equity
Interests or to the direct or indirect holders of its Equity
Interests in their capacity as such (other than dividends or
distributions payable in its Equity Interests (other than
Disqualified Stock) or to the
80
Company or any of its Restricted Subsidiaries), or
(b) purchases, redeems or retires for value Equity
Interests of the Company or any of its Restricted Subsidiaries
(other than Equity Interests owned by the Company or any of its
Restricted Subsidiaries); (2) makes any principal payment
on or with respect to, or redeems, repurchases, defeases or
otherwise acquires or retires for value prior to its scheduled
maturity, scheduled repayment or scheduled sinking fund payment,
any Indebtedness that is subordinated to the Notes or any
Subsidiary Guarantee or (3) makes any Restricted Investment.
Restricted Subsidiary means any Subsidiary of
the Company other than an Unrestricted Subsidiary.
S&P means Standard &
Poors Ratings Group, a division of The McGraw-Hill
Companies, and its successors.
SEC means the Securities and Exchange
Commission.
Secured Credit Documents means, collectively,
(i) the Indenture and Note Guarantees, and (ii) each
loan agreement, credit agreement, indenture or other agreement
entered into by the Company after the date of this Agreement, if
any, pursuant to which the Company or any of its Subsidiaries
will incur Pari Passu Obligations.
Securities Act means the Securities Act of
1933, as amended, or any successor statute or statutes thereto.
Security Documents means the Intercreditor
Agreement, if any, the Guarantee and Collateral Agreement, and
all other pledge agreements, collateral assignments, mortgages,
collateral agency agreements, deeds of trust or other grants or
transfers for security executed and delivered by the Issuer, a
Guarantor or the Parent creating (or purporting to create) a
Lien upon the Collateral as contemplated by the Indenture or the
Guarantee and Collateral Agreement, in each case, as amended,
modified, renewed, restated or replaced, in whole or in part,
from time to time in accordance with its terms.
Series means (a) with respect to the
Pari Passu Secured Parties, (i) the Holders of the Notes
and the Trustee (in their capacities as such, the Notes
Secured Parties) and (ii) the Pari Passu Secured
Parties that become subject to the Intercreditor Agreement after
the Closing Date and that are represented by a common Authorized
Representative; and (b) with respect to any Pari Passu
Obligations, each of the Note Obligations, and the Pari Passu
Obligations incurred pursuant to any applicable agreement,
which, in each case, pursuant to the Intercreditor Agreement or
a Joinder Agreement, are to be represented under the
Intercreditor Agreement by an Authorized Representative.
Significant Subsidiary means, at any date of
determination, with respect to any Person, means any Subsidiary
of such Person that satisfies the criteria for a
significant subsidiary set forth in
Rule 1-02(w)
of
Regulation S-X
under the Exchange Act, but shall not include any Unrestricted
Subsidiary.
Stated Maturity means, (1) with respect
to any debt security, the date specified in such debt security
as the fixed date on which the final installment of principal of
such debt security is due and payable and (2) with respect
to any scheduled installment of principal of or interest on any
debt security, the date specified in such debt security as the
fixed date on which such installment is due and payable.
Subsidiary means, with respect to any Person,
any corporation or other entity more than fifty percent (50%) of
whose Equity Interests having by the terms thereof, at that
time, ordinary voting power to elect a majority of the directors
(or comparable positions) of such entity is at the time owned by
such Person directly or indirectly through Subsidiaries.
Subsidiary Guarantor means any Guarantor that
is a Subsidiary.
Temporary Cash Investments means
(1) investments in marketable direct obligations issued or
guaranteed by the United States of America, or of any
governmental agency or political subdivision thereof, maturing
within 365 days of the date of purchase;
81
(2) repurchase obligations with a term of not more than
seven (7) days for underlying securities of the types
described in clauses (1) above entered into with any bank
organized under the laws of the United States of America or any
state thereof or the District of Columbia, in each case having
capital and unimpaired surplus totaling more than $500,000,000
and rated at least A by S&P and
A-2 by
Moodys;
(3) commercial paper or finance company paper issued by any
Person incorporated under the laws of the United States or any
state thereof and having one of the two highest ratings
obtainable from Moodys or S&P, in each case maturing
within 365 days of purchase; and
(4) Investments not exceeding 365 days in duration in
money market funds that invest substantially all of such
funds assets in the Investments described in the preceding
clauses (1) through (3).
Treasury Rate means, as of any redemption
date, the yield to maturity as of such redemption date of United
States Treasury securities with a constant maturity (as compiled
and published in the most recent Federal Reserve Statistical
Release H.15 (519) that has become publicly available at
least two business days prior to the redemption date (or, if
such statistical release is no longer published, any publicly
available source of similar market data)) most nearly equal to
the period from the redemption date to May 1, 2013;
provided, however, that if the period from the redemption date
to May 1, 2013 is not equal to the constant maturity of the
United States Treasury security for which a weekly average yield
is given, the Treasury Rate shall be obtained by linear
interpolation (calculated to the nearest one-twelfth of a year)
from the weekly average yields of United States Treasury
securities for which such yields are given, except that if the
period from such date of redemption to May 1, 2013 is less
than one year, the weekly average yield on actually traded
United States Treasury securities adjusted to a constant
maturity of one year shall be used.
Unrestricted Subsidiary means (1) any
Subsidiary of the Company that at the time of determination
shall be designated an Unrestricted Subsidiary by the Board of
Directors in the manner provided below; and (2) any
Subsidiary of an Unrestricted Subsidiary. The Board of Directors
may designate any Restricted Subsidiary (including any newly
acquired or newly formed Subsidiary of the Company) to be an
Unrestricted Subsidiary unless such Subsidiary owns any Equity
Interests of, or owns or holds any Lien on any property of, the
Company or any Restricted Subsidiary; provided that
(A) any Guarantee by the Company or any Restricted
Subsidiary of any Indebtedness of the Subsidiary being so
designated shall be deemed an incurrence of such
Indebtedness and an Investment by the Company or
such Restricted Subsidiary (or both, if applicable) at the time
of such designation; (B) either (I) the Subsidiary to
be so designated has total assets of $1,000 or less or
(II) if such Subsidiary has assets greater than $1,000,
such designation would be permitted under the Limitation
on Restricted Payments covenant and (C) if
applicable, the incurrence of Indebtedness and the Investment
referred to in clause (A) of this proviso would be
permitted under the Limitation on Indebtedness and
Limitation on Restricted Payments covenants. The
Board of Directors may designate any Unrestricted Subsidiary to
be a Restricted Subsidiary; provided that (a) no
Default or Event of Default shall have occurred and be
continuing at the time of or after giving effect to such
designation and (b) all Liens and Indebtedness of such
Unrestricted Subsidiary outstanding immediately after such
designation would, if incurred at such time, have been permitted
to be incurred (and shall be deemed to have been incurred) for
all purposes of the Indenture. Any such designation by the Board
of Directors shall be evidenced to the Trustee by promptly
filing with the Trustee a copy of the Board Resolution giving
effect to such designation and an Officers Certificate
certifying that such designation complied with the foregoing
provisions.
Wholly Owned means, with respect to any
Subsidiary of any Person, the ownership of all of the
outstanding capital stock of such Subsidiary (other than any
directors qualifying shares or Investments by foreign
nationals mandated by applicable law) by such Person or one or
more Wholly Owned Subsidiaries of such Person.
UNITED
STATES FEDERAL INCOME TAX CONSIDERATIONS
The following summary describes U.S. federal income tax
considerations relating to the exchange of old notes for
exchange notes and the ownership and disposition of the exchange
notes, but does not purport to be a complete analysis of all
potential tax effects. This summary is based on the Internal
Revenue Code of 1986,
82
as amended (the Code), Treasury Regulations,
judicial decisions, published positions of the Internal Revenue
Service (the IRS), and other applicable authorities,
all as in effect as of the date hereof and all of which are
subject to change or differing interpretations (possibly with
retroactive effect).
The discussion does not address all of the tax consequences that
may be relevant to a particular person or to persons subject to
special treatment under U.S. federal income tax laws (such
as financial institutions, broker-dealers, insurance companies,
regulated investment companies, real estate investment trusts,
cooperatives, traders in securities who elect to apply a
mark-to-market
method of accounting, persons that have a functional currency
other than the U.S. dollar, expatriates, tax-exempt
organizations, or persons that are, or hold their notes through,
partnerships or other pass-through entities), or to persons who
hold the notes as part of a straddle, hedge, conversion,
synthetic security, or constructive sale transaction for
U.S. federal income tax purposes, all of whom may be
subject to tax rules that differ from those summarized below. In
addition, this discussion does not address the consequences of
the alternative minimum tax, or any state, local or foreign tax
consequences or any tax consequences other than
U.S. federal income tax consequences. This summary deals
only with persons who hold the notes as capital assets within
the meaning of the Code (generally, property held for
investment). Holders are urged to consult their tax advisors as
to the particular U.S. federal tax consequences to them of
the acquisition, ownership and disposition of notes, as well as
the effects of state, local and
non-U.S. tax
laws.
For purposes of this summary, a U.S. holder
means a beneficial owner of a note (as determined for
U.S. federal income tax purposes) that is, or is treated
as, a citizen or individual resident of the U.S., a corporation
created or organized in the U.S. or under the laws of the
U.S. or any political subdivision thereof or the District
of Columbia, an estate the income of which is subject to
U.S. federal income taxation regardless of its source, or a
trust if (1) a court within the U.S. is able to
exercise primary supervision over the administration of the
trust and one or more U.S. persons have the authority to
control all substantial decisions of the trust, or (2) the
trust has a valid election in effect to be treated as a
U.S. person. A
non-U.S. holder
means any beneficial owner (other than a partnership or other
pass-through entity for U.S. federal income tax purposes)
that is not a U.S. holder.
If a partnership (including any entity treated as a partnership
or other pass-through entity for U.S. federal income tax
purposes) is a holder of a note, the U.S. federal income
tax treatment of a partner in the partnership will generally
depend on the status of the partner and the activities of such
partnership. Partners and partnerships should consult their tax
advisors as to the particular U.S. federal income tax
consequences applicable to them.
TO ENSURE COMPLIANCE WITH TREASURY DEPARTMENT CIRCULAR 230,
HOLDERS OF NOTES ARE HEREBY NOTIFIED THAT: (A) ANY
DISCUSSION OF FEDERAL TAX ISSUES IN THIS PROSPECTUS IS NOT
INTENDED OR WRITTEN TO BE RELIED UPON, AND CANNOT BE RELIED
UPON, BY HOLDERS FOR THE PURPOSE OF AVOIDING PENALTIES THAT MAY
BE IMPOSED ON HOLDERS UNDER THE INTERNAL REVENUE CODE;
(B) SUCH DISCUSSION IS BEING USED IN CONNECTION WITH THE
PROMOTION OR MARKETING (WITHIN THE MEANING OF CIRCULAR
230) BY US OF THE TRANSACTIONS OR MATTERS ADDRESSED HEREIN;
AND (C) HOLDERS SHOULD SEEK ADVICE BASED ON THEIR
PARTICULAR CIRCUMSTANCES FROM AN INDEPENDENT TAX ADVISOR.
Qualified
Reopening
We will treat the notes as having been issued in a
qualified reopening for United States federal income
tax purposes, and the following discussion assumes such
treatment will be respected. Consequently, the new notes will be
part of the same issue as the existing notes. Because the
existing notes were issued with original issue discount
(OID) for United States federal income tax purposes,
the new notes also will have OID. However, as discussed in
further detail below under
U.S. Holders Amortizable
Premium, since the initial offering price of the new notes
is greater than their stated principal amount, investors who
purchased new notes pursuant to the offering at their initial
offering price will not be required to include any OID in income
for United States federal income tax purposes.
83
Pre-issuance
Accrued Interest
The initial offering price for the notes will include amounts
attributable to interest accrued from May 1, 2011, which we
call pre-issuance accrued interest. Pre-issuance
accrued interest will be included in the accrued interest to be
paid on the notes on the first interest payment date after the
issuance of the notes. In accordance with applicable United
States Treasury regulations, for United States federal income
tax purposes, we will treat the notes as having been purchased
for a price that does not include any pre-issuance accrued
interest. If the notes are so treated, the portion of the first
stated interest payment equal to the pre-issuance accrued
interest will be deemed to be a non-taxable return of capital
and, accordingly, will not be taxable as interest on the notes.
Exchange
Offer
The exchange of old notes for exchange notes pursuant to the
exchange offer should not constitute a taxable event for
U.S. federal income tax purposes. As a result, (1) a
holder should not recognize a taxable gain or loss as a result
of exchanging such holders old notes for exchange notes;
(2) the holding period of the exchange notes should include
the holding period of the old notes exchanged therefor;
(3) the adjusted tax basis of the exchange notes should be
the same as the adjusted tax basis of the old notes exchanged
therefor immediately before such exchange; and (4) the
adjusted issue price (defined below under
U.S. Holders Original Issue Discount) of
the exchange notes will be the same as the adjusted issue price
of the old notes exchanged therefor immediately before such
exchange.
U.S. Holders
Stated Interest. Payments of stated interest
on the notes (other than any pre-issuance accrued interest
excluded from the purchase price of the notes, as discussed
above under Pre-issuance Accrued
Interest) will generally be taxable to a U.S. holder
as ordinary interest income at the time such holder receives or
accrues such amounts, in accordance with its regular method of
accounting.
Amortizable Premium. The notes are being
issued at a premium equal to the difference between
their initial purchase price (excluding any pre-issuance accrued
interest excluded from the purchase price of the notes, as
discussed above under Pre-issuance Accrued
Interest) and their stated principal amount. Accordingly,
even though the notes are treated as having OID (as a result of
being treated as issued in a qualified reopening, as discussed
above under Qualified Reopening), a
U.S. holder will not be required to include any OID with
respect to the notes in income. In addition, a U.S. holder
generally may elect to amortize the premium over the remaining
term of the notes on a constant yield method as an offset to
interest when includible in income under the
U.S. holders regular accounting method. A
U.S. holder who elects to amortize any premium on notes
must reduce its tax basis in the notes by the amount of the
premium amortized in any year. An election to amortize premium
applies to all taxable debt obligations held by the
U.S. holder at the beginning of the first taxable year to
which the election applies and to all such obligations
thereafter acquired by the U.S. holder and may be revoked
only with the consent of the IRS. Premium on notes held by a
U.S. holder who does not make such an election will
decrease the gain or increase the loss otherwise recognized on
the disposition of the notes. U.S. holders should consult
their tax advisors regarding these rules, including the period
over which the premium may be amortized and the amount of
premium (if any) allowed in a particular tax year.
Disposition. Upon the sale, exchange,
redemption or other taxable disposition of a note, a
U.S. holder will generally recognize taxable capital gain
or loss equal to the difference, if any, between the amount
realized and the holders adjusted tax basis in the note at
the time. A U.S. holders adjusted tax basis in a note
will generally equal the amount paid by the holder for the note
(excluding pre-issuance accrued interest excluded from the
purchase price of such note, as discussed above under
Pre-issuance Accrued Interest), reduced
by any amortized premium with respect to the note and decreased
by principal payments received by the U.S. holder. Such
gain or loss will be long-term capital gain or loss if the
U.S. holders holding period with respect to the note
disposed of is more than one year at the time. To the extent
that amounts received include accrued but unpaid interest that
the U.S. holder has not yet included in income, such
interest will not
84
be taken into account in determining gain or loss, but will
instead be taxable as ordinary interest income. Long-term
capital gains of non-corporate U.S. holders will generally
be subject to United States federal income tax at a reduced
rate. The deductibility of capital losses is subject to
limitations.
Information
Reporting and Backup Withholding
Information reporting requirements generally will apply to
payments of interest on the notes and to the proceeds of a sale
of a note paid to a U.S. holder unless the U.S. holder
is an exempt recipient (such as a corporation). Backup
withholding will apply to those payments if the U.S. holder
fails to provide its correct taxpayer identification number, or
certification of exempt status, generally by providing an IRS
Form W-9
or an approved substitute or if the U.S. holder is notified
by the IRS that the U.S. holder has failed to report in
full payments of interest and dividend income. Backup
withholding is not an additional tax. Any amounts withheld under
the backup withholding rules will be allowed as a refund or a
credit against a U.S. holders U.S. federal
income tax liability provided the required information is timely
furnished to the IRS.
Non-U.S. Holders
Stated Interest. A
non-U.S. holder
will generally not be subject to U.S. federal income tax on
interest (which, for this purpose, does not include any
pre-issuance accrued interest excluded from the purchase price
of the notes, as discussed above under
Pre-issuance Accrued Interest) paid or
accrued on a note if the interest is not effectively connected
with a U.S. trade or business (or, in the case of certain
tax treaties, is not attributable to a permanent establishment
or fixed base within the U.S.). In addition, subject to the
discussion of backup withholding below, a
non-U.S. holder
will generally not be subject to U.S. withholding tax on
interest paid or accrued on a note, provided that the
non-U.S. holder:
(1) does not actually or constructively, directly or
indirectly, own 10% or more of our voting stock; and
(2) is not a controlled foreign corporation that is related
to us (directly or indirectly) through stock ownership; and
(3) is not a bank that acquired the note in connection with
an extension of credit made pursuant to a loan entered into in
the ordinary course of business; and
(4) certifies to its
non-U.S. status
on IRS
Form W-8BEN.
Alternatively, a
non-U.S. holder
that cannot satisfy the above requirements will generally be
exempt from U.S. federal withholding tax with respect to
interest paid or accrued on the notes if the holder establishes
that such interest is not subject to withholding tax because it
is effectively connected with the
non-U.S. holders
conduct of a trade or business in the U.S. or, in the case
of certain tax treaties, is attributable to a permanent
establishment or fixed base within the U.S. (generally, by
providing an IRS
Form W-8ECI).
However, to the extent that such interest is effectively
connected with the
non-U.S. holders
conduct of a trade or business in the U.S. (or, in the case
of certain tax treaties, is attributable to a permanent
establishment or fixed base within the U.S.), the
non-U.S. holder
will be subject to U.S. federal income tax on a net basis
and, if it is a foreign corporation, may be subject to a 30%
U.S. branch profits tax (or lower applicable treaty rate).
If a
non-U.S. holder
does not satisfy the requirements described above, or does not
establish that the interest is effectively connected with the
non-U.S. holders
conduct of a trade or business in the U.S., the
non-U.S. holder
will generally be subject to U.S. withholding tax,
currently imposed at 30%. Under certain income tax treaties, the
U.S. withholding rate on payments of interest may be
reduced or eliminated, provided the
non-U.S. holder
complies with the applicable certification requirements
(generally, by providing a properly completed IRS
Form W-8BEN).
85
Disposition. Subject to the discussion below
regarding information reporting and backup withholding, a
non-U.S. holder
will generally not be subject to U.S. federal income
taxation with respect to gain realized on the sale, exchange,
redemption or other disposition of a note, unless:
(1) the
non-U.S. holder
holds the note in connection with the conduct of a
U.S. trade or business (or, in the case of certain tax
treaties, the gain is attributable to a permanent establishment
or fixed base within the U.S.); or
(2) in the case of an individual, such individual is
present in the U.S. for 183 days or more during the
taxable year in which gain is realized and certain other
conditions are met.
A
non-U.S. holder
described in clause (1) above will be subject to tax on the
net gain derived from the sale under regular graduated
U.S. federal income tax rates and, if it is a foreign
corporation, may be subject to a 30% U.S. branch profits
tax (or lower applicable treaty rate). An individual described
in clause (2) above will be subject to a flat 30% tax on
the gain derived from the sale, which may be offset by
U.S. source capital losses (even though the individual is
not considered a resident of the U.S.) but may not be offset by
any capital loss carryovers.
Information Reporting and Backup
Withholding. A
non-U.S. holder
may be subject to information reporting with respect to interest
paid or accrued on a note and with respect to amounts realized
on the disposition of a note. A
non-U.S. holder
not subject to U.S. income tax may nonetheless be subject
to backup withholding (currently imposed at 28%) on interest
paid or accrued on a note, and with respect to amounts realized
on the disposition of a note, unless the
non-U.S. holder
provides the withholding agent with the applicable IRS
Form W-8
or otherwise establishes an exemption.
Non-U.S. holders
should consult their tax advisors as to their qualifications for
an exemption from backup withholding and the procedure for
obtaining such an exemption. Backup withholding is not an
additional tax. Any amounts withheld under the backup
withholding rules from a payment to a
non-U.S. holder
may be credited against the
non-U.S. holders
U.S. federal income tax liability, if any, or refunded, if
the required information is furnished to the IRS in a timely
manner.
Non-U.S. holders
are urged to consult their tax advisors regarding the
applicability of the information reporting and backup
withholding rules to them.
PLAN OF
DISTRIBUTION
Each broker-dealer that receives exchange notes for its own
account pursuant to the exchange offer must acknowledge that it
will deliver a prospectus in connection with any resale of such
exchange notes. This prospectus, as it may be amended or
supplemented from time to time, may be used by a broker-dealer
in connection with resales of exchange notes received in
exchange for old notes where such old notes were acquired as a
result of market-making activities or other trading activities.
We have agreed that, starting on the expiration date of the
exchange offer and ending on the close of business 180 days
after the expiration date of the exchange offer, we will make
this prospectus available to any broker-dealer for use in
connection with any such resale.
We will not receive any proceeds from any sale of exchange notes
by broker-dealers. Exchange notes received by broker-dealers for
their own account pursuant to the exchange offer may be sold
from time to time in one or more transactions in the
over-the-counter market, in negotiated transactions, through the
writing of options on the exchange notes or a combination of
such methods of resale, at market prices prevailing at the time
of resale, at prices related to such prevailing market prices,
at prices related to such prevailing market prices or negotiated
prices. Any such resale may be made directly to purchasers or to
or through brokers or dealers who may receive compensation in
the form of commissions or concessions from any such
broker-dealer
and/or the
purchasers of any such exchange notes. Any broker-dealer that
resells exchange notes that were received by it for its own
account pursuant to the exchange offer and any broker or dealer
that participates in a distribution of such exchange notes may
be deemed to be an underwriter within the meaning of
the Securities Act and any profit on any such resale of exchange
notes and any commissions or concessions received by any such
persons may be deemed to be underwriting compensation under the
Securities Act. The letter of transmittal states that by
acknowledging that it will deliver and by delivering a
86
prospectus, a broker-dealer will not be deemed to admit that it
is an underwriter within the meaning of the
Securities Act.
For a period of 180 days after the expiration date of the
exchange offer, the company will promptly send additional copies
of this prospectus and any amendment or supplement to this
prospectus to any broker-dealer that requests such documents in
the letter of transmittal. We have agreed to pay all expenses
incident to the exchange offer (including the expenses of one
counsel for the holder of the old notes) other than commissions
or concessions of any brokers or dealers and will indemnify the
holders of the old notes (including any broker-dealers) against
certain liabilities, including liabilities under the Securities
Act.
LEGAL
MATTERS
The validity and enforceability of the exchange notes and the
related guarantees will be passed upon for us by McDermott
Will & Emery LLP.
EXPERTS
The consolidated financial statements of Merge Healthcare
Incorporated as of December 31, 2010 and 2009 and for each
of the three years in the period ended December 31, 2010
and managements assessment of the effectiveness of
internal control over financial reporting as of
December 31, 2010, incorporated by reference in this
Prospectus, have been so incorporated in reliance on the reports
of BDO USA, LLP, an independent registered public accounting
firm, incorporated herein by reference, given on the authority
of said firm as experts in auditing and accounting.
The consolidated financial statements of Merge Healthcare
Solutions Inc., formerly known as AMICAS, Inc. (Successor
Company), as of December 31, 2010 and for the period
April 28, 2010 through December 31, 2010 and AMICAS,
Inc. (Predecessor Company) as of December 31, 2009 and for
the period January 1, 2010 through April 27, 2010 and
for each of the two years in the period ended December 31,
2009, included in this Prospectus and in the Registration
Statement, have been so included in reliance on the reports of
BDO USA, LLP, an independent registered public accounting firm,
appearing elsewhere herein and in the Registration Statement,
given on the authority of said firm as experts in auditing and
accounting.
The consolidated financial statements of Emageon Inc. appearing
in Emageon Inc.s Annual Report (Form 10-K) for the year
ended December 31, 2008 have been audited by Ernst & Young
LLP, independent registered public accounting firm, as set forth
in their report thereon, included therein, and incorporated
herein by reference. Such consolidated financial statements are
incorporated herein by reference in reliance upon such report
given on the authority of such firm as experts in accounting and
auditing.
The consolidated financial statements of Ophthalmic Imaging
Systems appearing in Ophthalmic Imaging Systems Annual
Report (Form 10-K as amended by Form 10-K/A) for the
year ended December 31, 2010 have been audited by
Perry-Smith LLP, independent registered public accounting firm,
as set forth in their report thereon, included therein, and
incorporated herein by reference. Such consolidated financial
statements are incorporated herein by reference in reliance upon
such report given on the authority of such firm as experts in
accounting and auditing.
87
WHERE YOU
CAN FIND MORE INFORMATION
We have filed with the SEC a registration statement on
Form S-4
under the Securities Act with respect to the securities we are
offering by this prospectus. This prospectus does not contain
all of the information included in the registration statement,
including its exhibits and schedules. You should refer to the
registration statement, including the exhibits and schedules,
for further information about us and the securities we are
offering. Statements we make in this prospectus about certain
contracts or other documents are not necessarily complete. When
we make such statements, we refer you to the copies of the
contracts or documents that are filed as exhibits to the
registration statement because those statements are qualified in
all respects by reference to those exhibits.
We file reports, proxy and information statements, and other
information with the SEC. You may read and copy this information
at the Public Reference Room of the SEC located at
100 F Street, N.E., Washington, D.C. 20549.
Please call the SEC at
1-800-SEC-0330
for further information on the operation of the Public Reference
Room. Copies of all or any part of the registration statement
may be obtained from the SECs offices upon payment of fees
prescribed by the SEC. The SEC maintains an Internet site that
contains periodic and current reports, proxy and information
statements, and other information regarding issuers that file
electronically with the SEC. The address of the SECs
website is www.sec.gov.
We make available free of charge on our Internet address
www.merge.com our annual, quarterly and current reports, and
amendments to these reports, as soon as reasonably practicable
after we electronically file such material with, or furnish it
to, the SEC.
INCORPORATION
OF DOCUMENTS BY REFERENCE
The SEC requires us to incorporate by reference into
this prospectus information that we file with the SEC in other
documents. This means that we can disclose important information
to you by referring you to other documents that contain that
information. The information we incorporate by reference is
considered to be part of this prospectus. Information contained
in this prospectus and information that we file with the SEC in
the future and that we incorporate by reference in this
prospectus automatically updates and supersedes previously filed
information. We incorporate by reference the documents listed
below and any future filings we make with the SEC under
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act
after the date of this prospectus and prior to the sale of all
the exchange notes covered by this prospectus.
|
|
|
|
|
Merges Annual Report on
Form 10-K
for the year ended December 31, 2010, filed with the SEC on
March 16, 2011;
|
|
|
|
Merges Quarterly Reports on
Form 10-Q
for the periods ended March 31, 2011 and June 30,
2011, filed with the SEC on May 5, 2011 and August 9,
2011, respectively;
|
|
|
|
Merges Definitive Proxy Statement for its 2011 Annual
Meeting of Stockholders, filed with the SEC on April 21,
2011 and supplemented on April 26, 2011;
|
|
|
|
Merges Current Reports on
Form 8-K
filed with the SEC on January 6, 2011, June 6, 2011,
June 8, 2011 (Items 5.03, 8.01 and 9.01), June 8, 2011
(Items 5.02 and 5.07), June 15, 2011, June 20, 2011,
August 8, 2011 and August 11, 2011 (as amended on
August 22, 2011);
|
|
|
|
The (i) consolidated financial statements of Emageon Inc.
as of December 31, 2008 and 2007 and for each of the three
years in the period ended December 31, 2008 as set forth on
pages F-2 and
F-4 through
F-30 of Emageon Inc.s Annual Report on
Form 10-K
for the year ended December 31, 2008 filed with the SEC on
March 26, 2009 and (ii) unaudited pro forma condensed
consolidated financial statements (Exhibit 99.2) included
in AMICAS, Inc.s Current Report on
Form 8-K
filed with the SEC on April 3, 2009 (as amended by AMICAS,
Inc.s Current Report on
Form 8-K/A
filed with the SEC on June 16, 2009);
|
|
|
|
OIS Annual Report on Form 10-K for the year ended
December 31, 2010, filed with the SEC on April 15,
2011 and amended on July 1, 2011;
|
88
|
|
|
|
|
OIS Current Report on Form 10-Q for the quarterly period
ended March 31, 2011, filed with the SEC on May 13,
2011; and
|
|
|
|
Any future filings we may make with the SEC under Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of
filing of the initial registration statement relating to this
exchange offer and prior to the termination of any offering of
securities offered by this prospectus.
|
A statement contained in a document incorporated by reference
into this prospectus shall be deemed to be modified or
superseded for purposes of this prospectus to the extent that a
statement contained in this prospectus, any prospectus
supplement or in any other subsequently filed document which is
also incorporated in this prospectus modifies or replaces such
statement. Any statements so modified or superseded shall not be
deemed, except as so modified or superseded, to constitute a
part of this prospectus.
You can obtain a copy of any of our filings, at no cost, by
writing to or telephoning us at the following address:
Merge
Healthcare Incorporated
900 Walnut Ridge Drive
Hartland, Wisconsin 53029
Attention: Investor Relations
Phone:
(262) 367-0700
To ensure timely delivery, please make your request as soon as
practicable and, in any event, no later than five business days
prior to the expiration of the exchange offer.
You should rely only upon the information provided in this
prospectus or incorporated by reference into this prospectus.
Merge has not authorized anyone to provide you with different
information. You should not assume that the information in this
prospectus, including any information incorporated by reference,
is accurate as of any date other than the date of this
prospectus.
89
Merge Healthcare
Incorporated
Offer To Exchange
$52,000,000 aggregate principal amount of its 11.75% Senior
Secured Notes due 2015,
which have been registered under the Securities Act,
for any and all of its
outstanding 11.75% Senior Secured Notes due 2015
Guaranteed by
Abraxas Medical Solutions,
Inc.
AMICAS Inc. (now Merge Healthcare Solutions Inc.),
Confirma Europe LLC,
Merge Asset Management
Corp.,
Merge eClinical Inc.,
Ophthalmic Imaging Systems,
Requisite Software Inc., and
Stryker Imaging Corporation
PROSPECTUS
,
2011
The Exchange Agent for the Exchange Offer is:
THE BANK OF NEW YORK MELLON
Corporate Trust Operations
Reorganization Unit
101 Barclay Street 7 East
New York, New York 10286
Attn:
[ ]
Facsimile:
(212) 298-1915
PART II
INFORMATION NOT REQUIRED IN THE PROSPECTUS
|
|
Item 20.
|
Indemnification
of Directors and Officers
|
(a) Merge Healthcare Incorporated
Merge Healthcare is a Delaware corporation. Reference is made to
Section 102(b)(7) of the General Corporation Law of the
State of Delaware (the DGCL), which enables a
corporation in its original certificate of incorporation or an
amendment to eliminate or limit the personal liability of a
director for violations of the directors fiduciary duty,
except:
|
|
|
|
|
for any breach of the directors duty of loyalty to the
corporation or its stockholders;
|
|
|
|
for acts or omissions not in good faith or which involve
intentional misconduct or a knowing violation of law;
|
|
|
|
pursuant to Section 174 of the DGCL (providing for
liability of directors for unlawful payment of dividends or
unlawful stock purchases or redemptions); or
|
|
|
|
for any transaction from which a director derived an improper
personal benefit.
|
Reference is also made to Section 145 of the DGCL, which
provides that a corporation may indemnify any persons, including
officers and directors, who are, or are threatened to be made,
parties to any threatened, pending or completed legal action,
suit or proceeding, whether civil, criminal, administrative or
investigative (other than an action by or in the right of such
corporation), by reason of the fact that such person is or was a
director, officer, employee or agent of such corporation or is
or was serving at the request of such corporation as a director,
officer, employee or agent of another corporation or enterprise.
The indemnity may include expenses (including attorneys
fees), judgments, fines and amounts paid in settlement actually
and reasonably incurred by such person in connection with such
action, suit or proceeding, provided such director, officer,
employee or agent acted in good faith and in a manner the person
reasonably believed to be in or not opposed to the best
interests of the corporation and, with respect to any criminal
action or proceeding, had no reasonable cause to believe that
the persons conduct was unlawful. A Delaware corporation
may indemnify officers and directors in an action by or in the
right of the corporation under the same conditions, except that
no indemnification is permitted without judicial approval if the
officer or director is adjudged to be liable to the corporation.
Where an officer or director is successful on the merits or
otherwise in the defense of any action referred to above, the
corporation must indemnify him against the expenses that such
officer or director actually and reasonably incurred. The
indemnification permitted under the DGCL is not exclusive, and a
corporation is empowered to purchase and maintain insurance
against liabilities, whether or not indemnification would be
permitted by statute.
Article XI of Merges Bylaws provides in effect that,
subject to certain limited exceptions, Merge Healthcare shall
indemnify its directors and officers to the extent not
prohibited by the DGCL. Merges directors and officers are
insured under policies of insurance maintained by Merge
Healthcare, subject to the limits of the policies, against
certain losses arising from any claims made against them by
reason of being or having been such directors or officers. In
addition, Merge Healthcare has entered into contracts with
certain of its directors providing for indemnification of such
persons by Merge Healthcare to the full extent authorized or
permitted by law, subject to certain limited exceptions.
(b) Abraxas Medical Solutions, Inc., AMICAS, Inc.
(now Merge Healthcare Solutions Inc.), Confirma Europe LLC,
Merge Asset Management Corp., Merge eClinical Inc., Ophthalmic
Imaging Systems, Requisite Software Inc. and Stryker Imaging
Corporation.
See the discussion of Delaware General Corporation Law above. In
addition, as noted above, each of Abraxas Medical Solutions,
Inc., AMICAS, Inc. (now Merge Healthcare Solutions, Inc.),
Confirma Europe LLC, Merge Asset Management Corp., Merge
eClinical Inc., Ophthalmic Imaging Systems, Requisite Software
Inc. and Stryker Imaging Corporation enter into indemnification
agreements with their directors and executive officers that
cover their service as an officer and director of such entities.
II-1
|
|
Item 21.
|
Exhibits
and Financial Statement Schedules.
|
(a) Exhibits
See the Exhibit Index, which follows the signature pages
and which is incorporated herein by reference.
(b) Financial Statement Schedules.
None.
The undersigned Registrants hereby undertake:
(a) To file, during any period in which offers or sales are
being made, a post-effective amendment to this registration
statement:
(i) To include any prospectus required by
Section 10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events
arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which,
individually or in the aggregate, represent a fundamental change
in the information set forth in the registration statement.
Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered)
and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of
prospectus filed with the Commission pursuant to Rule 424(b) if,
in the aggregate, the changes in volume and price represent no
more than 20 percent change in the maximum aggregate
offering price set forth in the Calculation of
Registration Fee table in the effective registration
statement; and
(iii) To include any material information with respect to
the plan of distribution not previously disclosed in the
registration statement or any material change to such
information in the registration statement.
(b) That, for the purpose of determining any liability
under the Securities Act of 1933, each such post-effective
amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of
such securities at that time shall be deemed to be the initial
bona fide offering thereof.
(c) To remove from registration by means of a
post-effective amendment any of the securities being registered
which remain unsold at the termination of the offering.
(d) That, for the purpose of determining liability of the
registrants under the Securities Act of 1933 to any purchaser,
each prospectus filed pursuant to Rule 424(b) as part of a
registration statement relating to an offering, other than
registration statements relying on Rule 430B or other than
prospectuses filed in reliance on Rule 430A, shall be
deemed to be part of and included in the registration statement
as of the date it is first used after effectiveness. Provided,
however, that no statement made in a registration statement or
prospectus that is part of the registration statement or made in
a document incorporated or deemed incorporated by reference into
the registration statement or prospectus that is part of the
registration statement will, as to a purchaser with a time of
contract of sale prior to such first use, supersede or modify
any statement that was made in the registration statement or
prospectus that was part of the registration statement or made
in any such document immediately prior to such date of first use.
(e) That, for the purpose of determining liability of the
registrants under the Securities Act of 1933 to any purchaser in
the initial distribution of the securities:
The undersigned registrants undertake that in a primary offering
of securities of the undersigned registrants pursuant to this
registration statement, regardless of the underwriting method
used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the
II-2
following communications, the undersigned registrants will be a
seller to the purchaser and will be considered to offer or sell
such securities to such purchaser:
(i) Any preliminary prospectus or prospectus of the
undersigned registrants relating to the offering required to be
filed pursuant to Rule 424;
(ii) Any free writing prospectus relating to the offering
prepared by or on behalf of the undersigned registrants or used
or referred to by the undersigned registrants;
(iii) The portion of any other free writing prospectus
relating to the offering containing material information about
the undersigned registrants or their securities provided by or
on behalf of the undersigned registrants; and
(iv) Any other communication that is an offer in the
offering made by the undersigned registrants to the purchaser.
(f) That, for purposes of determining any liability under
the Securities Act of 1933, each filing of the registrants
annual report pursuant to section 13(a) or
section 15(d) of the Securities Exchange Act of 1934 (and,
where applicable, each filing of an employee benefit plans
annual report pursuant to section 15(d) of the Securities
Exchange Act of 1934) that is incorporated by reference in
the registration statement shall be deemed to be a new
registration statement relating to the securities offered
therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.
Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors,
officers and controlling persons of the registrants pursuant to
the foregoing provisions, or otherwise, the registrants have
been advised that in the opinion of the Commission such
indemnification is against public policy as expressed in the
Securities Act of 1933 and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities
(other than the payment by the registrants of expenses incurred
or paid by a director, officer or controlling person of the
registrants in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the
registrants will, unless in the opinion of their counsel the
matter has been settled by controlling precedent, submit to a
court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in
the Securities Act of 1933 and will be governed by the final
adjudication of such issue.
(g) The undersigned registrants hereby undertake to respond
to requests for information that is incorporated by reference
into the prospectus pursuant to Item 4, 10(b), 11, or 13 of
this form, within one business day of receipt of such request,
and to send the incorporated documents by first class mail or
other equally prompt means. This includes information contained
in documents filed subsequent to the effective date of the
registration statement through the date of responding to the
request.
(h) The undersigned registrants hereby undertake to supply
by means of a post-effective amendment all information
concerning a transaction, and the company being acquired
involved therein, that was not the subject of and included in
the registration statement when it became effective.
II-3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as
amended, the Registrant has duly caused this registration
statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Hartland, Wisconsin on this
14th day
of October, 2011.
Merge Healthcare Incorporated
|
|
|
|
By:
|
/s/ Jeffery
A. Surges
|
Name: Jeffery A. Surges
|
|
|
|
Title:
|
Chief Executive Officer
|
Pursuant to the requirements of the Securities Act of 1933, as
amended, this registration statement has been signed by the
following persons in the capacities indicated on this
14th day
of October, 2011.
|
|
|
|
|
Signature
|
|
Title
|
|
|
|
|
*
Michael
W. Ferro, Jr.
|
|
Chairman of the Board
|
|
|
|
/s/ Jeffery
A. Surges
Jeffery
A. Surges
|
|
Director and Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
*
Justin
C. Dearborn
|
|
Director, President and Chief Financial Officer
(Principal Financial Officer)
|
|
|
|
*
Steven
M. Oreskovich
|
|
Chief Accounting Officer
(Principal Accounting Officer)
|
|
|
|
*
Dennis
Brown
|
|
Director
|
|
|
|
*
Gregg
G. Hartemayer
|
|
Director
|
|
|
|
*
Richard
A. Reck
|
|
Director
|
|
|
|
*
Neele
E. Stearns, Jr.
|
|
Director
|
|
|
|
* Pursuant to power of Attorney
|
|
|
|
|
|
/s/ Ann
G. Mayberry-French
Attorney-in-Fact
|
|
|
II-4
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as
amended, the Registrant has duly caused this registration
statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Hartland, Wisconsin on this
14th day
of October, 2011.
Abraxas Medical Solutions, Inc.
|
|
|
|
By:
|
/s/ Justin
C. Dearborn
|
Name: Justin C. Dearborn
|
|
|
|
Title:
|
President and Chief Executive Officer
|
Pursuant to the requirements of the Securities Act of 1933, as
amended, this registration statement has been signed by the
following persons in the capacities indicated on this
14th day
of October, 2011.
|
|
|
|
|
Signature
|
|
Title
|
|
|
|
|
/s/ Justin
C. Dearborn
Justin
C. Dearborn
|
|
Director, President and Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
*
Steven
M. Oreskovich
|
|
Director, Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)
|
|
|
|
/s/ Ann
G. Mayberry-French
Ann
G. Mayberry-French
|
|
Director
|
|
|
|
* Pursuant to Power of Attorney
|
|
|
|
|
|
/s/ Ann
G. Mayberry-French
Attorney-in-Fact
|
|
|
II-5
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as
amended, the Registrant has duly caused this registration
statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Hartland, Wisconsin on this
14th day
of October, 2011.
AMICAS, Inc. (now Merge Healthcare Solutions Inc.)
|
|
|
|
By:
|
/s/ Justin
C. Dearborn
|
Name: Justin C. Dearborn
|
|
|
|
Title:
|
President and Chief Executive Officer
|
Pursuant to the requirements of the Securities Act of 1933, as
amended, this registration statement has been signed by the
following persons in the capacities indicated on this
14th day
of October, 2011.
|
|
|
|
|
Signature
|
|
Title
|
|
|
|
|
/s/ Justin
C. Dearborn
Justin
C. Dearborn
|
|
Director, President and Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
*
Steven
M. Oreskovich
|
|
Director, Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)
|
|
|
|
/s/ Ann
G. Mayberry-French
Ann
G. Mayberry-French
|
|
Director
|
|
|
|
* Pursuant to Power of Attorney
|
|
|
|
|
|
/s/ Ann
G. Mayberry-French
Attorney-in-Fact
|
|
|
II-6
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as
amended, the Registrant has duly caused this registration
statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Hartland, Wisconsin on this
14th day
of October, 2011.
Confirma Europe LLC
|
|
|
|
By:
|
/s/ Justin
C. Dearborn
|
Name: Justin C. Dearborn
|
|
|
|
Title:
|
President and Chief Executive Officer of the Sole Manager and
Chief Executive Officer of the Registrant
|
Pursuant to the requirements of the Securities Act of 1933, as
amended, this registration statement has been signed by the
following persons in the capacities indicated on this
14th day
of October, 2011.
|
|
|
|
|
Signature
|
|
Title
|
|
|
|
|
/s/ Justin
C. Dearborn
Justin
C. Dearborn
|
|
President and Chief Executive Officer of the
Sole Manager and Chief Executive Officer of the Registrant
(Principal Executive Officer)
|
|
|
|
*
Steven
M. Oreskovich
|
|
Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)
|
|
|
|
* Pursuant to Power of Attorney
|
|
|
|
|
|
/s/ Ann
G. Mayberry-French
Attorney-in-Fact
|
|
|
II-7
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as
amended, the Registrant has duly caused this registration
statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Hartland, Wisconsin on this
14th day
of October, 2011.
Merge Asset Management Corp.
|
|
|
|
By:
|
/s/ Justin
C. Dearborn
|
Name: Justin C. Dearborn
|
|
|
|
Title:
|
President and Chief Executive Officer
|
Pursuant to the requirements of the Securities Act of 1933, as
amended, this registration statement has been signed by the
following persons in the capacities indicated on this
14th day
of October, 2011.
|
|
|
|
|
Signature
|
|
Title
|
|
|
|
|
/s/ Justin
C. Dearborn
Justin
C. Dearborn
|
|
Director, President and Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
*
Steven
M. Oreskovich
|
|
Director, Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)
|
|
|
|
/s/ Ann
G. Mayberry-French
Ann
G. Mayberry-French
|
|
Director
|
|
|
|
* Pursuant to power of Attorney
|
|
|
|
|
|
/s/ Ann
G. Mayberry-French
Attorney-in-Fact
|
|
|
II-8
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as
amended, the Registrant has duly caused this registration
statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Hartland, Wisconsin on this
14th day
of October, 2011.
Merge eClinical Inc.
|
|
|
|
By:
|
/s/ Justin
C. Dearborn
|
Name: Justin C. Dearborn
|
|
|
|
Title:
|
President and Chief Executive Officer
|
Pursuant to the requirements of the Securities Act of 1933, as
amended, this registration statement has been signed by the
following persons in the capacities indicated on this
14th day
of October, 2011.
|
|
|
|
|
Signature
|
|
Title
|
|
|
|
|
/s/ Justin
C. Dearborn
Justin
C. Dearborn
|
|
Director, President and Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
*
Steven
M. Oreskovich
|
|
Director, Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)
|
|
|
|
/s/ Ann
G. Mayberry-French
Ann
G. Mayberry-French
|
|
Director
|
|
|
|
* Pursuant to power of Attorney
|
|
|
|
|
|
/s/ Ann
G. Mayberry-French
Attorney-in-Fact
|
|
|
II-9
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as
amended, the Registrant has duly caused this registration
statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Hartland, Wisconsin on this
14th day
of October, 2011.
Ophthalmic Imaging Systems
By: /s/ Justin C. Dearborn
Name: Justin C. Dearborn
|
|
|
|
Title:
|
President and Chief Executive Officer
|
Pursuant to the requirements of the Securities Act of 1933, as
amended, this registration statement has been signed by the
following persons in the capacities indicated on this
14th day
of October, 2011.
|
|
|
|
|
Signature
|
|
Title
|
|
|
|
|
/s/ Justin
C. Dearborn
Justin
C. Dearborn
|
|
Director, President and Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
*
Steven
M. Oreskovich
|
|
Director, Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)
|
|
|
|
/s/ Ann
G. Mayberry-French
Ann
G. Mayberry-French
|
|
Director
|
|
|
|
* Pursuant to Power of Attorney
|
|
|
|
|
|
/s/ Ann
G. Mayberry-French
Attorney-in-Fact
|
|
|
II-10
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as
amended, the Registrant has duly caused this registration
statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Hartland, Wisconsin on this
14th day
of October, 2011.
Requisite Software Inc.
|
|
|
|
By:
|
/s/ Justin
C. Dearborn
|
Name: Justin C. Dearborn
|
|
|
|
Title:
|
President and Chief Executive Officer
|
Pursuant to the requirements of the Securities Act of 1933, as
amended, this registration statement has been signed by the
following persons in the capacities indicated on this
14th day
of October, 2011.
|
|
|
|
|
Signature
|
|
Title
|
|
|
|
|
/s/ Justin
C. Dearborn
Justin
C. Dearborn
|
|
Director, President and Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
*
Steven
M. Oreskovich
|
|
Director, Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)
|
|
|
|
/s/ Ann
G. Mayberry-French
Ann
G. Mayberry-French
|
|
Director
|
|
|
|
* Pursuant to Power of Attorney
|
|
|
|
|
|
/s/ Ann
G. Mayberry-French
Attorney-in-Fact
|
|
|
II-11
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as
amended, the Registrant has duly caused this registration
statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Hartland, Wisconsin on this
14th day
of October, 2011.
Stryker Imaging Corporation
By: /s/ Justin C. Dearborn
Name: Justin C. Dearborn
Pursuant to the requirements of the Securities Act of 1933, as
amended, this registration statement has been signed by the
following persons in the capacities indicated on this
14th day
of October, 2011.
|
|
|
|
|
Signature
|
|
Title
|
|
|
|
|
/s/ Justin
C. Dearborn
Justin
C. Dearborn
|
|
Director and President
(Principal Executive Officer)
|
|
|
|
*
Steven
M. Oreskovich
|
|
Director and Treasurer
(Principal Financial and Accounting Officer)
|
|
|
|
/s/ Ann
G. Mayberry-French
Ann
G. Mayberry-French
|
|
Director
|
|
|
|
* Pursuant to power of Attorney
|
|
|
|
|
|
/s/ Ann
G. Mayberry-French
Attorney-in-Fact
|
|
|
II-12
EXHIBIT INDEX
|
|
|
|
|
|
2
|
.1
|
|
Agreement and Plan of Merger, dated as of May 30, 2009, by
and among Registrant, Merge Acquisition Corp., a wholly owned
subsidiary of Registrant, and etrials Worldwide, Inc.(A)
|
|
2
|
.2
|
|
Agreement and Plan of Merger, dated as of August 7, 2009,
by and among Registrant, Merge Acquisition Corporation, a wholly
owned subsidiary of Registrant, Confirma, Inc. and John L.
Brooks(B)
|
|
2
|
.3
|
|
Agreement and Plan of Merger dated as of February 28, 2010
by and among Registrant, Project Ready Corp. and AMICAS, Inc.(C)
|
|
2
|
.4
|
|
Stock Purchase Agreement, dated as of July 2, 2010, by and
among Stryker Corporation, Stryker Imaging Corporation and the
Registrant(D)
|
|
2
|
.5
|
|
Asset Purchase Agreement, dated as of July 30, 2010,
between Registrant and Merrick Healthcare Solutions, LLC d/b/a
Olivia Greets(E)
|
|
2
|
.6
|
|
Agreement and Plan of Merger, dated as of June 5, 2011 by
and among the Registrant, ES Acquisition Corp., a wholly owned
subsidiary of Registrant and Ophthalmic Imaging Systems(F)
|
|
3
|
.1
|
|
Certificate of Incorporation as filed on October 14, 2008,
and Certificate of Merger as filed on December 3, 2008 and
effective on December 5, 2008(G)
|
|
3
|
.2
|
|
Series A Preferred Stock Certificate of Designations(H)
|
|
3
|
.3
|
|
Amendment to the Certificate of Incorporation as filed on
September 27, 2010(I)
|
|
3
|
.4
|
|
Bylaws of Registrant(G)
|
|
4
|
.1
|
|
Indenture, dated as of April 28, 2010, by and among
Registrant, the guarantors of the Notes and The Bank of New York
Mellon Trust Company, N.A., as Trustee, governing the
11.75% Senior Secured Notes due 2015(H)
|
|
4
|
.2
|
|
First Supplemental Indenture dated as of June 14, 2011(J)
|
|
4
|
.3
|
|
Second Supplemental Indenture dated as of June 20, 2011(K)
|
|
4
|
.4
|
|
Third Supplemental Indenture dated as of September 1, 2011**
|
|
4
|
.5
|
|
Registration Rights Agreement dated as of June 20, 2011 by
and among the Company, the guarantors of the Notes and Morgan
Stanley & Co. LLC(K)
|
|
5
|
.1
|
|
Opinion of McDermott Will & Emery LLP**
|
|
10
|
.1
|
|
Registration Rights Agreement, dated June 4, 2008, by and
between Registrant and Merrick RIS, LLC(L)
|
|
10
|
.2
|
|
Securities Purchase Agreement, dated May 21, 2008, by and
among Registrant, the subsidiaries listed on the Schedule of
Subsidiaries attached thereto, and Merrick RIS, LLC(M)
|
|
10
|
.3
|
|
Employment Letter Agreement between the Registrant and Justin C.
Dearborn entered into as of June 4, 2008(N)
|
|
10
|
.4
|
|
Employment Letter Agreement between the Registrant and Steven M.
Oreskovich entered into as of June 4, 2008(N)
|
|
10
|
.5
|
|
Amendment dated July 1, 2008 to that certain Securities
Purchase Agreement, dated May 21, 2008, by and among the
Registrant, certain of its subsidiaries and Merrick RIS, LLC(O)
|
|
10
|
.6
|
|
Consulting Agreement, effective as of January 1, 2009, by
and between Registrant and Merrick RIS, LLC(G)
|
|
10
|
.7
|
|
Amendment effective as of January 1, 2010 to that certain
Consulting Agreement, effective as of January 1, 2009, by
and among the Registrant and Merrick RIS, LLC(N)
|
|
10
|
.8
|
|
1996 Stock Option Plan for Employees of Registrant dated
May 13, 1996(Q), as amended and restated in its entirety as
of September 1, 2003(R)
|
|
10
|
.9
|
|
1998 Stock Option Plan for Directors(S)
|
|
10
|
.10
|
|
2000 Employee Stock Purchase Plan of Registrant effective
July 1, 2000(T)
|
|
10
|
.11
|
|
2005 Equity Incentive Plan adopted March 4, 2005, and
effective May 24, 2005 as amended(U)
|
|
10
|
.12
|
|
Employment Agreement by and between the Registrant and Jeffery
A. Surges entered into as of November 5, 2010(D)
|
|
12
|
.1
|
|
Computation of Ratio of Earnings to Fixed Charges**
|
|
14
|
.1
|
|
Code of Ethics(G)
|
|
14
|
.2
|
|
Whistleblower Policy(G)
|
|
|
|
|
|
|
23
|
.1
|
|
Consent of BDO USA, LLP, Independent Registered Public
Accounting Firm, with respect to the financial statements of the
Registrant*
|
|
23
|
.2
|
|
Consent of BDO USA, LLP, Independent Registered Public
Accounting Firm, with respect to the financial statements of
AMICAS, Inc. (now Merge Healthcare Solutions Inc.)*
|
|
23
|
.3
|
|
Consent of Ernst & Young LLP Boca Raton,
Florida, Independent Registered Public Accounting Firm, with
respect to the financial statements of Emageon Inc.*
|
|
23
|
.4
|
|
Consent of Perry-Smith LLP, Independent Registered Public
Accounting Firm, with respect to the financial statements of
Ophthalmic Imaging Systems*
|
|
23
|
.5
|
|
Consent of McDermott Will & Emery LLP (included in the
opinion filed as Exhibit 5.1)
|
|
24
|
.1
|
|
Powers of Attorney (included in the signature pages hereto)
|
|
25
|
.1
|
|
Form T-1,
Trustees Statement of Eligibility**
|
|
99
|
.1
|
|
Letter of Transmittal*
|
|
99
|
.2
|
|
Notice of Guaranteed Delivery**
|
|
99
|
.3
|
|
Letter to Registered Holders**
|
|
99
|
.4
|
|
Letter To Clients and Instructions To Registered Holder
from Beneficial Owner**
|
|
99
|
.5
|
|
Merge Healthcare Incorporated and AMICAS, Inc. (now Merge
Healthcare Solutions Inc.) Unaudited Pro Forma Condensed
Consolidated Financial Information for the Year Ended
December 31, 2010**
|
|
99
|
.6
|
|
Ophthalmic Imaging Systems Condensed Consolidated Financial
Statements and Notes for the Three and Six Months Ended
June 30, 2011 and 2010**
|
|
99
|
.7
|
|
Merge Healthcare Solutions Inc. Consolidated Financial
Statements and Notes as of December 31, 2010 and 2009, and
for the Periods Ended December 31, 2010 and April 27,
2010, and the Years Ended December 31, 2009 and 2008**
|
|
99
|
.8
|
|
Merge Healthcare Solutions Inc. Condensed Consolidated Financial
Statements and Notes for the Six Months Ended June 30,
2011 and 2010**
|
|
|
|
** |
|
Previously filed with the initial filing of this Registration
Statement on September 1, 2011 |
|
|
|
(A) |
|
Incorporated by reference from the Registrants Current
Report on
Form 8-K
dated June 2, 2009. |
|
(B) |
|
Incorporated by reference from the Registrants Current
Report on
Form 8-K
dated August 10, 2009. |
|
(C) |
|
Incorporated by reference from the Registrants Current
Report on Form 8-K dated March 4, 2010. |
|
(D) |
|
Incorporated by reference from the Registrants Annual
Report on Form 10-K for the fiscal year ended
December 31, 2010. |
|
(E) |
|
Incorporated by reference from the Registrants Current
Report of
Form 8-K
dated July 30, 2010. |
|
(F) |
|
Incorporated by reference from the Registrants Current
Report on Form 8-K dated June 6, 2011. |
|
(G) |
|
Incorporated by reference from the Registrants Annual
Report on
Form 10-K
for the fiscal year ended December 31, 2008. |
|
(H) |
|
Incorporated by reference from the Registrants Current
Report on Form 8-K dated March 30, 2010. |
|
(I) |
|
Incorporated by reference from the Registrants Current
Report on Form 8-K dated September 30, 2010. |
|
(J) |
|
Incorporated by reference from the Registrants Current
Report on
Form 8-K
dated June 15, 2011. |
|
|
|
(K) |
|
Incorporated by reference from the Registrants Current
Report on
Form 8-K
dated June 20, 2011. |
|
(L) |
|
Incorporated by reference from the Registrants Current
Report on
Form 8-K
dated June 6, 2008. |
|
(M) |
|
Incorporated by reference from the Registrants Current
Report on
Form 8-K
dated May 22, 2008. |
|
(N) |
|
Incorporated by reference from the Registrants Current
Report on
Form 8-K
dated July 15, 2008. |
|
(O) |
|
Incorporated by reference from the Registrants Current
Report on
Form 8-K
dated July 7, 2008. |
|
(P) |
|
Incorporated by reference from the Registrants Current
Report on Form 8-K dated April 2, 2010. |
|
(Q) |
|
Incorporated by reference from Registration Statement on
Form SB-2
(No. 333-39111)
effective January 29, 1998. |
|
(R) |
|
Incorporated by reference from the Registrants Quarterly
Report on
Form 10-Q
for the period ended September 30, 2003. |
|
(S) |
|
Incorporated by reference from the Registrants Annual
Report on
Form 10-KSB
for the fiscal year ended December 31, 1997. |
|
(T) |
|
Incorporated by reference from the Registrants Proxy
Statement for the Annual Meeting of Shareholders on May 23,
2000. |
|
(U) |
|
Incorporated by reference from the Registrants Proxy
Statement for the Annual Meeting of Shareholders on June 2,
2011. |